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1
Scope of the thesis

Prion diseases or transmissible spongiform encephalopathies (TSEs) are a unique group
of fatal neurodegenerative disorders that affect both humans and animals. TSEs are
characterized neuropathologically by spongiform degeneration of the gray matter,
neuronal loss, astrocytosis and the accumulation of the protease resistant prion protein
(PrPSc). Even though they share some similarities with other conventional
neurodegenerative diseases such us Alzheimer's disease, they are unique in that they are
transmissible. According to the protein-only hypothesis, PrPSc is itself the main or only
component of the transmissible agent.1
Human TSEs comprise a number of diseases with different etiology. Under this
acronym we currently include: entities with unknown etiology, like sporadic Creutzfeldt-
Jakob disease (sCJD), genetic syndromes associated to mutations of the human gene
encoding the prion protein (PRNP) referred to as genetic CJD (gCJD), Gerstmann-
Sträussler-Scheinker syndrome (GSS) and fatal familial insomnia (FFI), and transmitted
cases via medical procedures like iatrogenic CJD (iCJD) or via consumption of human
(Kuru) or bovine infected material (variant CJD (vCJD)).
TSEs are rare disorders. The annual incidence of all human TSEs has been
estimated to be around 1.67 cases per million.2 However, remarkable attention has been
focused on these rare diseases in the past century. This is mainly because of their unique
pathogenic mechanisms and also because of their public health implications. The bovine
spongiform encephalopathy (BSE) epizootic in the UK and the subsequent appearance
of vCJD, as a consequence of the transmission of the BSE agent to humans through
contaminated bovine products, brought these rare disorders to the centre of the world's
attention. Consequently, there has been an enormous amount of publications on the
subject. Indeed, if the number of publications on any disease is divided by the incidence
of such disease, human prion diseases posses by far the highest 'interest factor'.
It was the BSE outbreak in the UK in the middle 1980s that motivated the
establishment in 1993 of a network EUROCJD to coordinate the epidemiological
surveillance in a number of European countries with the main aim of identifying any
change in incidence or characteristics of CJD that might be attributable to the BSE
epizootic. The data collected since 1993 has allowed the realization of multiple studies
addressing fundamental questions about key aspects of this group of diseases. This
original collaboration seeded new collaborations focusing on extending CJD monitoring
to other countries (NEUROCJD) or diagnostic aspects (EPICJD).
All the studies presented in this thesis are fruit of the work of these international
CJD surveillance networks. The objective of the research presented in this book is
twofold: the first aim is to obtain new insights about TSE etiology and risk factors. The
second aim of the thesis is to evaluate the main tests used for the diagnosis of TSEs. Both
topics are analyzed under the prism of two different methodological tools, classical
epidemiology in search of environmental factors, and genetic epidemiology in search of
genetic determinants and gene-gene or gene-environment interactions.
Chapter 2 introduces the concept of the epidemiological CJD surveillance systems
as the cornerstone of the studies part of this thesis. In chapter 2.1 we discuss in depth
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the main methodological issues concerning the set up of a multinational collaborative
network like NEUROCJD. We present the results of the monitoring activities of the ten
countries included in the NEUROCJD collaboration from 1996 to 2004. In chapter 2.2
we present the description of the first case of vCJD detected in the Netherlands. This
patient was ascertained as part of the EUROCJD monitoring of CJD. The ascertainment
of cases with new phenotypes of the disease is one of the main objectives of the CJD
surveillance systems.
In chapter 3 we present several etiological studies. Chapter 3.1 analyses the role of
UK bovine exports during the 1980s or indigenous BSE cases, in the spread of vCJD to
other countries beyond the UK borders. In chapter 3.2 we present the results of a case
control study carried out in the UK in which we studied whether ophthalmic surgery has
contributed to the transmission of sporadic and variant CJD. The last part of the third
chapter is devoted to the study of possible genetic factors associated to risk of sporadic
CJD. In chapter 3.3 we performed a population based genetic association study to assess
the role of a polymorphism located inside the regulatory region of PRNP. In chapter 3.4
we carried out a genetic association study aiming to assess the role of the genetic
variations of Tau protein gene (MAPT) in susceptibility to vCJD and sCJD.
Chapter four is entirely focused on diagnostic aspects of CJD. The studies included
in this chapter are all international collaborative efforts that collected a huge amount of
data, allowing to address important questions related to the tests commonly employed in
the diagnosis of this extremely rare group of diseases. Chapter 4.1 analyses the
diagnostic sensitivity and specificity of various brain derived proteins in the
cerebrospinal fluid (CSF) of patients of CJD and other dementias. Several biological
factors that influence the sensitivity and specificity of these tests are assessed. Chapter
4.2 addresses the influence of timing on CSF tests value for CJD diagnosis, and the
usefulness of sequentially repeated tests. Chapter 4.3 summarizes the main findings of
the routine CSF tests carried out in TSE patients. Finally, in chapter 4.4 we present a
comprehensive study analyzing the main determinants of the diagnostic sensitivity of the
three main tests (EEG, CSF 14-3-3 test, and MRI) performed on TSE patients. We
specifically assessed the performance of those three diagnostic tests across the clinical
spectrum of sporadic CJD. In the last chapter the main findings of these studies and their
implications are discussed together with methodological issues.
References
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2.1
The 'NEUROCJD' collaboration:
CJD surveillance systems and results in ten countries 
Abstract
This paper describes the extended collaborative study group of Creutzfeldt-Jakob
disease (CJD) 'NEUROCJD' and the results of their monitoring activities during a 8-
years period in 10 countries with relatively small population size like Belgium,
Denmark, Finland, Greece, Iceland, Ireland, Israel, Norway, Portugal, Sweden, plus the
United Kingdom (UK). The overall annual mortality rate of sporadic CJD in the studied
countries from 1997 to 2004 was 1 case per million inhabitants. The most common
clinical presentations of sporadic CJD were the rapidly progressive dementia (74%),
followed by the ataxic onset (9%). Although much less frequent than the first two, visual
presentation (Heidenhein's syndrome) (4%) was also well recognized. Other clinical
presentations, psychiatric (3%), sensory (2%), and extrapyramidal (0.4%) were
recognized less frequently. Finally, 6% of the cases presented with a slowly progressive
dementia syndrome. During the study period we ascertained 27 sCJD patients (6% of the
total) younger than 50 years at onset, 51 sCJD patients (12% of the total) with disease
duration superior to one year, and 69 (6%) sCJD patients with atypical clinical onset.
Excluding the UK, only one case of vCJD, in the Republic of Ireland, was diagnosed
during the period of observation. In conclusion, we have stablished CJD monitoring
successfully in 9 new European countries, plus Israel, which are characterised by
relatively small population size. 
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Introduction
Creutzfeldt-Jakob disease (CJD), a rare disease, has become the centre of intense
clinical, scientific and media attention. The emergence of bovine spongiform
encephalopathy (BSE) in United Kingdom (UK) cattle in the 1980s prompted the
institution of national CJD surveillance in the UK, to detect any resulting change in the
incidence or nature of CJD.1 An EU-funded CJD surveillance collaborative group
('EUROCJD') began in 1993, with the following members: Austria, France, Germany,
Italy, the Netherlands, Slovakia, Spain and the UK, joined in 1996 by Australia, Canada
and Switzerland.2 In 1996, variant CJD (vCJD, previously 'new variant CJD') was
reported and it has been causally linked to BSE.3,4 The rapid availability of comparative
data from other countries was an important factor in the early identification of variant
CJD in the UK.
BSE has not been confined to the UK and past UK exports of live animals, animal
products and animal feed are a potential risk to other countries. Many individuals travel
widely and thus may become exposed to risks present in other countries. VCJD has been
transmitted from human to human by blood and there is concern about risk from blood
products and other treatments that have a potential world-wide distribution.5,6 VCJD is
therefore a problem without national boundaries. 
In 1998, a further EU-funded group ('NEUROCJD') was established with ten
member countries which are characterised by relatively small population size (<12
million inhabitants): Belgium, Denmark, Finland, Greece, Iceland, Israel, Norway,
Portugal and Sweden, joined in 1999 by the Republic of Ireland. In this paper we
describe the design of this collaborative group, the nature of their individual surveillance
systems and discuss the CJD data collected from 1997 to 2004.
Methods: the NEUROCJD collaborative system
The NEUROCJD collaborative group was established in 1998. Initial funding from the
EU ran from 1998 to 2000, with a further grant covering the period 2001 to 2005. The
member countries, with their population sizes are given in Table 1 and Table 2. The UK
acted as the chair of the NEUROCJD system. There were six-monthly meetings of the
members at which data were presented, problems discussed, methods harmonised and
research collaborations coordinated. The collaborative project employed a Study
coordinator who organized the meetings, acted as a point of contact and visited the
member countries on a regular basis. The core aims of NEUROCJD were the
harmonization of CJD surveillance methodologies, the collection of basic CJD data, the
sharing of particular expertise and collaborative research projects. A basic data set (the
'Minimal Monitoring Data Set') was provided by each country, on a regular basis, to a
central data base at Erasmus University, Rotterdam, which also acted as the data centre
for the EUROCJD project. Sub-groups within NEUROCJD addressed neuropathology,
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CSF testing, genetics, atypical cases and public health issues. Although methods were
harmonized as far as possible, especially concerning CJD diagnostic criteria/case
definitions, CSF 14-3-3 methodologies, genetic testing methodologies and the collection
of common data sets, each country was responsible for establishing, designing, funding
and running its own surveillance system. There were therefore differences in structure
and approach between the member countries. There are various key parameters of CJD
surveillance systems, including whether they are essentially based on pathological or
clinical identification, whether case notification is mandatory, and whether cases are
examined directly by surveillance system personnel. The essential characteristics of each
member country system are given in Table 1. For example, in the UK, Belgium and
Iceland, notification of cases of CJD was not mandatory during the 1997-2004 period,
being officially notifiable in the remaining 8 NEUROCJD countries. Mandatory
notification was introduced at different times: from 1996 in Greece, Ireland, Israel and
Portugal, from1997 in Norway and Portugal, from 1998 in Sweden and from 1999 in
Finland. 
The information collected correspond to an 8-years monitoring period (1997-
2004). All reported patients who died for any form of transmissible spongiform
encephalopathy (TSE) were included in the study. Only patients fulfilling the diagnostic
criteria for probable or definite disease were accepted for the data analyses.7 The clinical
presentation of sporadic CJD cases was determined whenever possible, according to
agreed definitions (Appendix 1).
Statistical analysis
Crude and age-and sex-specific mortality rates were calculated using as denominator
population data from the 2004 revision of the world population prospects from the
United Nations (www.unpopulation.org). Four age-interval classes were defined for the
analysis (up to 14, 15 to 59, 60 to 79 and more than 80 years). Differences in mortality
from sCJD among countries were assessed by means of a Standardized Mortality Ratio
(SMR) based on the overall age and sex-specific mortality rates from 1997 to 2004. The
95% Confidence Intervals (CIs) were calculated assuming a Poisson distribution. Global
differences of mortality among countries and among years of study were assessed by
fitting a Poisson regression model, gender and age being included as covariates.
Chapter 2
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Table 1: Basic characteristics of each member country surveillance system
Results: CJD data
A total of 1320 deaths from any form of TSE were reported during the observation
period. This includes 1037 sporadic CJD patients (sCJD), 119 genetic CJD (gCJD)
(including 9 Gerstmann-Sträussler-Scheinker syndrome cases and 1 fatal familial
insomnia case), 28 iatrogenic CJD (iCJD) (all but one Irish case from the UK) and 136
variant CJD cases (vCJD) (all but one Irish case from the UK). The overall mean annual
mortality rate for all TSE in the NEUROCJD countries for the 8 year period (January
1997 to December 2004) was 1.3/million person-years (Table 2).
Country Nature of the
surveillance system
Notifiable 
disease
Criteria & type of
notification
Patient 
seen in life
Belgium
Epidemiology/
Neuropathology
No All suspect cases No
Denmark
Epidemiology/
Neuropathology
Since 1997
Suspect or definite cases
Causes of death register
No
Finland
Neuropathological/
Neurological
Since1999
Death certificates, referred
cases, hospital records
Partial
Greece
Neurological/
Neuropathological
Since 1996 Not specified Partial
Iceland
Pathological/
Neurological
No Not specified Yes
Ireland
Neurological/
Neuropathological
Since 1996 Suspect cases Partial
Israel Neuroepidemiological Since 1999
Hospital
Autopsy
Death certificates
Neurogenetic labs
Personal communication
Family contacts
Partial
Norway Epidemiological Since1997
Suspect or definite cases
Death certificate register
Neurologists/neuropathologists
No
Portugal
Neuropathology/
Epidemiology
Since1996 All suspect cases No
Sweden Epidemiological Since1997 Not specified No
Table 2: Human prion diseases mortality rates and country surveillance parameters
*Only sporadic CJD patients
Figure 1: Annual mortality rates for sporadic CJD, by year for all countries combined over the 
period 1997-2004.
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Country Country
population
All
TSE
Sporadic
CJD
Autopsy
rates (%)*
CSF 14-3-3
testing (%)*
PRNP Mutation
testing (%)*
PRNP codon 129
genotyping (%)*
Belgium 10,898,274 1.5 1.5 75.2 84.1 15.9 40.7
Denmark 5,659,102 1.2 1.2 66.0 50.0 20.0 24.0
Finland 5,458,960 1.4 1.3 88.9 25.9 22.2 22.2
Greece 11,520,320 0.7 0.7 59.3 89.8 0.0 0.0
Iceland 303,114 0.4 0.4 100.0 0.0 0.0 100.0
Rep. of
Ireland
4,259,996 1.0 0.9 86.2 65.5 0.0 69.0
Israel 6,899,850 2.0 0.7 29.7 94.6 59.5 2.7
Norway 4,838,187 0.9 0.8 96.8 32.3 0.0 0.0
Portugal 10,892,772 0.8 0.9 40.6 67.2 43.8 45.3
Sweden 9,529,214 1.3 1.3 94.7 36.2 1.1 9.6
UK 62,293,392 1.4 1.0 75.9 59.9 50.8 66.2
Total 132,553,181 1.3 1.0 73.8 60.9 33.2 44.4
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1997 1998 1999 2000 2001 2002 2003 2004 Whole
period
Year of death
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Sporadic CJD
The overall mean annual mortality rate of sCJD was 1.0/million person-years, the
numbers of deaths and the annual mortality rates are given in Table 2, Table 3 and Figure
1. The Standardised Mortality Ratios (SMRs) for sCJD are given in Table 3. The
calculation of the SMR requires demographic data that were not available in all cases
and is therefore based on a total of 1007 cases. Belgium has a slightly increased SMR,
with Greece and Portugal having relatively low SMRs. Because of missing data, the
SMR in all three countries is likely to be an underestimate, especially for Portugal.
However, a Poisson regression model suggests that there are no significant differences
in the sCJD annual mortality rates between the different NEUROCJD countries over this
8 year period. The annual mortality rates for specific age categories and sex, given in
Figure 2, are slightly higher in women aged more than eighty years than in men of the
same age. However, as shown in Table 4, the overall sex ratio of sCJD patients is almost
50:50. The basic age, illness duration and case classification are also given in Table 4a
for the sporadic and Table 4b genetic CJD cases. The median age at onset in sCJD was
66.7 years, varying from 61.5 years in Norway to 69 years in Sweden. GCJD cases
presented at an earlier age than sCJD (median of 59.4 years; range from 31.7 to 81.8
years). The median disease duration was of 5 months for both sCJD and gCJD cases. The
percentage of neuropathological confirmation was almost 74% for the sCJD, but these
figures varied considerably ranging from almost 100% in some Scandinavian countries
to only 30% in Israel. For gCJD cases this percentage was much lower (27%).
Table 3: Standaridzed mortality rates and 95% confidence intervals for each country
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Country Total deaths from
sporadic CJD 
Mean annual mortality
rate sporadic CJD
SMR SMR 95% CI
Belgium 123 1.5 1.27 1.04-1.53
Denmark 50 1.2 1.21 0.90-1.59
Finland 54 1.3 1.24 0.93-1.63
Greece 59 0.7 0.63 0.48-0.81
Iceland 1 0.4 0.53 0.01-2.93
Rep. of  Ireland 29 0.9 1.07 0.71-1.55
Israel 37 0.7 0.82 0.56-1.16
Norway 31 0.8 0.87 0.59-1.24
Portugal 65 0.9 0.65 0.49-0.84
Sweden 94 1.3 1.19 0.96-1.46
UK 494 1.0 1.03 0.95-1.13
Total 1037 1.0
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Figure 2: Age-specific mortality rates for sporadic CJD in all countries over the period 1997-2004.
Table 4a: Basic demographic and clinica characteristics of sporadic CJD patients
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Males
Females
Countries Number % Definite % Female Median age at
onset (range)
Median duration
(range)
Belgium 123 75.2 44.2 65.3 (31.8-88.0) 4 (1-36)
Denmark 50 66.0 52.0 65.9 (40.0-87.7) 5 (1-18)
Finland 54 88.9 51.9 67.8 (47.6-82.2) 3 (0-44)
Greece 59 59.3 52.4 63.0 (30.0-88.0) 6 (1-15)
Iceland 1 100.0 100.0
Rep. of  Ireland 29 86.2 51.7 67.9 (49.0-82.9) 3 (1-14)
Israel 37 29.7 51.4 66.7 (34.5-81.7) 4 (1-38)
Norway 31 96.8 61.3 61.5 (53.8-85.9) 4 (1-16)
Portugal 65 40.6 56.3 67.3 (17.6-81.9) 7 (1-52)
Sweden 94 94.7 53.2 69.0 (43.0-82.0) 4 (1-30)
UK 494 75.9 50.4 66.8 (15.6-94.9) 4 (0-62)
Overall sample 1037 73.8 51.1 66.7 (15.6-94.9) 5 (0-38)
Table 4b: Basic demographic and clinica characteristics of genetic CJD patients
*Included 9 GSS patients
Basic data concerning the main investigation for sCJD diagnosis (EEG, MRI scan
and CSF 14-3-3 analysis) are summarized in Table 5. The most sensitive test was 14-3-3
CSF analysis, which was positive in 91.6% of the sCJD patients. The other two main
tests, EEG and MRI, showed less sensitivity than CSF analysis. Periodical complexes in
the EEG were present in 44.6% of the sCJD patients and basal ganglia hyperintensity in
the MRI scan only in 34.0% of them. Table 5 shows PRNP codon 129 genotypic
distribution of sCJD patients. We observe an excess of homozygous cases (80%) with
predominance of the methionine/methionine (MM) genotype. There are some variations
across countries most likely explained by the fact that the partial sample sizes are low.
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Countries Number % Definite % Female Median age at
onset (range)
Median duration
(range)
Belgium 3 66.7 66.7 51.4 (40-53.7) 8 (2-14)
Denmark
Finland 4 75.0 25.0 41.4 (37.4-61.2) 15.5 (3-52)
Greece
Iceland
Rep. of  Ireland 1(FFI) 100.0 0.0
Israel 73 5.5 52.1 60.5 (35.0-78.0) 5 (1-78)
Norway 4 75.0 50.0 78.2 (68.5-81.8) 5.5 (2-9)
Portugal
Sweden
UK 34* 58.8 55.9 51.7 (31.7-72.2) 4 (0-216)
Overall sample 119 27.5 52.5 59.4 (31.7-81.8) 5 (0-216)
Table 5: Diagnostic investigations in sporadic CJD
The clinical presentations of cases (as defined in Appendix 1) are given in Table 6
and Figure 3. The clinical presentation of sCJD was classified in as many cases as
possible and this was possible in 897 out of 1037 (86%) cases (being a little lower at
76%, 411/543, if the UK data are excluded). Difficulties included, for example, clinical
notes failing to record the presence or absence of a clinical feature and absent data or
insufficient detail on whether a particular feature, like cerebellar ataxia, remained in
isolation for the specified period. In these cases, the clinical presentation was recorded
as 'missing'. The commonest clinical presentations of sporadic CJD were the rapidly
progressive dementia (74%), followed by the ataxic onset (9%). Although much less
frequent than the first two, visual presentation (Heidenhein's syndrome) (4%) was also
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Country EEG no
data
Positive
EEG
14-3-3
test no
data
Positive 
14-3-3
MRI no
data
Typical
MRI
Codon
129 no
data
MM (%) MV (%) VV (%)
Belgium 28
42/95
(44.2)
31
88/92
(95.6)
81
29/42
(69.0)
78
32/45
(71.1)
8/45
(17.8)
5/45
(1.1)
Denmark 2
35/48
(72.9)
26
22/24
(91.7)
15
7/35
(20.0)
38
9/12
(75.0)
1/12
(8.3)
2/12
(16.7)
Finland 7
37/47
(78.7)
43
10/11
(90.1)
16
23/38
(60.5)
46
6/8
(75.0)
0/8
(0.0)
2/8
(25.0)
Greece 19
17/40
(42.5)
6
53/53
(100.0)
30
9/29
(31.0)
59 0/0 0/0 0/0
Iceland 0
1/1
(100.0)
1 0/0 0
0/1
(0.0)
0
1/1
(100.0)
0/1
(0.0)
0/1
(0.0)
Rep. of
Ireland
2
18/27
(66.7)
10
17/19
(89.5)
8
3/21
(14.3)
9
11/20
(55.0)
4/20
(20.0)
5/20
(25.0)
Israel 1
15/36
(41.7)
2
32/35
(91.4)
21
1/16
(6.2)
36
0/1
(0.0)
1/1
(100.0)
0/1
(0.0)
Norway 10
17/21
(80.9)
21
9/10
(90.0)
31 0/0 31 0/0 0/0 0/0
Portugal 5
44/60
(73.3)
22
38/43
(88.4)
17
12/48
(25.0)
40
16/25
(64.0)
5/25
(20.0)
4/25
(16.0)
Sweden 43
29/51
(56.9)
62
25/32
(78.1)
66
7/28
(25.0)
85
6/9
(66.7)
1/9
(11.1)
2/9
(22.2)
UK 86
117/408
(28.7)
215
254/279
(91.0)
255
78/239
(32.6)
167
195/327
(59.8)
66/327
(10.1)
66/327
(10.1)
Total 203
372/834
(44.6)
439
548/598
(91.6)
540
169/497
(34.0)
589
276/448
(61.6)
86/448
(19.2)
86/448
(19.2)
Codon 129
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well recognized. Other clinical presentations, psychiatric (3%), sensory (2%), and
extrapyramidal (0.4%) were recognized less frequently. Finally, 6% of the cases
presented with a slowly progressive dementia syndrome. The percentages of some of the
clinical presentation categories varied significantly across the NEUROCJD participants
(Table 6). For example, rapidly progressive dementia accounted for only 38% of Greek
cases and only 60% of Israeli cases, compared with 96% of cases in Norway and 74%
of cases overall. The greatest variation in rapidly progressive dementia, in Greece,
mostly paralleled a difference in cerebellar onset (being 38% in Greece, compared to 9%
overall).
Figure 3: Clinical presentations of sporadic CJD patients.
73.9
3.8 3 6
8.9
0.6 0.6 2 1.2
0
10
20
30
40
50
60
70
80
90
100
Rapidly
progressive
dementia
Heidenhain Psychiatric Progressive
dementia
Cerebellar Extrapyramidal Stroke-like Sensory Other
Clinical presentation
g
Epidemiology of Creutzfeldt-Jakob disease: the role of international collaborative studies
27
T
ab
le
 6
:
C
li
ni
ca
l 
pr
es
en
ta
ti
on
 o
f 
sp
or
ad
ic
 C
JD
 c
as
es
C
ou
nt
ry
N
 (
%
 o
f
da
ta
 
m
is
si
ng
)
“D
at
a 
qu
al
it
y
as
se
ss
m
en
t”
R
ap
id
ly
pr
og
re
ss
iv
e
de
m
en
ti
a 
(%
)*
H
ei
de
nh
ai
n
(%
)
P
sy
ch
ia
tr
ic
(%
)*
P
ro
gr
es
si
ve
de
m
en
ti
a
(%
)
C
er
eb
el
la
r
(%
)*
E
xt
ra
py
ra
m
id
al
(%
)*
St
ro
ke
-
lik
e 
(%
)*
Se
ns
or
y
(%
)
O
th
er
(%
)*
B
el
gi
um
90
 (
20
.4
)
ye
s
56
 (
62
.2
)
4 
(4
.4
)
10
 (
11
.1
)
8 
(8
.9
)
12
 (
13
.3
)
0
0
0
0
D
en
m
ar
k
44
 (
12
.0
)
ye
s
35
 (
79
.5
)
3 
(6
.8
)
0
1 
(2
.3
)
3 
(6
.8
)
1 
(2
.3
)
0
1 
(2
.3
)
0
Fi
nl
an
d
46
 (
14
.8
)
ye
s
32
 (
69
.6
)
1 
(2
.2
)
1 
(2
.2
)
1 
(2
.2
)
6 
(1
3.
0)
0
0
1 
(2
.2
)
4 
(8
.7
)
G
re
ec
e
53
 (
10
.2
)
ye
s
20
 (
37
.7
)
1 
(1
.9
)
3 
(5
.7
)
7 
(1
3.
2)
20
 (
37
.7
)
1 
(1
.9
)
1 
(1
.9
)
0
0
Ic
el
an
d
1 
(0
.0
)
ye
s
0
0
0
0
0
1 
(1
00
.0
)
0
0
0
R
ep
. o
f
Ir
el
an
d
23
 (
20
.7
)
ye
s
17
 (
73
.9
)
1 
(4
.3
)
0
2 
(8
.7
)
3 
(1
3.
0)
0
0
0
0
Is
ra
el
37
 (
0.
0)
no
22
 (
59
.5
)
3 
(8
.1
)
2 
(5
.4
)
4 
(1
0.
8)
3 
(8
.1
)
2 
(5
.4
)
1 
(2
.7
)
0
0
N
or
w
ay
27
 (
12
.9
)
no
26
 (
96
.3
)
0
0
0
0
0
1 
(3
.7
)
0
0
Po
rt
ug
al
36
 (
43
.7
)
ye
s
27
 (
75
.0
)
1 
(2
.8
)
1 
(2
.8
)
2 
(5
.6
)
0
0
0
0
5 
(1
3.
9)
S
w
ed
en
54
 (
42
.5
)
ye
s
40
 (
74
.1
)
1 
(1
.9
)
0
1 
(1
.9
)
8 
(1
4.
8)
0
2 
(3
.7
)
1 
(1
.9
)
1 
(1
.9
)
U
K
48
6 
(5
.0
)
ye
s
38
8 
(7
9.
8)
19
 (
3.
9)
10
 (
2.
1)
28
 (
5.
8)
25
 (
5.
1)
0
0
15
 (
3.
1)
1 
(0
.2
)
To
ta
l
89
7 
(2
2.
7)
66
3 
(7
3.
9)
34
 (
3.
8)
27
 (
3.
0)
54
 (
6.
0)
80
 (
8.
9)
5 
(0
.6
)
5 
(0
.6
)
18
 (
2.
0)
11
 (
1.
2)
During the study period we ascertained 27 sCJD patients (6% of the total) younger
than 50 years at onset, 51 sCJD patients (12% of the total) with disease duration superior
to one year, and 69 (6%) sCJD patients with atypical clinical onset. Basic details and
investigation results in atypical cases are given in Table 7.
Table 7: Characteristics of atypical sporadic CJD cases
*Clinical presentation other than rapidly progressive dementia, Heidenhaim or cerebellar onset.
Genetic CJD
Genetic cases are very rare. They were identified in Belgium, Finland, Norway, Israel and
the UK, accounting for 9% of all TSE cases. Diagnosis was based, whenever possible, on
PRNP genetic analysis; a clear family history was not present in all cases. The only
underlying mutations identified, in countries other than the UK, were E200K (n=74) and
D178N (n=6) (Table 8).
Table 8: Frequence of PRNP genetic mutations by country
*Deaths per million inhabiants/year
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N Duration
>1year
(%)
Females
(%)
MM (%) MV (%) VV (%)
Positive
14-3-3
test (%)
Typical
EEG (%)
Typical
MRI (%)
Pathological
confirmation
(%)
Clinical onset
below fifties
27
6/23
(26.1)
13/27
(48.1)
4/8
(50.0)
3/8
(37.5)
1/8
(12.5)
16/18
(88.9)
10/23
(43.5)
6/16
(37.5)
21/27
(77.8)
Atypical 
presentation*
66
22/53
(41.5)
33/66
(50.0)
15/23
(65.2)
7/23
(30.4)
1/23
(4.4)
42/46
(91.3)
27/60
(45.0)
15/35
(42.8)
42/65
(63.6)
Atypical 
presentation
below fifties
6
4/5
(80.0)
4/6
(66.7)
0/1
(0.0)
1/1
(100.0)
0/1
(0.0)
4/4
(100.0)
0/5
(0.0)
1/4
(25.0)
2/6
(33.3)
Codon 129 genotype
Country E200K D178N Family history Total % of all TSE
cases
Mortality
rate*
Belgium 1 0 2 3 2.4 0.04
Denmark 0 0 0 0 0.0 0.00
Finland 1 3 0 4 6.9 0.10
Greece 0 0 0 0 0.0 0.00
Iceland 0 0 0 0 0.0 0.00
Rep. of Ireland 0 1 0 1 3.5 0.03
Israel 70 2 1 73 66.4 1.36
Norway 2 0 2 4 11.4 0.11
Portugal 0 0 0 0 0.0 0.00
Sweden 0 0 0 0 0.0 0.00
UK 9 0 16 34 3.7 0.05
Total 83 6 21 119 9.0 0.11
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Iatrogenic CJD
In countries other than the UK, there was only one iatrogenic case identified in the 8
year period, in the Republic of Ireland. This was due to cadaveric-derived human growth
hormone, in a male, aged 37 years at onset, presenting with cerebellar ataxia and dying
in 2001, with neuropathological confirmation of CJD.
Variant CJD
In the NEUROCJD zone one variant case was identified in the period 1997-2004, in the
Republic of Ireland. The individual was female, PRNP codon 129-MM, dying in 1999
after an illness duration of 7 months. Because this individual had spent a significant
period of time living in the UK during the relevant UK dietary risk period, it was
considered that she had actually contracted the illness while in the UK. In the UK 135
death of vCJD were registred during the study period.
Discussion
The surveillance of CJD poses certain problems that are particular (although not unique)
to this disease. Firstly, CJD is rare with even the commonest form (sCJD) having an
annual mortality rate of only around 1/million/ year. Therefore, it can be difficult to
maintain awareness and interest in the disease.2,8 However, the identification of variant
CJD stimulated intense general and medical interest in prion diseases. Secondly, there
are no validated simple, non-invasive, pre-mortem diagnostic tests. Cases should be
definitively detected at autopsy, but not all suspect cases have autopsies, reflecting
different cultural and medical practices. Case ascertainment based solely on autopsy
confirmation is likely to be incomplete. Cerebral biopsy is invasive, requires particular
precautions, and is not usually necessary on strictly clinical grounds.
Clinical diagnostic criteria have been established and validated, especially for
sporadic and variant forms of CJD, but their appropriate and reliable application requires
the involvement of suitably experienced clinicians.7 The necessary clinical experience or
laboratory techniques (such as CSF 14-3-3 analysis) may be difficult to obtain in a
country with a relatively small population and, hence, a small number of cases. However,
collaborative systems, such as NEUROCJD, are designed to help with such problems, by
sharing of expertise and common provision of laboratory tests.
It should be emphasized that the reliable and complete identification of cases of
vCJD requires the identification of all types of CJD. The diferential diagnosis may differ
across populations. In the UK, the most important differential diagnosis of vCJD is
sCJD, while in the remaining countries is other non-CJD dementias. Atypical cases of
sCJD may affect uncharacteristically young individuals, have prolonged duration and
present with atypical symptoms, all of which may suggest the possibility of vCJD.9
NEUROCJD is based on each country's individual surveillance systems. The
available funding and facilities varies from country to country with different
geographical, cultural or medical system factors dictating the need for different
surveillance approaches. Methods applicable in a densely populated, geographically
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small country, with a relatively small neuroscience community, like the UK, may not be
ideal in a country with a larger geographical area, a smaller population and a different
neurological service structure. Three main medical specialities are usually involved in
CJD surveillance: epidemiologists/public health doctors, clinical neurologists and
neuropathologists. Some involvement of all of these disciplines is essential at some point
of case evaluation, but the primary responsibility for the surveillance system varies from
country to country (see Table 1). For example, in the UK, the primary point of
notification is to clinical neurologists, an attempt is made to see all individual cases in
life, and neuropathology is an integral aspect of the system. In Belgium, the primary
method of case ascertainment is through epidemiology systems with neuropathology.
Clinical neurologists are involved, but individual cases are not seen in life by the
surveillance system. There are three broad methods of clinical data collection. Firstly,
the CJD surveillance system (CJDSS) may obtain them from routine clinical case
records. Secondly, they may request special forms to be completed by clinicians,
relatives and others. Finally, a CJDSS clinician may personally assess the suspect case,
including a direct interview with the relatives. General clinical experience and anecdotal
data strongly suggest that the last method is likely to yield the most complete, detailed
and reliable information. However, this is a relatively expensive method; involving the
employment of a suitably trained clinician and travel over a potentially wide area. In five
of the NEUROCJD countries, cases are not seen in life by the system and only one
country (the UK) has a definitive policy of visiting all suspect cases when possible.
While visiting cases should increase the quality of the diagnosis and clinically diagnosed
patients, may encourage referral of atypical cases and allows the collection of more
detailed data, it may not be vital for simple case ascertainment (as the relative uniformity
of data in Table 2 and Table 3 suggest).
Notification & Sporadic CJD Mortality Rates
The actual notification criteria and routes vary from all clinically suspect cases, through
neuropathogically confirmed cases, to death certificate registers, with some countries
employing multiple methods (Table 1). In some countries, the criterion is simply 'all
suspect cases' without further definition. There are, of course, potential difficulties in
trying to precisely define notification criteria. Any very general clinical criteria such as
'atypical dementias' or 'neuro-psychiatric disease in the young' may lead to
unmanageable numbers of referrals. If the primary notifiers are clinical neurologists, it
should be possible to base notification criteria on sensible clinical judgment. On the
other hand, very specific criteria, based on previous experience, may overlook atypical
cases or those without autopsy. Unless all cases undergo cerebral biopsy and/or autopsy,
notification based purely on neuropathological criteria will, necessarily, overlook cases.
The available autopsy rates are given in Table 2. Case identification based on death
certification may lead to detection of cases not notified in life, but is likely to be
unreliable. Notification based on investigation reports and results has obvious problems
in the absence of a definitive diagnostic test (this issue is discussed further below). For
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a rare disease like CJD, especially if one wishes to detect atypical cases, multiple, over-
lapping methods of case ascertainment are advisable.
The overall annual mortality rate of sCJD was 1.0 per million for the 11 countries
during 1997-2004. There was some variation over time (Figure 1), but this would be
expected especially in countries with relatively small populations and, after fitting a
Poisson regression model, the overall differences in mortality across the study years
were not statistically significant (p=0.42). There was variation between countries (Table
3) and there was one country (Belgium) and two countries (Greece and Portugal) with
high and low SMRs respectively. However, the Poisson regression analysis did not
suggest any significant difference in the annual mortality rates of the 11 countries.
In this collaborative study, there is no clear indication that one form of notification
system is inherently superior to another. The lack of mandatory formal notification is not
associated with relatively lower incidence figures. Indeed, in Belgium, the annual
mortality rate (AMR) and SMR are relatively high despite voluntary notification and
both Greece and Portugal, with mandatory notification, have relatively low AMRs and
SMRs. In countries that introduced formal notification during the 1997-2004 period,
there is no evidence of a subsequent rise or fall in numbers of cases identified. 
The age-specific mortality rates for males and females are given in Figure 2. The
overall profile is generally similar to that reported in other countries, with the highest
rates in the 60-79 age band and a fall in the later age band.8,10 The significance of this
age profile is uncertain. In particular, it is unclear if there is under ascertainment in the
elderly. However, whatever the explanation, it appears to affect all countries, both within,
and without, NEUROCJD in a similar way. The sex ratio is almost 50:50, comparable to
data from other countries, although some previous reports have shown a slight female
preponderance.2,8 The latest data from EUROCJD, which is monitoring CJD in a larger
population, is around 50:50 (personal communication Sánchez-Juan).
Clinical Presentation of sCJD
As discussed previously, the clinical data collection policy is not homogeneous in all
NEUROCJD countries. This fact resulted in incomplete data sets on clinical data for
many countries and also may account for some of the variation in findings between
countries.
The clinical presentation categories were defined after discussion at the early
meetings of the NEUROCJD group and reflected the known clinical profile of sCJD and
unusual features that might cause diagnostic difficulty, including with respect to
differentiating from vCJD (Table 6). In general, the categories were based on identifying
the typical 'rapidly progressive dementia' cases and those characterized by initial
specific features (that typically, later, progress into more general brain involvement).The
final definitions of these categories inevitably included some relatively arbitrary
elements (for example, the required duration of pure cerebellar features in the definition
of a 'cerebellar onset' case). However, they were based on the considerable previous
clinical experience of the study participants. The complete definitions are given in
Appendix 1.
Chapter 2
32
A few points should be emphasized. Firstly, the category of 'rapidly progressive
dementia' covers the typical presentation of sCJD and, while dementia is a vital
component, other neurological features are commonly associated and, in retrospect, a
better term might have been 'rapidly progressive encephalopathy'. Secondly, while
cerebellar features are very common in the early phase of sCJD, the 'cerebellar' category
was specifically defined as only those cases with a progressive pure cerebellar
syndrome, without other features, for a period of at least 2 weeks. Thirdly, visual
symptoms and cortical blindness are relatively common features in the course of sCJD,
but 'Heidenhain's' presentation was specifically defined as only those cases with
progressive pure visual features for at least 2 weeks. Finally, the 'progressive dementia'
category was defined as those cases with a relatively slowly progressive cognitive
impairment (without other specific neurological features) that might therefore suggest
dementia diagnoses other than CJD.
The overall most common presentations were, unsurprisingly, a rapidly progressive
dementia and a cerebellar onset, accounting overall for 74% and 9% of sporadic cases,
respectively. Cerebellar onset (which has been termed the Brownell-Oppenheimer form
of sCJD) is well recognized and can pose initial diagnostic difficulties as there a number
of causes of a progressive isolated cerebellar syndrome.11,12 The precise frequency of this
presentation has not been clearly established. Cerebellar features are relatively common
initial or early accompaniments of the typical rapidly progressive encephalopathy so
characteristic of sCJD, but, in this study, we wanted to specifically delineate the pure
cerebellar onset cases.13 Heidenhein's syndrome, another well recognized form of sCJD,
is rare but the true frequency has been uncertain; it accounted for only 4% of cases in
NEUROCJD.14 Visual symptoms and eventual cortical blindness are not uncommon in
typical sCJD, but we concentrated on those cases with a progressive pure visual problem
which can pose diagnostic problems and may lead to initial referral to ophthalmology
services. Presentations with psychiatric or sensory features, that might cause differential
diagnostic difficulty with vCJD, accounted overall for only 3% and 2% of presentations
respectively. Progressive dementia cases (as defined here), with their relatively slow
clinical course and the absence of early non-dementia features may be particularly
difficult to differentiate from other more common diseases. Rather surprisingly, as we
expected them to be exceptionally rare, they represented 6% of all cases. However, this
amounts to only 54 such cases in a total population of around 133 million, over an 8 year
period. Extra-pyramidal and stroke-like presentations were indeed very rare (each being
only 0.6% of cases). Stroke-like presentation was reported in 5.6% of 532 cases of
definite and probable sporadic CJD in the UK but, this was not confirmed in our cases,
prospectively applying an agreed definition15 (Appendix 1).
The significance of different presenting modes of sCJD is uncertain. Of course, if
sCJD results from a spontaneous somatic PRNP mutation or spontaneous PrP protein
misfolding, then it is reasonable to expect a variety of presentations reflecting random
anatomical distributions of the original event (although this would not, in itself, explain
why certain specific presentations are commoner than others). Following Parchi and
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colleagues, the clinical features of sCJD can be correlated, to some extent, with the
associated PRNP codon 129 polymorphism and the PrP protein type.16 However, this
does not explain the clinical variations and we do not have sufficiently complete data
(especially with respect to PrP type) in NEUROCJD to classify the cases in this manner.
Different presentations could conceivably reflect different causes and two recent studies
have reported that surgical procedures are a risk factor for sCJD, suggesting that perhaps
at least some sCJD cases might be iatrogenically acquired.17,18 Therefore, the observed
differences in presenting patterns between countries could be of interest. 
The presentation definitions were agreed by all participants, discussed regularly at
collaborative group meetings and their application reviewed, on a case by case basis, by
two collaborators (PSJ & RK) prior to the final results analysis. However, it is difficult
to be absolutely certain that these variations are definite, especially given the variations
in source material (such as case note review versus direct examination). Further study
would be necessary to confirm these variations.
In 10 cases (1.3% of all sCJD cases from the 11 countries, including the UK), the
clinical presentation was classified as 'other'. This group included the following
presenting features: an isolated progressive hemiparesis, focal seizures, and isolated
dysphasia. These represent very exceptional modes of presentation of sCJD.
Atypical sCJD 
'Atypical sCJD' cases were considered according to three criteria: age at onset <50 years
(27 cases), illness duration >1 year (51 cases), and 'atypical clinical presentation', being
defined as any presentation other than rapidly progressive dementia, cerebellar or
Heidenhein's, (66cases) (Table 7). Onset of sCJD below the age of 50 is a relatively rare
phenomenon, our figure of 27 out of 439 (6%) with available information (UK data
excluded) being in line with previously reported figures and the latest EUROCJD
comparative figure is 5%2,8 (personal communication Sánchez-Juan).
The median duration of illness in this study was 5 months and only 51 out of 418
(12.2%) with available information (UK data excluded) had illness durations of greater
than 1 year, broadly in line with other reports.9,19
Of the 66 that were 'atypical' by virtue of their clinical presentation, illness duration
data were available on 53 and, of these 53, 22 had durations of >1 year. If the 'atypical'
cases presenting with progressive dementia are excluded, then only 10 of them had
durations >1 year. Data on age at onset were available on 56 and, of these 56, only 6 were
<50 years at onset. There were 6 cases in total who were both <50 years at onset and had
illness durations of >1 year; representing 6 such cases out of a total population of around
133 million over 7 years. 
It is obviously important to have neuropathological confirmation particularly in
clinically atypical cases. This was achieved in 78% of those with onset under 50 years
and in 64% of those with atypical clinical presentations; all the cases met the agreed
criteria for 'probable sCJD'.7
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Males and females were represented equally in the 'atypical' cases, although
females were apparently over-represented in those cases with both an atypical
presentation and young age at onset, there were only 6 such cases in total. The
distribution of PRNP codon 129 genotypes in cases with illness onset below 50 years,
showed a relative reduction of MM and a relative increase in MV (compared with the
usual distribution for sCJD). This is in line with previous reports.9 However, the numbers
here are too small for statistical significance (p=0.49), with only 8 of the <50 years onset
group being genotyped. The investigation results in this group are discussed below.
Genetic CJD
Overall, genetic cases accounted for 9% of all TSE cases, which is a slightly lower figure
than that generally reported.20 There was a striking variation between the member
countries. Five countries reported no cases, in 3 countries genetic cases represented from
2.4% to 3.7% of all cases (Belgium, Republic of Ireland, UK), in Finland the figure was
6.9%, in Norway 11.4% and in Israel, 66.4% (Table 8). Israel was already recognized to
have a high incidence of genetic cases.21 Although the differences among countries were
highly significant (p<0.001) there may represent the presence of founder mutations.
PRNP genotyping is required for the absolute distinction of gCJD from sCJD as a
positive family history is not always present in genetic cases.20 This can be performed on
a simple blood sample and it also allows for the PRNP codon 129 genotype to be
determined, which may be important in the characterization of atypical cases, and for
research purposes. Genetic analysis is available in 6 countries. In other countries,
samples have been analyzed through the collaborative project, where necessary and
possible.
Variant CJD
One important aim of the NEUROCJD collaboration was the identification of any cases
of vCJD in the 10 non-UK countries. It is, of course, impossible to state with absolute
confidence that no cases of vCJD were missed in the 1997-2004 period. However, with
the individual surveillance systems operating, the collaborative mechanisms of
NEUROCJD and the discussion of any atypical cases, there is a high degree of
confidence that vCJD did not occur in any of the 11 countries outside of the UK and
Ireland. The single case in Ireland is detailed in the results section above.
This analysis relates to the 1997-2004 period, but in 2005, a case of vCJD was
identified in Portugal; the Portuguese surveillance system and the NEUROCJD
collaboration successfully identifying the case. A further three cases have been
identified in Ireland since 2004; one case considered as contracting the illness while in
the UK, but two cases being regarded as truly intrinsic to Ireland. 
Investigations
The EEG has been an important part of the investigation of suspect CJD cases, mainly
because a characteristic periodic pattern is seen in the majority, but not all, of sporadic
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cases. This finding has been incorporated into the internationally accepted clinical
diagnostic criteria.7,22,23 In practice, the EEG has become significantly less important in
case classification since the incorporation of the CSF 14-3-3 test into the diagnostic
criteria. In our study, the EEG showed the characteristic changes in around 45% of all
sporadic cases (Table 5) which is broadly comparable with figures from other studies. In
a study of 29 cases from Germany, with repeated EEGs being undertaken, periodic
activity was found in 67%.22 In a further study from a grouping of countries involving
over 2000 cases, the EEG showed such changes in 58.4%.23 There are variations between
the collaborating countries from 30% to 81% of cases with typical EEGs (ignoring
Iceland, with only one case in total). This almost certainly reflects different testing
policies, repeat EEGs being undertaken with different frequencies in different countries,
partly according to how much reliance is placed on EEG rather than CSF 14-3-3. The
EEG is generally less useful in atypical CJD so it is notable that characteristic changes
were seen in about the same percentage of our 'atypical' cases, at 44% (Table 7) (although
in none of the 5 cases with both atypical presentation and young age of onset).16,23
CSF 14-3-3 has been found to be sensitive and specific for sCJD (provided testing is
undertaken in a carefully selected context).23,24 14-3-3 testing has been established in
most of the NEUROCJD countries. For small population countries, with relatively few
suspect cases, it is possible for samples to be sent to laboratories elsewhere in
particularly important cases. 14-3-3 testing has potential technical difficulties and it is
important that any laboratory providing such a service should have sufficient numbers
of samples to gain and maintain experience. Laboratories therefore tend to be
established on a national basis (as is true for the NEUROCJD countries). Exchange of
samples and comparison of experience is important to maintain standards. The
NEUROCJD collaboration has allowed and encouraged these practices. Referral of
cases for 14-3-3 testing is, of course, another means of case ascertainment. Within
NEUROCJD, close collaboration between the laboratory service and the surveillance
system has proved invaluable. 14-3-3 was positive in 92% of our cases (Table 5), overall
which is in line with previous reports.24 There was some statistically significant variation
between countries (p=0.04), with the lowest figure being 78% in Sweden. Interestingly,
the 14-3-3 test was similarly useful in our 'atypical' cases, with around 90% showing
positive results (Table 7).
A vital role of the MRI in the investigation of suspect cases is in the exclusion of other
possible diagnoses. In sCJD, certain relatively specific features have been described, but
the MRI has not yet been incorporated into the standard diagnostic criteria.25,26 In variant
CJD, however, very characteristic changes have been found in around 85% of cases.27
The changes may be relatively difficult to reliably identify and requires an update of the
radiologist. An international collaboration allows for more experienced countries to
review suspect scans in situations of uncertainty. Overall, 34% of our sCJD MRI scans
showed characteristic changes, although there were highly significant variations
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(p<0.001) between countries, from 6-69% of cases (Table 5). These variations in
sensitivities will reflect the use of different MRI sequences, differential policies
concerning repeat studies in individual cases and the increased understanding over time
of the changes characteristic of sCJD.
In this article we summarize the design and characteristics of the extended
collaborative study group of CJD 'NEUROCJD', and the results of their monitoring
activities during an 8-years period. Relevant methodological issues and the main
problems encountered are discussed. We describe our experience and results focusing on
the clinical presentation of sCJD and the atypical subtypes. VCJD cases in Ireland and
in Portugal were successfully detected by their national surveillance systems. 
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Appendix: classification of presenting symptoms
The following is an attempt to classify the different modes of presentation. Since it may
not be possible to accurately classify a particular case, if the case does not clearly fit one
of the specified categories then the code 8 'missing' value should be used.
Code 0: rapidly progressive dementia
The majority of cases will probably be in this category. The precise presenting symptom
will vary from case to case, but the picture is an encephalopathic illness with dementia
(and other neurological features), progressing rapidly over weeks to a few months, with
no individual cognitive or physical deficit being present alone for more than two weeks.
Code 1: slowly progressive dementia
These cases present with a slowly progressive dementia, developing over months to
years, without any other significant neurological features for the first six months.
Code 2: cortical blindness (Heidenhain)
These cases present with impairment of visual acuity and/or field, progressing onto
cortical blindness, without other significant clinical deficit for the first two weeks of
illness. The visual symptoms might include visual loss, visual inattention, visual
illusions and visual hallucinations. It is essential that the symptoms progress to cortical
blindness. Cases with other onsets that progress to include cortical blindness are not
included in this category.
Code 3: psychiatric onset
These cases present with psychiatric symptoms such as depression, anxiety, paranoia,
and delusions, without the presence of other features for a period of at least four weeks.
Non-specific malaise or apathy do not count unless accompanied by some of the above
symptoms. Visual or auditory hallucinations alone do not count, but may accompany the
above features.
It may be difficult to distinguish between the early features of dementia and a more
specifically psychiatric onset. Behavioural change straightforwardly due to a developing
dementia is not included in this category. The essential characteristic of this presentation
is that the patients present with a disturbance that suggests a psychiatric disturbance
rather than an obvious dementia and that specifically neurological features are absent.
Code 4: cerebellar onset
The presentation is with a progressive cerebellar syndrome without other significant
features, for at least two weeks.
Code 5: extrapyramidal onset
The presentation is with an extrapyramidal syndrome involving Parkinsonian features
with or without chorea, athetosis or dystonia, but without other significant features for
at least two weeks.
Code 6: stroke-like onset
The presentation is abrupt enough for a diagnosis of stroke to be entertained in the initial
stages.
Code 7: other
None of the above described presentations is applicable.
Code 8: missing
There is no clear clinical information available or the information does not allow a
definite classification according to the above criteria.
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2.2
The first case of variant Creutzfeldt-Jakob disease in
the Netherlands
Abstract
As of July 2006, 191 cases of variant Creutzfeldt-Jakob (vCJD) disease have been
identified. We report the first case of vCJD in the Netherlands. The patient was a young
Dutch woman who had never traveled to the United Kingdom (UK). The brain MRI scan
played a fundamental role in the clinical diagnosis. After death the diagnosis was
confirmed by neuropathological examination and western blot analysis of the brain. The
clinical characteristics of the patient, MRI scan images, neuropathological study, PrPSc
western blot profile and PRNP M129V genotype, were all indistinguishable from that
reported in UK vCJD patients. The identification of this patient had important public
health implications for the country.
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Introduction
In 1996, a new variant of Creutzfeldt-Jakob disease (vCJD) linked to the cattle bovine
spongiform encephalopathy (BSE) epidemic was described in the United Kingdom
(UK).1,2 Up until now, 191 cases have been reported worldwide. Most of these cases have
occurred in the UK (n=159), but in recent years vCJD has been identified in a number
European countries with indigenous outbreaks of BSE, including 18 cases in France,
four in Ireland, two in the Netherlands and single cases in Portugal, Italy and Spain.
However, a growing number of cases of vCJD have also been identified in countries
outside Europe including Japan (n=1), the United States (n=2) and Canada (n=1) and
also in Saudi Arabia (n=1), in which BSE has not been identified. A number of the non-
UK cases, including two Irish, the Canadian, the two US cases, and possibly the
Japanese case, may well have been infected during periods of residence in the UK, but
the majority of cases (n=25) occurring outside the UK, like the two cases happened in
the Netherlands, had never visited the UK.3 In this study we describe the first patient
identified with vCJD in the Netherlands.4
Case report
The patient is a 26-year-old woman with previous medical history of two abortions in
1996 and in 1998 and psychiatric history of anxiety and a phobic disorder since 1999.
However, one year previous to the vCJD disease onset, she had completely recovered
from her psychiatric problems and was able to function normally. She worked in a
catering and food-processing business for 6 years, from 1998 to the disease onset. She
consumed all types of meat frequently, including raw meat, and particularly processed
meat products. She had no history of neurosurgical procedures, hormonal treatments, or
tissue or organ grafts, and she had never received or donated blood. She never traveled
to the UK. She had no family history of dementia or any other neurodegenerative
disorder. 
From November 2003, the patient developed new psychiatric symptoms,
particularly anxiety and aggressive behavior. In spring 2004, the family also noticed
some forgetfulness. A few months later, the psychiatric symptoms worsened. She
suffered from panic attacks, became very dependent and apathetic, and showed
regressive behavior. She also had visual hallucinations in which she saw animals. In July
2004, two weeks after a dental extraction, she started complaining of severe facial pain
in her upper jaw. Her dentist examined her but no organic cause was found. At that point
she was seen by a psychiatrist who suspected that she was suffering from anxiety and a
conversion disorder. 
In September 2004, the patient developed involuntary movements of her right foot,
with dystonic eversion-inversion posturing and occasionally some jerking movements.
She also developed paraesthesiae in the lower limbs and gait difficulties, especially
when walking in the dark. In November, the family also noticed dysarthria and problems
in the motor coordination of the upper limbs. She had several episodes of blurring of
vision. During this period, she was twice hospitalized in a psychiatric ward because of
increasing anxiety, regressive behavior and facial pain.
From January to March 2005 the involuntary movements worsened significantly,
accompanied by generalized stiffness, now involving all extremities. In March the
patient was again hospitalized in a psychiatric ward with the clinical diagnosis of a
conversion disorder, and treatment with Haloperidol was started. Two days later she
suffered a tonic-clonic seizure followed by hyperthermia that required admission to an
intensive care department. No cause was found for the persistent high temperature, and
the neuroleptic medication was withdrawn. The patient was treated for malignant
neuroleptic syndrome without success. The neurological state of the patient worsened
rapidly.
On neurological examination she was mute, opened her eyes to verbal stimuli but
there was no visual fixation. She had variable extrapyramidal rigidity in the extremities
with dystonic movements of the hands and feet, and she had a positive Babinski sign in
her right foot. Routine laboratory examinations only revealed mild increases of the
aspartate aminotranspherase (ASAT) and creatine phosphokinase (CPK), which later
normalized. The cerebrospinal fluid was normal, and 14-3-3 protein was not detectable.
Tau protein determination in CSF was performed after the referral of the patient to the
CJD registry, and it showed abnormally high levels (1314 ng/l). The electroen-
cephalogram showed generalized slowing, more evident in the left hemisphere, but
without any periodic complexes. Brain MRI showed symmetrical hyperintensities in the
pulvinar and the dorsomedial nuclei of the thalami on T2- and fluid-attenuated inversion
recovery (FLAIR)-weighted images (Figure 1). Genotyping of the prion protein gene
(PRNP) identified no mutation and homozygosity for methionine at codon 129.
Following the current WHO criteria, the patient was diagnosed in life with probable
vCJD based on the clinical features, laboratory findings, brain MRI images and PRNP
genotyping.5 In May 2005 the patient died, and the diagnosis was confirmed by post
mortem neuropathological examination of the brain, which showed typical features of
vCJD, including florid plaques (Figure 2). Western blot analysis of unfixed brain tissue
showed a characteristic type 2B PrPSc isoform (Figure 3).
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Figure 1: FLAIR-weighted images of the brain MRI study, showing bilateral symmetrical regions of hyperintensity
in the pulvinar and the dorsomedial nuclei of the thalami ('hockey stick sign').
Figure 2: Neuropathology of variant CJD:
A. A florid plaque surrounded by small areas of spongiform change in the occipital cortex (Luxol-PAS stain).
B. Multiple small cluster plaques in the occipital cortex (Luxol-PAS stain).
C. A kuru-type plaque in the cerebellar cortex (Luxol-PAS stain).
D. Immunohistochemistry for prion protein (using monoclonal antibody 3F4) shows strong staining of plaques
in the occipital cortex, along with amorphous and pericellular deposits.
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Figure 3: Western blot analysis of protease-resistant prion protein in this patient (Case) shows an identical pattern
of glycosylation and size of the unglycosylated fragment (lowest band ~ 19Kd) to a control case of vCJD (Type 2B),
which is markedly different from a case of sporadic CJD (Type 1). (Reproduced with permission of Prof. Dr. A.J.P.M.
Overbeke editor of NTVG4).
Discussion
Non-UK cases of vCJD may potentially have been infected during a period of residence
in the UK in the 1980s and early 1990s (for example the US and Canadian cases). Our
patient had never traveled to the UK, but may have been exposed through either
indigenous BSE infected animals or BSE infected exports from the UK to the
Netherlands during the 1980s and early 1990s. Thus far, all non-UK cases of vCJD who
had never previously visited the UK show disease characteristics analogous to the UK
cases. The clinical features, PRNP codon 129 genotype, neuropathological findings and
western blot PrPSc isoform of our patient are indistinguishable from the United Kingdom
vCJD cases, pointing towards a common etiological agent.
The Netherlands CJD surveillance system is part the EUROCJD group, a EU-
funded network established in 1993 with the aim of monitoring the disease incidence
and detecting new vCJD cases.6 In the Netherlands, only 80 BSE cases have been
reported.7 The first case of variant CJD diagnosed in the Netherlands highlights the
importance of continuing multinational surveillance of human prion diseases, even in
countries with a low BSE incidence, as a matter of fact, during the preparation of this
manuscript a second probable vCJD case has been ascertained in our country.8
The early detection of vCJD patients is crucial as there are major public health
implications, including of tracing of blood products from patients who were blood
donors and tracing of surgical instruments, in this case dental instruments. Despite of a
long disease course (18 months) the diagnosis in this patient was particularly difficult
due to the past psychiatric history. The brain MRI findings played a crucial role in the
diagnosis by the treating neurologist (J.I.H.). This triggered the notification to the CJD
registry in Rotterdam. This case report underscores the value of the MRI in the diagnosis
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of vCJD and the need for an increased awareness of radiologists and neurologists of the
MRI findings in vCJD, including in countries with a low incidence of BSE.
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3
Aetiological aspects of 
Creutzfeldt-Jakob disease
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3.1
What is the source of variant 
Creutzfeldt-Jakob disease outside the UK?
Abstract
A growing number of cases of variant Creutzfeldt-Jakob disease (vCJD) in countries
outside the United Kingdom (UK) are being identified. The correlation between the
number of vCJD cases and that of indigenous bovine spongiform encephalopathy (BSE)
is low, raising the question whether the spread of vCJD is rather due to import products
from the UK. We have analysed the occurrence of vCJD cases outside the UK in rela-
tion to the level of imported bovines and bovine products from the UK from 1980 to
1990. Our studies suggest that the numbers of live bovine imported from the UK corre-
lates to the occurrence of vCJD cases outside the UK as good if not better than that with
indigenous BSE cases. An important lesson from a public health perspective is that
imports of livestock and bovine products from the UK have contributed substantially to
a global spread of vCJD.
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Introduction
In 1996 a new variant of Creutzfeldt-Jakob disease (vCJD) was described in the United
Kingdom (UK).1 By August 24th 2006, 196 cases had been reported worldwide, with the
majority (83%) (n=162) occurring in the UK. Laboratory and epidemiological studies
have yielded convincing evidence for a causal link between vCJD and the bovine
spongiform encephalopathy (BSE) epizootic in cattle2, 3 with the likely route of primary
human infection through dietary exposure to bovine tissues containing high levels of
infectivity.3
In recent years vCJD has been identified in a number European countries with
indigenous outbreaks of BSE, including 20 cases in France, four in Ireland, two in the
Netherlands and single cases in Portugal, Italy and Spain. However, a growing number
of cases of vCJD have also been identified in countries outside Europe with a minimal
incidence of BSE including Japan, the United States and Canada and also in Saudi
Arabia, in which BSE has not been identified.4 A number of the non-UK cases, notably
two Irish, one Canadian and two US cases, and possibly the Japanese case, may have
been infected during periods of residence in the UK, but the majority of cases (28 out of
34) occurring outside the UK had never visited the UK. On the other hand, although
vCJD cases have occurred in countries with very low incidence of BSE, no cases have
been reported in countries with higher incidence of BSE such as Switzerland (460
reported cases of BSE) and Germany (395 cases).5 Thus, there is a rather poor
correlation between the incidence of indigenous BSE and the incidence of vCJD in some
countries, raising questions as to the source of infection in the cases outside the UK.
Were they exposed to infectivity derived from indigenous cases of BSE or to infected
bovine material imported from the UK? An analysis of infection risk in France suggests
that the most likely source of vCJD in that country is the import of infected material
from the UK,6 while in the Republic of Ireland the transmission of BSE to humans was
estimated to be equally likely from indigenous BSE or from UK imports.7 Given the
apparently weak association between the occurrence of indigenous BSE and vCJD in
some countries, we studied the occurrence of vCJD cases outside the UK in relation to
the level of imported bovines and bovine products from the UK from 1980 to 1990.
Methods
An EU surveillance network, established in 1993, assures prospective surveillance for
CJD using standard methods8 in 18 European countries and the USA, Canada, Israel and
Australia. By 24th August 2006, 32 cases of vCJD had been identified in these countries
(excluding the UK) (Table 1).A further two cases had been identified in countries
outside the Surveillance network (in Japan and Saudi Arabia). Cases in Canada (n=1),
the USA (n=2), Ireland (n=2), and possibly Japan (n=1) were considered as likely to
have been infected during their period of residence in the UK. 
Table 1: Worldwide vCJD cases up to August 2006
*Most likely exposed to BSE in the UK.
Data on indigenous BSE cases detected by both passive and active surveillance
were obtained from the World Organization for Animal Health web page
(http://www.oie.int/eng/info/en_esbmonde.htm).5 The number of live cattle and the
tonnage of carcase meat exported from the UK were derived from UK Custom and
Excise Data.9
We have included in our analysis all countries covered by the EU surveillance
network. As the exposure was expressed as a total amount rather than per capita, we
performed the analysis based on number of vCJD cases rather than rates. We plotted the
incidence of vCJD (number of cases) by country against (1) the number of cases of
indigenous BSE, (2) the numbers of live bovines imported from the UK from 1980 to
1990 and (3) the tonnage of carcase meat imported from the UK during the same period
of time. In the analysis we included only the non-UK vCJD cases that are thought likely
to have been infected outside the UK. A factor likely to be important for BSE exposure
is the temporal distribution of UK exports. It has been estimated that the number of BSE
infected cattle entering the human food supply peaked in the UK around 1989,7 although
with respect to exports peak exposure may have been later, around 1992-1993. For
example, although Germany imported the second greatest tonnage of carcass meat
globally, 85% of these imports were before 1988. In contrast, 70% of the live stock
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Country of residence at 
disease onset
N
UK 162
France 20
Rep. of Ireland 2+2*
Italy 1
USA 2*
Canada 1*
Saudi Arabia 1
Japan 1*
Netherlands 2
Portugal 1
Spain 1
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imports to the Netherlands were between 1987 and 1990. To account for this factor we
weighted the number of live bovines and the carcase meat tonnage imported each year
by the size of the UK BSE epizootic that year (reported clinical cases). Non-parametric
Spearman's rank correlation coefficients (rs) were calculated to evaluate whether there
was evidence of a correlation between exposure and outcome.
In order to assess the independent effects of each of the exposure sources we fitted
a Poisson regression model with number of cases of indigenous BSE, numbers of live
bovines imported from the UK, and the tonnage of carcase meat imported from the UK,
the last two variables with the weighting described above. We included in the Poisson
analysis all EU network countries. 
Results
Figure 1 shows a scatter plot of the number of cases of indigenous BSE in non-UK
countries and the number of non-UK vCJD cases per country. There is strong evidence
of a correlation between these two variables (rs=0.7; 95% CI 0.37 to 0.87; p=0.001) in
the countries belonging to the EU network (Table 2). However, when we include in our
analysis Japan and Saudi Arabia as well, the only two countries outside the EU network
where vCJD cases have been detected, the correlation coefficient drops substantially
(rs=0.55; 95% CI 0.17 to 0.79; p=0.008) (Table 2). Figure 2 shows a scatter plot of live
bovine imports from the UK and non-UK vCJD cases by country. The correlation
between these two variables is high in EU network countries (rs=0.73; 95% CI=0.42 to
0.89; p<0.001). Including Japan and Saudi Arabia results in a slightly lower estimate
(rs=0.65; 95% CI=0.31 to 0.84; p=0.001) (Table 2). Figure 3 shows a scatter plot of the
tonnage of carcass meat imports from the UK and the number of non-UK vCJD cases
by country. The correlation between these two variables is also high in EU network
countries (rs=0.65; 95% CI=0.29 to 0.85; p=0.002). When we include Japan and Saudi
Arabia in the analysis, we obtain very similar results (rs=0.67; 95% CI=0.35 to 0.85;
p=0.001) (Table 2).
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We evaluated whether our findings were dependent on the data from France, which
has the largest number of non-UK cases. We repeated the analyses excluding France: all
three correlation coefficients remained statistically significant (Table 2). We also
repeated the analysis including the 6 cases detected outside the UK but thought to have
been infected in the UK. The inclusion of these cases resulted in a reduction in all three
correlation coefficients (Table 2). To analyse the independent effect of each of the three
exposure sources we fitted a Poisson regression model including all EU network
countries. When all three variables were included in the model, there was some evidence
that both the number of live bovine imported from UK (p=0.04) and the number of
indigenous BSE cases (p=0.001) were associated with the number of vCJD cases, but no
evidence of an association with imports of carcase meat from the UK. When we included
in the model Japan and Saudi Arabia, the association between number of vCJD cases and
the same two variables (live bovine (p=0.05); indigenous BSE (p=0.02)) remained of
statistical significance.
Discussion
The data suggest that live bovine imports from the UK from 1980 to 1990 correlate with
the numbers of vCJD cases in countries outside the UK. Specifically, the correlation
between vCJD cases and live bovine imports may be as good if not better than
correlation with indigenous BSE cases, suggesting that live bovine imports from the UK
may have been an important source of exposure in at least some of the countries where
vCJD have been detected. These results are consistent with an analysis of French data
suggesting that UK bovine imports were likely to have been a more important source of
infectivity than indigenous BSE.6 Thus, a proportion of cases observed to date outside
the UK may have been infected by imports from the UK rather than by exposure to
indigenous BSE.
The inclusion in the analysis of the 6 non-UK cases thought to be infected in the
UK reduced all three correlation coefficients, as one would expect if the supposition that
they were infected in the UK is correct. 
These findings come with a number of important caveats attached. First, they are
based on small numbers of vCJD cases. Even a small number of additional non-UK
cases in future could alter the findings substantially. Second, the analyses of imports are
based on UK Customs and Excise data, and not all of which been validated by importing
countries. Even if these data are reasonably accurate, the actual level of BSE infectivity
entering the human food chain in importing countries cannot be estimated as there are
many important unknown variables such as the age distribution of imported live bovines,
the age at slaughter of these animals, the culinary habits in each country and the
possibility that some of the UK imports may have been re-exported to other countries.
Third, a proportion of indigenous BSE-infected cattle will have gone undetected until the
introduction throughout the EU of the active abattoir testing program for BSE in
2000/2001; and even now cattle in the early stages of infection are unlikely to be detected.
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It is also of interest that none of the 162 UK cases of vCJD identified up to August
2006 were born after 1989, the year in which the specified bovine offal ban was
introduced to minimize human exposure to BSE, while two of the 34 non-UK vCJD
cases have dates of birth after 1989. Measures equivalent to the UK SBO ban were not
introduced in many continental European countries until 2000. 
Despite these caveats, our results support that, globally, imports from the UK may
have been an important source of infection, and for some countries they even may have
been the main source. If this is so, our findings have a number of implications: (1) past UK
exports, and in particular export of live bovines, may be the major determinant of the
current incidence of vCJD outside the UK. (2) The greatest volume of these exports was
to France, the Netherlands and Ireland. (3) Outside the UK, exposure to BSE via imports
from the UK ceased in 1996, while exposure to indigenous BSE is likely to have continued
at some level until the measures introduced in 2000. 
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3.2
Ophthalmic surgery and Creutzfeldt-Jakob 
disease 
Abstract
This paper reviews the data on ophthalmic surgery in sCJD and vCJD from the archives
of the National CJD Surveillance Unit from 1990-2002, including information on both
sporadic and variant Creutzfeldt-Jakob disease (CJD) .We did not find evidence of any
association between past history of ophthalmic surgery and risk of either sporadic or
variant CJD. One interesting finding in our study is that sporadic CJD patients with early
visual symptoms are often referred at first to ophthalmologists, and not infrequently they
are diagnosed with cataracts and often treated. The information included in our study is
of potential interest for ophthalmologists and public health. 
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Introduction
The occurrence of variant Creutzfeldt-Jakob Disease (vCJD) and the probable causal
link with bovine spongiform encephalopathy in cattle have increased interest in the
search for possible environmental sources of sporadic CJD (sCJD). Iatrogenic CJD is
rare. Up to the year 2000 there had been 267 cases reported worldwide: 3 cases
secondary to human corneal grafting (one confirmed, one probable and one possible
case), 114 related to human dura mater grafts, 139 related to human growth hormone
treatment, 4 related to human pituitary gonadotrophin therapy and 7 linked to
neurosurgical procedures or stereotactic EEG electrodes.1
Because of the marked resistance of the infectious agent of CJD to conventional
sterilisation techniques, there is concern about the possibility of transmission of
infection via surgical instruments in contact with infected tissue, especially in
neurosurgery or ophthalmic surgery. Other forms of surgery have also been putatively
linked to iatrogenic CJD with epidemiological studies showing that a history of past
surgical interventions may be a significant risk factor for sCJD.2,3 In vCJD the presence
of prion protein (PrP) immunostaining in systemic lymphoreticular tissues suggests that
the risk from contaminated surgical instruments may be greater than in sCJD, in which
these tissues do not stain for PrP.
In addition to the iatrogenic cases of CJD related to corneal grafts, there is
experimental evidence of infectivity in eye tissues in CJD patients. The infectious form
of PrP, PrPSc , has been found in the retina of sCJD and vCJD cases with comparable
levels to those found in brain.4 Intracerebral inoculation of pooled CJD eye tissue in
nonhuman primates transmitted the disease,5 as did inoculation of infected cornea in the
anterior chamber of uninfected guinea pigs.6 Although, to our knowledge there have not
been documented cases of CJD secondary to ophthalmic surgery other than corneal
transplantation, there is a possibility that ophthalmic surgery might be a risk procedure
for the accidental iatrogenic transmission of CJD. Because the levels of infectivity in
prion diseases increase to high levels in the brain, and probably the eye, late in the
incubation period, cases of CJD undergoing eye surgery during the clinical illness are
most likely to represent the greatest risk of contaminating surgical instruments.
Recently it has been shown that the experimental transmission of metallic suface-
bound prions is highly efficient.7 Steel wires in contact with the brain of pre-
symptomatic mice needed only 5 minutes to acquire an infectious load equivalent to the
injection of a 1% homogenate of brain. Infected wires were inserted transiently into the
brains of indicator mice and only 30 minutes of exposure was sufficient to result in
infection. The same wires remained infective when reintroduced into another set of
indicator mice. 
The evidence from laboratory studies underlines the importance of precautions to
minimise the risks of iatrogenic transmission of CJD, but an important question is
whether the concerns raised by experimental work translate into an actual risk in the
clinical setting. This paper reviews the data on ophthalmic surgery in sCJD and vCJD
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from the archives of the National CJD Surveillance Unit from 1990-2002, including
information on both sCJD and vCJD.
Methods
We have analysed the past surgical history of sCJD and vCJD cases with specific
reference to ophthalmic surgery. Cases of CJD were identified in the current prospective
UK national surveillance project (1990-October 2002) by direct notification or from
death certificates (see reference 8 for detailed methodology) and were classified as
definite, probable or possible cases of sCJD or vCJD according to published diagnostic
criteria. Only definite or probable cases were included in this analysis. All cases with a
history of ophthalmic surgery were identified from the database, which has a specific
code for this type of surgery. Information on past ophthalmic surgery was obtained from
relatives, general practitioner records and/or copies of case notes. Case files were
examined to identify the type of surgery, date of surgery and hospital in which the
surgery had taken place. In cases in which the surgery was carried out after the onset of
clinical symptoms of CJD detailed information on the clinical course was extracted.
The frequency of a history of eye surgery in sCJD and vCJD was compared with
data on the frequency of past eye surgery in age and sex-matched control groups. During
the period of the study the case-control study has evolved. Between 1990-1998 a single
hospital control was obtained for the sCJD cases and from 1999-2002 a single
community based control was identified. From 1996-2002 a single hospital control was
obtained for vCJD cases and since 1998 attempts have been made to obtain 4 community
based controls per case of vCJD. Because of the limited numbers of controls in sCJD
and the infrequency of past eye surgery this study reports on unmatched comparisons of
the frequency of past eye surgery.
Results
58 cases of sCJD (11%) out of 510 with information available had a history of intraoc-
ular surgery, with an average of 1.34 interventions per patient. The types of operation in
the total of 81 cases having undergone any form of ocular surgery are listed in Table 1
and the years of operation in Figure 1. Eight patients with vCJD (6%) out of 125 with
information available had a history of eye surgery and all were squint corrections in
childhood, with the exception of one case with a history of surgery for retinal detach-
ment carried out 15 months before the development of symptoms.  Ten cases of sCJD
underwent eye surgery during the prodromal (within 3 months of onset) or early symp-
tomatic phase of the disease, the majority cataract operations. Four out of these 10
patients had the Heidenhain variant of sCJD, with visual onset and early development of
cortical blindness (Table 2). Below are three illustrative case reports.
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Table 1: Types of operation
*Cataract, Trauma and Glaucoma
Figure 1: Year of eye surgery in sporadic CJD.
Cases
(n=78)
Hospital Controls
(n=39)
Community
Controls
(n=20)
Intraocular surgery* 55 (70%) 29 (74%) 17 (85%)
Extraocular surgery 17 (22%) 6 (16%) 3 (15%)
Laser Therapy 4 (5%) 2 (5%) -
Information not available 2 (3%) 2 (5%) -
Table 2: Sporadic CJD patients with ophthalmic surgery after clinical onset
Case 3
A 78 year-old woman presented with deteriorating vision. Two years previously she had
undergone a right cataract extraction, and her recent visual symptoms were attributed to
maturation of the untreated left eye cataract. This was operated on without improvement
in vision. Post-operatively her general condition deteriorated rapidly, with the
development of dementia, incoordination, cortical blindness, rigidity and mutism. Apart
from mild anaemia, investigations were normal. EEG was abnormal, but not
characteristic of CJD. She died two months after the onset of symptoms. At post mortem
examination of the brain the characteristic changes of sCJD were identified.
Case 8
A 73 year-old woman presented with blurred vision, photophobia and occasional double
vision. She was referred by her GP to an eye clinic and underwent left eye cataract
extraction. After the operation she developed confusion and memory loss and was
admitted to hospital.  She subsequently deteriorated rapidly with the development of
myoclonic jerks and on examination cortical blindness was noted. CT scan was normal.
EEG showed the 'characteristic' appearances of CJD and 14-3-3 protein in the
cerebrospinal fluid was positive. She died in a state of akinetic mutism and post-mortem
examination confirmed sCJD. Genetic analysis showed methionine homozygosity at
codon 129 of the PrP gene.
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Date of Surgery Intervention Heidenhain
Variant
Diagnosis
Case 1 1992 Cataract Definite
Case 2 1992 Laser Therapy * Definite
Case 3 1992 Cataract * Definite
Case 4 1993 Cataract Definite
Case 5 1996 Cataract Definite
Case 6 1998 Dacryocystorhinostomy Definite
Case 7 1998 Cataract Definite
Case 8 1999 Cataract * Definite
Case 9 1999 Laser Therapy * Definite
Case 10 2000 Cataract Definite
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Case 9
A 73 year old woman presented with bilateral progressive visual deterioration and
occipital headache. She had had two cataract operations a few years earlier. On
examination she had bilateral thickened posterior capsules, and a laser capsulotomy was
performed. Her eyesight worsened and she developed visual hallucinations. She became
confused and agitated. Examination showed cognitive impairment, extrapyramidal
features and a supranuclear gaze palsy. MRI was normal, EEG was characteristic of CJD
and the 14-3-3 protein was positive. She died 7 months after the onset, and the post
mortem examination confirmed sCJD. Genetic analysis showed methionine
homozygosity at codon 129 of the PrP gene.
The frequency of past eye surgery was compared with the control groups in sCJD
and vCJD (Table 3). In the hospital control group for sCJD, 31 (14%) out of 226 had a
history of ophthalmic surgery, with an average of 1.25 procedures per patient and in the
community control group for sCJD 14 (13%) out of 106, with an average of 1.43
procedures per patient. In the hospital control group for vCJD (15%) 10 out of 67 had a
history of ophthalmic surgery and in the community control group for vCJD 5 (3%) out
of 155 had had eye surgery. There were no significant differences between the
frequencies of past eye surgery between the cases and any of the control groups.
Details of the year and hospital of each surgical procedure were listed and in the
great majority there was no temporal or geographic link between operations. A group of
6 cases of sCJD had been operated on in one hospital and in 2 pairs of cases the
procedures had been carried out in the same year. Enquiry about the specific dates of
these procedures, however, indicated that the operations had been carried out months
apart. 
Table 3: Past eye surgery in sporadic CJD compared with control groups
Cases
(n=510)
Hospital Controls
(n=226)
Community
Controls
(n=106)
Patients with eye operations 58 (11%) 31 (14%) 14 (13%)
Total number of operations 78 39 20
Average per patient 1.34 1.26 1.43
Figure 2: Interval in years between last eye surgery and onset of symptoms in sporadic CJD.
*In four cases information was not available.
Discussion 
The aim of this paper is to document the frequency of past eye surgery in CJD and to
determine whether there is evidence of transmission of CJD through contaminated
ophthalmic instruments. About 10% of cases of sCJD have a history of eye surgery, of
which about 70% involved open surgery on the anterior chamber of the eye. In the great
majority of cases the surgical instruments were re-used on subsequent patients, usually
because CJD developed years after the original procedure. Despite this, the evidence in
this paper does not suggest that there is onward iatrogenic transmission of sCJD through
eye surgery, a finding consistent with some previous studies.2,9
An important question is whether cases of CJD caused by this type of transmission
would be identified by this study. The clinicopathological features and incubation period
of iatrogenic CJD vary according to the route of transmission, with, for example, a
cerebellar syndrome and only limited cognitive impairment in human growth hormone
related CJD. In CJD caused by corneal transplantation the clinical and pathological
phenotype is similar to sCJD and the incubation periods in the 3 cases were 15 months,
18 months and 30 years.10,11 The surveillance system for CJD in the UK is efficient at
identifying cases as judged by annual incidence rates of sCJD around 1 case per million
and it is likely that cases with a typical phenotype would be identified. The period of
observation of CJD from 1990-2002, with additional information from 1980-1989,
suggests that there is the potential to identify case-to-case transmission through past eye
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surgery, on the assumption that the incubation period of such cases would be months or
years rather than decades.
The data from our case-control study shows no significant risk related to a past
history of eye surgery in sCJD in comparison to two control groups. The methodology
of the case-control study in our analysis is not ideal. There is a deficit in the numbers of
controls in comparison to the numbers of cases and an unmatched analysis was
undertaken. The results of our study are consistent with the results of a previous case-
control study in Europe,2,9 but contrast with the results of an Australian study in which
prior cataract/eye surgery was associated with an over 6-fold increase in the risk of
sporadic CJD.3 The studies used different types of control group, the European study
hospital controls and the Australian study community controls. However, in a reanalysis
of the European data using a community control group eye surgery was again found not
to increase the risk of sporadic CJD. The disparity in outcome in the two studies relates
primarily to the frequency of prior eye surgery in the control groups (European studies
34/406, 37/325: Australian 24/784) rather than the cases (European studies 33/401,
37/328: Australian 24/241). Although this type of study cannot exclude the possibility
of rare instances of iatrogenic transmission of CJD through eye surgery, the balance of
evidence does not support the hypothesis that exposure to potentially contaminated
ophthalmic instruments is a significant risk for developing CJD. 
Evidence of transmission of sCJD through contaminated neurosurgical instruments
rests on the close temporal relationship between operations carried out on CJD cases and
unaffected individuals who subsequently developed CJD.12,13 An analysis of the dates and
sites of eye operations in cases of sCJD in this study showed no such relationship. The
elegant experiments by Weismann et al7 raise the possibility that surgical instruments
contaminated during neurosurgery might pose a significant risk of iatrogenic
transmission. In this context it is of interest that a number of cases of sporadic (and
iatrogenic) CJD have undergone brain surgery (12/400 cases in the European study), but
there is no evidence from case-control studies that prior neurosurgery increases the risk
of developing sporadic CJD. This is despite the fact that potentially contaminated
neurosurgical instruments have inadvertently been reused on other patients on a number
of occasions.
The data on vCJD is limited and the period of observation is shorter than in sCJD.
Although there is currently no evidence of transmission of vCJD through contaminated
ophthalmic instruments, this possibility cannot be excluded, not least because the
incubation period in vCJD is unknown.
The 10 cases of sCJD undergoing eye surgery in the early clinical stages of the
illness may represent the greatest risk of onward transmission of infection, because there
are probably higher levels of infection in the eye late in the incubation period due to
centrifugal spread of infection along the optic nerve.4 The diagnosis of sCJD can be very
difficult in the early stages of the clinical illness and this is particularly true of cases with
isolated cortical visual symptoms (the Heidenhain variant of sCJD), which affected 4 of
these 10 cases. The presence of confusion, memory impairment, or other neurological
Aetiological aspects of Creutzfeldt-Jakob disease
67
signs may raise the suspicion of a neurodegenerative disorder.
Although the evidence in this paper does not suggest that contaminated ophthalmic
instruments represent a risk of onward transmission of sporadic CJD, this conclusion
should be treated with caution. The eye contains significant levels of infection in sCJD
and vCJD and even limited exposures can result in the iatrogenic transmission of CJD.14
It is essential to follow current guidelines in relation to surgical, including ophthalmic
and neurosurgical, instruments used in suspect cases of CJD of all types.15 Such
instruments should be destroyed or quarantined until a definitive diagnosis is available
and all cases of suspect CJD should be reported to the local consultant in communicable
diseases in order that appropriate measures to protect public health are instituted,
including a review of previous surgery. 
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3.3
A polymorphism in the regulatory region of PRNP is
associated with increased risk 
of sporadic Creutzfeldt-Jakob disease
Abstract
Creutzfeldt-Jakob disease (CJD) is a rare transmissible neurodegenerative disorder. An
important determinant for CJD risk and phenotype is the M129V polymorphism of the
human prion protein gene (PRNP), but there are also other coding and non-coding
polymorphisms inside this gene. We tested whether a non-coding polymorphism located
inside the PRNP regulatory region (PRNP G310C) was associated with risk of CJD and
with age at onset in a UK population-based sample of 131 sporadic CJD (sCJD) patients
and 194 controls. PRNP 310C allele was in strong linkage disequilibrium with PRNP
129V allele. As expected, methionine and valine homozygosity at PRNP M129V
increased significantly the risk of sCJD, alone and adjusted by PRNP G310C (OR
MM/MV=7.3; 95%CI 3.9 to 13.5 and OR VV/MV=4.0; 95%CI 1.7 to 9.3). Although the
crude analysis did not show a significant association between PRNP G310C and sCJD
(OR: 1.5; 95%CI=0.7 to 2.9), after adjusting by PRNP M129V genotype, being a C
allele carrier at PRNP G310C was significantly (p=0.03) associated with a 2.4 fold
increased risk of developing sCJD (95%CI=1.1 to 5.4). Cases of sCJD carrying a PRNP
310C allele presented at a younger age (on average 8.9 years younger than those without
this allele), which was of statistical significance (p=0.05). Our findings support the
hypothesis that genetic variations in the PRNP promoter may have a role in the
pathogenesis of sCJD possibly due to an increased level of PRNP expression.
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Introduction
The polymorphism coding for methionine (M) or valine (V) at codon 129 of the prion
protein gene (PRNP M129V) plays a pivotal role in the susceptibility to Creutzfeldt-
Jakob disease (CJD), influencing familial, transmitted and sporadic forms of the
disease.1 Moreover, the PRNP M129V genotype, in combination with the type of
disease-associated prion protein (PrPsc) deposited in the brain, is a major determinant of
the clinical phenotype of sporadic2 and genetic forms3 and also susceptibility to variant
CJD (vCJD). All vCJD cases studied to date have been methionine homozygous at this
locus.4
Transgenic animal models5,6 suggest that the level of expression of PRNP has a
significant influence on the incubation period of disease. This finding has led to the
hypothesis that variations in the regulatory region of PRNP, which may lead to an
increased expression of the gene, may influence susceptibility and age at onset in
sporadic CJD, independent of the influence of PRNP M129V.
In a previous study we defined the PRNP regulatory region, and identified three
infrequent single nucleotide polymorphisms, PRNP-C101G located upstream of the
transcription start site, and two intronic SNPs: PRNP G310C and PRNP T385C. An
initial association study carried out in 25 sporadic CJD (sCJD) and 77 controls showed
that a subgroup that carried any of the rare alleles in the regulatory region had an
increased risk for sCJD.7
Based on our initial results, we genotyped PRNP G310C in a larger population of
131 sporadic CJD patients and 194 healthy controls from the UK. The aims of the study
were to assess the association between PRNP G310C polymorphism and the risk of CJD
in an independent set of sCJD patients and to examine for differences in age at disease
onset between carriers versus non-carriers of the PRNP 310C allele.
Methods
Cases were derived from a population-based survey of CJD in the UK carried out by the
UK National CJD Surveillance Unit.8 Those with DNA available from 1991 to 2003
were selected for the study. Only patients with sCJD who fulfilled the WHO diagnostic
criteria for definite or probable CJD were included. Definite sCJD diagnosis was based
on neuropathological examination. Probable cases required an appropriate clinical
profile, supported by characteristic findings on EEG or CSF 14-3-3 protein detection.9
Whenever possible, all EEGs were reviewed by a member of the surveillance system and
scored for the presence or absence of typical or characteristic diagnostic features.10 The
CSF 14-3-3 immunoassays were performed using Western-blotting.11 Randomly selected
anonymous blood donors formed the control group; they were collected from two
geographical areas in the UK; one in Northern Ireland (Belfast) and one in Scotland
(Edinburgh). None of the cases or controls were included in the previous study.
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Demographical and clinical data were collected for patients. Information on PrPsc type
was included in the database when available. 
The PRNP M129V polymorphism and the PRNP regulatory region polymorphism
G310C were genotyped in cases and controls as described in a previous article.7
Hardy Weinberg proportions of both genotyped polymorphisms, PRNP M129V
and PRNP G310C, were tested. We assessed linkage disequilibrium (LD) between the
PRNP regulatory polymorphism and PRNP M129V. Haplotype frequencies were
estimated using EH program, and Lewontin's D' and r2 coefficients were subsequently
calculated.12 Due to the low frequency of the rare allele, there were no PRNP 310C
homozygous cases or controls. We compared the heterozygotes group (carriers of PRNP
310C) with the wild type homozygotes group (non carriers of PRNP 310C). Firstly, we
tested the association between being a carrier of the PRNP 310C allele and the risk of
developing the disease. Odds ratios (OR) and 95% confidence intervals (CI) were
calculated using logistic regression and adjusted for PRNP M129V genotype. Secondly,
we compared differences in age at onset between CJD cases with and without the PRNP
310C allele. Fitting a general linear model, we assessed the differences in age at disease
onset between cases, carriers versus non-carriers, adjusted by the molecular subtype (the
combination of PRNP M129V genotype and PrPsc type), which is a major determinant
of age at onset.2,13 All statistical analyses were performed using SPSS 11.0 for Windows
2000 (SPSS, Inc, Chicago, Illinois).
Results
A general description of the 131 cases included in this study is given in Table 1. There
was a non-statistically significant predominance of women. For most of the patients
(n=110 (84%)) the diagnosis was neuropathologically confirmed. The molecular
classification of the case cohort showed a predominance of the MM1 subtype (53%),
corresponding to the classical disease phenotype.2,13 The most sensitive diagnostic test
was the 14-3-3 immunoassay (90%).
None of the polymorphisms genotyped (PRNP M129V and PRNP G310C)
deviated significantly from Hardy Weinberg proportions in the control group (p=0.4 and
p=0.5 respectively). In the sCJD group PRNP M129V genotypic distribution deviated
significantly (p<0.001) from Hardy Weinberg proportions. We found that PRNP 310C
was in LD with PRNP 129V, in the control group (D'=0.88, p<0.001; r2=0.072, p<0.001),
in the group of s CJD patients (D'=0.37, p=0.01; r2=0.042, p<0.001), and overall
(D'=0.57, p<0.001; r2=0.045, p<0.001). 
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Table 1: Overall descriptives of sporadic CJD patients (n=131)
Although the crude analysis did not show a statistically significant difference
between the proportions of PRNP 310C carriers in both groups (OR=1.5; 95%CI=0.7 to
2.9; p=0.3), after adjusting by PRNP M129V genotype we found a significant
association between this regulatory region polymorphism and the risk of sporadic CJD.
Being a C allele carrier at PRNP G310C was significantly (p=0.03) associated with a
2.4 fold increased risk of developing sCJD (95%CI=1.1 to 5.4) (Table 2). The
distribution of PRNP G310C, stratified by PRNP M129V genotypes, showed in all three
strata a trend to a higher proportion of individuals with PRNP 310C allele in the sCJD
cases than in the controls, this difference was highest and of borderline statistical
significance (p=0.07) in the MM group (OR=7.2; 95%CI=0.9 to 58.8) (Table 3).
Table 2: Overall distribution of PRNP 310C allele and risk of sporadic CJD
* Adjusted by PRNP M129V polymorphism.
Characteristic
Gender: female (%) 77 (58.8)
Diagnosis classification: definite (%) 110 (84.0)
Mean age at onset (years)±SD 65.6±9.5
Mean duration of disease (months)±SD 6.6±7.0
Molecular subtype
MM1 (%)
MM2 (%)
MV1 (%)
MV2 (%)
VV1 (%)
VV2 (%)
33 (53.2)
4 (6.5)
1 (1.6)
8 (12.9)
2 (3.2)
14 (22.6)
Clinical characteristics:
Typical EEG/total EEGs (%)
Positive MRI/total MRIs (%)
Positive CSF 14.3.3 test/total tests (%)
50/125 (40.0)
12/28 (42.9)
46/51 (90.2)
PRNP 310C
allele
Cases (%) Controls (%) OR 
(95% CI)
P- value OR 
(95% CI) *
P- value*
Carriers
Non carriers
17(13.0)
114 (87.0)
18 (9.3)
176 (90.7)
1.5 (0.7-2.9) 0.3 2.4 (1.1-5.4) 0.03
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Table 3: Distribution of PRNP 310C allele, stratified by PRNP M129V genotypes, and risk of spo-
radic CJD
Methionine and valine homozygosity at PRNP M129V increased significantly
the risk of sCJD, in the crude analysis (OR MM/MV=4.3; 95%CI=2.5 to 7.2 and OR
VV/MV=2.9; 95%CI=1.3 to 6.3) and adjusted by PRNP G310C (OR MM/MV=7.3;
95%CI=3.9 to 13.5 and OR VV/MV=4.0; 95%CI=1.7 to 9.3).
When we assessed differences in the age at onset between sCJD patients who were
carriers and not carriers of the PRNP 310C allele, we found a statistically significant
(p=0.05) association. Patients carrying the PRNP 310C allele presented with disease at
an earlier age, being on average 8.9 years younger than non-carriers (Table 4). Table 4
shows that the decrease in age at onset was independent of the molecular subtype. The
differences were more pronounced in the MM1 and VV1 strata although in the latter
only one patient carried the PRNP 310C allele. The numbers of patients were too low
and the differences across each molecular subtype strata were not statistically
significant, but when we tested the overall means adjusted by molecular subtype this
difference was statistically significant (p=0.05) (Table 4).
Table 4: Mean age at onset ± standard errors of sporadic CJD patients across molecular subtypes
and PRNP 310C allele distribution
* Adjusted by molecular subtype (PRNP M129V and PrPSc type).
PRNP M129V genotype PRNP 310C
allele
Cases (%) Controls (%) OR 
(95% CI)
P- 
value
Methionine/methionine
Carriers
Non carriers
8 (8.2)
90 (91.8)
1 (1.2)
81 (98.6)
7.2 (0.9-58.8) 0.07
Methionine/valine
Carriers
Non carriers
4 (23.5)
13 (76.5)
12 (13.0)
80 (87.0)
2.1 (0.6-7.3) 0.3
Valine/valine
Carriers
Non carriers
5 (31.3)
11 (68.8)
5 (25.0)
15 (75.0)
1.4 (0.3-5.9) 0.7
Molecular
subtype
PRNP 310C
carriers 
N PRNP 310C
non carriers 
N Mean difference
(Years)
P-value
MM1
MM2
MV1
MV2
VV1
VV2
57.7±8.1
-
-
64.8
41.0
64.3±10.5
2
-
-
1
1
4
67.9±9.1
53.8±6.9
78.1
66.2±5.4
64.0
64.8±11.2
31
4
1
7
1
10
-10.2
-
-
-1.4
-23
-0.5
0.1
-
-
0.8
-
0.9
Overall
means*
56.9±3.8 8 65.8±2.4 54 -8.9 0.05
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Discussion
There are two important findings in this study. Firstly, we found a significant association
between the regulatory polymorphism PRNP G310C and the risk of sCJD. Secondly,
those patients who carried the PRNP 310C allele presented with disease at an earlier
age.
Being a carrier of the PRNP 310C allele increased the risk of developing the
disease 2.4 fold independently of the PRNP M129V polymorphism. However, this
association was only apparent when we adjusted for the PRNP M129V genotype. 
The genetic of CJD is exceptional in that homozygotes of both PRNP M129V
alleles are at increased risk of the disease. The protective effect of the PRNP codon 129
MV genotype (47.2% of the controls versus 18.3% of cases) and the predominance of
the PRNP 129 MM genotype in sCJD patients (70.4% of cases) implies that the
proportion of valine alleles is lower in cases (20.4%) than in controls (33.8%). 
In our LD assessment we observed that PRNP 310C is linked to PRNP 129V.
However, the association between the two alleles was stronger in controls than in cases.
There is an excess of PRNP M129V homozygosity for both alleles in our sCJD cohort;
since homozygosity increases LD, the lower LD in cases as compared to controls is
unexpected.
The stratified analysis of PRNP G310C across the PRNP M129V genotypes
showed a trend in all three strata to a higher proportion of individuals with PRNP 310C
allele in the sCJD cases than in the controls. However, comparing the association
between PRNP 310C and risk of sCJD across to the three PRNP M129V genotypes, the
MM individual carriers of PRNP 310C presented a higher risk than the MV and VV
individuals who also carried PRNP 310C (MM group OR=7.2 versus MV group
OR=2.1 and VV group OR=1.4) (Table 3). 
An interaction between the effects associated to the two SNPs may explain why the
PRNP 310C allele is more often found (10 fold) coupled with the PRNP 129M allele in
cases than in controls. If this haplotype (PRNP 310C-129M) is associated with an
increased risk of sCJD, we will find it over represented in cases. The excess of the PRNP
310C-129M haplotype in sCJD cases is leading to a reduction of LD in comparison to
the controls. Moreover, the interaction between the two alleles may also explain why the
relationship between PRNP G310C and sCJD is masked when no adjustment is made by
PRNP M129V. Although the p-value for the interaction term was not statistically
significant in the logistic regression model, the analysis presented in Table 4 highly
suggests that there is a non-additive relationship between PRNP 310C and PRNP 129M.
We found that the PRNP G310C polymorphism may influence the age at onset of
disease. Patients with sCJD carrying the PRNP 310C allele presented at an earlier age,
being on average 8.9 years younger than non-carriers. This difference was of borderline
statistical significance (p=0.05). In the analysis stratified by molecular subtypes, the
highest difference in age at disease onset between PRNP 310C carriers and non-carriers
was found in the MM1 group which would also support the hypothesis of an interacting
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effect between PRNP 310C and PRNP 129M alleles.
According to the stochastic protein conformational change theory, the risk of
developing CJD may increase proportionally with the level of the PRNP product, the
cellular prion protein (PrPC) available.14 Our finding of an association between the PRNP
310C allele, which is located in the regulatory region of the gene, and an increased risk
and earlier age at onset of sCJD suggests that the PRNP 310C allele may increase the
expression of PRNP. This hypothesis is in line with experimental studies in animals.
Transgenic mice models indicate that the level of expression of PRNP determines the
length of the incubation period following inoculation with infectious material. Mice
over-expressing murine Prnp have shorter incubation periods.5 A similar relationship is
observed in mice with decreased levels of PrPC. Animals with only one functional copy
of murine Prnp consistently have longer incubation periods than wild-type mice when
inoculated with the same agent.6 In addition, a study in inbred mice has identified three
loci on chromosomes 2, 11 and 12, that significantly influence the incubation period.
The Prnp region in mice, located on chromosome 2, mapped for a peak lod score of 8.2.
The mice studied were all identical for the PrPC amino acid sequence, suggesting that the
regulatory region of this gene may play an important role in the length of the incubation
period.15
The molecular subtype of sCJD patients, determined by the combination of the
PrPSc type (type 1 or 2A) with the PRNP M129V genotype, is a major determinant of
age at disease onset.2,13 For example in our cohort, in MM or MV type 1 cases the disease
developed at age 67 years on average whereas the mean age at onset in VV type 1 cases
was 52 years (p=0.004). Despite these trends, in all molecular subtypes except the MV1
group (in which there were only three cases), there are cases with symptom onset at an
age of less than 50 years (data not shown). This suggests that although molecular
subtype is an important determinant of age at onset, there are other influencing factors.
Although numbers of cases are limited in our study, it is interesting that within each
molecular subtype, on average, carriers of the PRNP 310C allele are younger at onset
than non-carriers.
In vitro experiments have suggested that the PRNP 129M allele results in a higher
propensity of the PrP to form beta-sheet-rich oligomers.16 This indicates that PRNP
129M may facilitate self-perpetuating conformational changes of the human prion
protein. Therefore, an increased expression of PrP may work synergistically with PRNP
129M increasing the risk of sCJD and diminishing the age at symptoms onset.
A possible source of bias in our study is the use as controls of randomly selected
anonymised blood donors who are not matched for age or sex with the patients. For
example, if the distribution of the genotypes studied differed with age this would
introduce bias. However, a recent report indicated that the distribution of the PRNP
M129V genotypes in a Finnish population did not differ with gender or age.17
Although PRNP 310C is a rare allele, and is not present in the majority of patients
with sCJD, our findings may offer a new insight into the elusive aetiology of CJD. The
results of our study would suggest that a PRNP dosage effect could play a role in the
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causal pathway of sCJD. Nevertheless, we have to emphasize that these conclusions are
based on the assumption that PRNP 310 is associated to PrP gene expression due to the
fact that it is located inside the gene regulatory region. Therefore, functional studies to
assess the effect of the PRNP 310C allele should be carried out as a test for this
hypothesis.
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3.4
No evidence for association between Tau haplotypic
variants and susceptibility to Creutzfeldt-Jakob 
disease
Abstract
In the present study we test the association between the Tau protein gene (MAPT)
haplotypic variants and risk of Creutzfeldt-Jakob disease. We examined 6 haplotype
tagging SNPs (htSNPs), which capture 95% of MAPT genetic variability in Caucasians,
in a Dutch population-based sample of sCJD patients and a cognitively normal control
group of similar age distribution. We genotyped the same polymorphisms in two other
sCJD samples from Italy and the UK. Single locus and haplotype analyses did not detect
any significant difference between sCJD cases and controls. We did not find any
differences in allelic or genotypic distributions between the two groups. When we
compared MAPT haplotypes, we found that two of them were represented differently in
sCJD and vCJD patients (H1f: 8% in sCJD versus 2% in vCJD; H1j:1% in SCJD versus
7% in vCJD). However, these two haplotypes were rare in both groups of patients, and
taking the small sample sizes into account, we cannot exclude that the differences are
due to chance. None of the p-values (p=0.04 and p=0.01) remain statistically significant
after applying a multiple testing correction like Bonferroni. In brief, our study shows no
evidence for an association between MAPT gene variations and CJD, and some evidence
for an association to vCJD.
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Introduction
A polymorphism at codon 129 of the prion protein gene (PRNP M129V) is the only
well-known genetic risk factor for sporadic Creutzfeldt-Jakob disease (sCJD).1 However,
there is increasing evidence that other loci outside PRNP open reading frame might play
a role in sCJD etiology as well.2-6 Even though variant CJD (vCJD) is acquired from
infected cattle with bovine spongiform encephalopathy (BSE)7 its susceptibility is
strongly genetically determined. All vCJD patients tested are methionine (M)
homozygous at PRNP M129V.8 As for sCJD, there are likely to be other genetic factors
determining the risk of a particular individual developing vCJD.
Tau protein plays a key role in the pathogenesis of several neurodegenerative
disorders. Neurofibrillary tangles (NFTs) consisting of accumulation of truncated and
hyperphosphorilated Tau are one of the hallmarks of Alzheimer's disease (AD). NFTs
are also present in other neurodegenerative diseases, including progressive supranuclear
palsy (PSP), cortico basal degeneration (CBD), Pick's disease, and argyrophilic grain
disease and Parkinsons' disease (PD).9-12 In patients with sporadic CJD, the Tau protein
is profusely released to the CSF. This process is most likely related to the rapid neuronal
damage. Tau quantification with Enzyme Linked Immunoabsorvent Assay (ELISA) is a
very valuable test for sCJD diagnosis.13 In contrast to sCJD, in vCJD there is an increase
of phosphorilated-Tau forms in CSF.14 The pathogenic implications of this finding are
unknown, but it suggests that Tau phosphorilation may differ between sCJD and vCJD.
Tau protein is encoded by MAPT gene, located in chromosome 17. Mutations in
MAPT have been identified in frontotemporal dementia and pallidopontonigral
degeneration.15-20 There are two common MAPT extended haplotypes in Caucasians, H1
and H2. The H1 haplotype has been linked to several sporadic neurodegenerative
disorders like PSP21-23, CBD24, FTD25, Parkinson's26 and some studies suggest to
Alzheimer's disease.27
A recent study using data from the HapMap project (http://www.hapmap.org)
identified 6 haplotype tagging SNPs (htSNPs) capturing 95% of MAPT genetic
variability in Caucasians.28 The same group showed that H1c, one of the H1 sub-
haplotypes, was linked to late onset AD.27 In the present study we examined the
association between MAPT haplotypic variants and risk of sCJD and vCJD.
Methods
Cases were derived from population-based surveys of CJD carried out by national CJD
registries from 1991 to 2005 in Italy (n=194 sCJD), the United Kingdom (UK) (n=48
sCJD and 52 vCJD) and the Netherlands (n=79 sCJD). All three countries are part of the
European CJD surveillance network EuroCJD (http://www.eurocjd.ed.ac.uk). Only
patients of Caucasian origin who fulfilled the WHO diagnostic criteria for definite or
probable CJD were included.29 Definite CJD diagnosis was based on neuropathological
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examination. Probable cases required an appropriate clinical profile, supported by
characteristic findings on MRI, EEG or CSF 14-3-3-protein detection. Whenever
possible, all EEGs and MRIs were reviewed by a member of the surveillance system and
scored for the presence or absence of typical or characteristic diagnostic features.30,31 The
CSF 14-3-3 immunoassays were performed using Western-blotting.32 Healthy controls
(n=309) were participants of the Rotterdam Study, which is a population-based study of
7385 subjects age 55 years or older.33 Controls are all cognitively normal from Caucasian
origin. Table 1 displays the main characteristics of cases and controls. Signed informed
consent to participate in genetic research was obtained from all controls and patients'
relatives. The protocols of the studies were approved by the local medical ethical
committees.
Table 1: Descriptive statistics
For all patients and controls DNA has been extracted from peripheral leucocytes
according to a standard protocol. We genotyped five polymorphisms, which had been
previously shown to tag the haplotype diversity of MAPT in Caucasians.28 Additionally,
the H1/H2 clade was defined by typing the SNP g.8117G>A (numbering according to
GenBank accession number AC091628.2), with the allele G tagging H1, and the allele
A tagging H2.34 DNA samples were genotyped using a TaqMan allelic discrimination
assay. Table 2 shows the primers sequence for each of the SNPs.
Origin Series n % Females % Definite
diagnosis
Median age
(range) MM n (%) MV n (%) VV n (%)
sCJD 79 59 52 67 (34-87) 48 (67) 16 (22) 8 (11)
controls 309 56 N/A 71 (55-93) 135 (44) 145 (48) 23 (8)
sCJD 48 58 50 67 (49-81) 22 (46) 13 (27) 13 (27)
vCJD 52 31 74 25 (12-62) 52 (100) 0 (0) 0 (0)
Italy sCJD 194 57 73 67 (35-87) 141 (73) 31 (16) 22 (11)
PRNP M129V genotype
NL
UK
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Table 2: SNP sequencies
Hardy-Weinberg equilibrium (HWE) was calculated for the 6 htSNPs genotypes in
the control population using χ2 statistics. We set a significance level of 0.01 in order to
take into account the number of tests performed. We assessed pairwise linkage
disequilibrium (LD) between the 6 htSNPs using D' and r2 calculated from the
expectation-maximization estimated haplotypes. We used the program SNPStats
(http://bioinfo.iconcologia.net/SNPstats) for the LD analysis. Single locus analyses were
performed using SPSS software version 13. Allelic and genotypic frequencies were
compared using χ2 statistics. Adjusted analyses were performed using multiple logistic
regression analysis. Age, gender and PRNP c129 were included in the model as
covariates. We first compared Dutch sCJD cases and controls using the Italian and UK
sCJD populations as replication samples. In a separate analysis we compared UK sCJD
with vCJD. Haplotype analyses were performed using the program hplus
(http://qge.fhcrc.org/hplus/). We performed haplotype analysis comparing controls
versus all sCJD patients and UK sCJD patients with vCJD patients.
Results
Table 1 shows the basic characteristics of our patients and controls. SCJD patients from
the UK presented a significantly different PRNP M129V genotypic distribution in
comparison to Italian and Dutch cases (p=0.005), the latter populations showing a higher
proportion of the M allele. 
SNP Primer sequence
rs242559 AGAAAGTTCTCCCAGGAAACAAGAG
ATTCCTTAGCTGTTACCAGTCACTG
rs242557 CGTTTCTTCTTCCTTACAAAGCAGTT
TGTCACGGGACCAGGG
rs3785883 GCTCAGCGATATTGTCACATGAC
AGTGTCGGCTGGATGGAC
rs2471738 AGTGGCCTGGTTAGAGACCTT
TCTGTCCTGTACCGCAGC
H1/H2 GCCGTCCGCCTCTGT
CATCGGTCGGGGCCA
rs7521 CCTGCGTGTCCCATCTACAG
TCTTCAGCTTTGAAAAGGGTTACCC
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All htSNPs were in HWE (p>0.01). All 5 htSNPs used to define H1 sub-haplotypes
were in complete LD with the htSNP tagging H1/H2. In contrast, among each other, LD
was more variable. These observations are in line with the hypothesis that the markers
are defining H1 sub-haplotypes.
In the first analysis we tested whether MAPT genetic variations were associated
with risk of sCJD. None of the htSNPs genotypes showed a statistically significant
association with the disease when comparing the Dutch cases to controls nor when
comparing the other patients. We did not find association in any of the different sCJD
populations studied independently neither when they all were collapsed. When we
adjusted by age, gender and PRNP M129V genotype, we did not find any significant
relationship with sCJD risk either (Table 3). When we compared in a separate analysis
MAPT genetic variants between UK sCJD and vCJD, we also failed to find any
statistically significant association (Table 4).
The htSNPs genotyped allowed us to define the two major clades, H1 and H2,
which have been described in Caucasians in several previous studies.35 In order to
facilitate comparisons we have adopted the same terminology for H1 sub-haplotypes as
that used by Pittman et al.28 We did not find any evidence of association between any of
the MAPT haplotypes and sCJD (Table 5). We specifically did not find association with
the subhaplotype H1c, which has been previously reported to be related to several
neurodegenerative diseases. We also compared MAPT haplotypes between sCJD and
vCJD from the UK. We found that the frequency of two rare haplotypes, H1f and H1j,
were significantly different in sCJD and vCJD patients (p=0.04) and (p=0.01) (Table 6).
However, these two variants were present in a small proportion of patients, and after
adjusting by the number of test performed (14 pairwise haplotypic comparisons were
made) the results were not statistically significant (p=0.56) and (p=0.14).
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Table 4: MAPT single locus analysis UK sCJD and vCJD
P-values are not corrected for multiple testing.
In brackets p-values adjusted by PRNP M129V genotype, age at onset and gender.
Table 5: MAPT haplotype association with sCJD
P-values are not corrected for multiple testing.
SNP Major ellele UK sCJD
n (%)
UK vCJD
n (%) Allelic Genotypic
Mrs242559 A 69 (72) 67 (66) 0.36 0.28 [0.26]
rs242557 G 65 (68) 64 (63) 0.55 0.39 [0.79]
rs3785883 G 82 (85) 90 (87) 0.84 0.99 [0.96]
rs2471738 C 71 (74) 80 (78) 0.51 0.80 [0.60]
H1/H2 G (H1) 69 (72) 67 (67) 0.54 0.55 [0.27]
rs7521 G 59 (61) 61 (60) 0.88 0.65 [0.99]
Haplotype
rs242559 rs242557 rs3785883 rs2471738 H1/H2 rs7521 % Controls % sCJD
P-value
H1e A G G C G A 25 26 ref
H2a C G G C A G 23 22 0.64
H1c A A G T G G 12 15 0.46
H1d A A G C G A 13 10 0.08
H1f A G A C G G 5 5 0.88
H1g A A G C G G 5 5 0.91
H1h A G A C G A 4 4 0.64
H1i A A A C G A 3 3 0.68
H1j A A A T G G 3 2 0.45
H1b A G G C G G 2 2 0.55
Alleles Frequency
P-value
Table 6: MAPT haplotype analysis  UK sCJD and vCJD
P-values are not corrected for multiple testing.
Included all haplotypes present in both sCJD and vCJD.
Discussion
Our study assesses the relationship between MAPT haplotypic variations and CJD for
the first time. We examined 6 htSNPs, which are part of an extended MAPT haplotype,
in a Dutch population-based sample of sCJD patients and a cognitively normal control
group of similar age distribution. We genotyped the same polymorphisms in two other
sCJD samples from Italy and the UK. All three populations of cases showed similar
demographical characteristics. In the UK sCJD cases we found a higher proportion of
VV cases (27% versus 11%). This difference might be due to geographical variations in
the genotypic distribution of PRNP gene codon 129. According to published data, the
frequency of the M allele increases gradually from north-western to south-eastern
European countries. An alternative explanation may be a possible higher percentage of
young sCJD patients tested for codon 129 in the UK. Earlier disease onset could be
linked to higher proportions of MV and VV patients, who usually tend to start the
disease at a younger age than the MM. This might be driven by the higher concern in the
UK about vCJD cases, who are younger than sCJD and up until now all homozygotes
for M. However, in our study, the median age at onset of the UK sCJD population did
not differ from the other countries. Finally, we cannot rule out that the differences may
be explained by the small numbers.
Statistical analysis revealed no significant differences between cases and controls,
with all p-values higher than 0.05 before correcting for multiple testing. Haplotype
analysis still failed to detect any significant difference. We specifically did not find
significant association with the sub-haplotype H1c which has been previously reported
to be related to several neurodegenerative diseases. We found that H1c was slightly
overrepresented in sCJD (15%) versus controls (12%), but this difference was not
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Haplotype
rs242559 rs242557 rs3785883 rs2471738 H1/H2 rs7521 % UK sCJD % UK vCJD
P-value
H2a C G G C A G 28 31 ref
H1e A G G C G A 24 20 0.51
H1c A A G T G G 16 10 0.40
H1d A A G C G A 7 16 0.18
H1f A G A C G G 8 2 0.04
H1j A A A T G G 1 7 0.01
Alleles Frequency
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statistically significant (p=0.46). We did not find significant differences either between
Dutch controls and vCJD. 
When we compared other MAPT haplotypes between UK sCJD and vCJD
patients, we found that two of them were represented differently (H1f:8% in sCJD versus
2% in vCJD; H1j:1% in SCJD versus 7% in vCJD). When we compared the frequency
of these haplotypes in vCJD versus the Dutch control population only the difference in
H1j (3% in controls versus 7% in vCJD) was of borderline significance (p=0.06).
However, these two haplotypes were rare in both groups of patients, and taking the
small sample sizes into account, we cannot exclude that the differences are due to
chance. In any case, none of the p-values (p=0.04 and p=0.01) remain statistically
significant after applying correction like Bonferroni for the 14 pairwise haplotypic
comparisons that were made (p=0.56 and p=0.14).
One possible explanation for our results may be a lack of statistical power. We
think that this is unlikely. As a proof of principle, the association of sCJD with PRNP
M129V genotypes in the overall sample yielded a very low p-value (<10-11). The sCJD
risk of PRNP 129 M homozygotes versus PRNP 129 heterozygotes was 3.8 folds higher
(95%CI from 2.6 to 5.5). Without multiple testing corrections we estimated that the
statistical power of our genotypic analysis would be of 85% to detect an odds ratio as
low as 1.6.
In brief, our study shows no evidence for an association between MAPT gene
variations and CJD some evidence for an association to vCJD.
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4.1
CSF tests in the differential diagnosis 
of Creutzfeldt-Jakob disease
Abstract
We analysed the diagnostic sensitivity and specificity of various brain-derived proteins
(14-3-3, Tau, NSE and S100b) in the CSF of patients with Creutzfeldt-Jakob disease
(CJD) and the biological factors that modify these parameters. CSF was tested for 
14-3-3, Tau, NSE and S100b in 1859 patients with sporadic, genetic, iatrogenic and
variant CJD, and in 1117 controls. The highest sensitivity was achieved for 14-3-3 and
Tau in sporadic CJD (85% and 86%), and a combined determination of 14-3-3 and either
Tau, S100b or NSE increased the sensitivity to over 93%. A multivariate analysis showed
that the sensitivity of all tests was highest in patients with the shortest disease duration,
age at onset >40 years, and homozygosity at codon 129 of the prion protein gene. In a
group of patients with repeated lumbar punctures, a second test also increased the
diagnostic sensitivity. The detection of elevated levels of brain-derived proteins in the
CSF in patients with suspected CJD is a valuable diagnostic test. Second lumbar
puncture should be preformed in patients with atypical clinical course in whom the first
test was negative.
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Introduction
The detection of 14-3-3 protein in the cerebrospinal fluid (CSF) plays an important role
in the clinical diagnosis of CJD.1-5 14-3-3 proteins are reported to be elevated in 95% of
sporadic CJD (sCJD), but the sensitivity is lower in patients with other forms of CJD
(such as iatrogenic, variant and genetic CJD).5-7 The sensitivity of 14-3-3 also varies in
different sCJD phenotypes.8-14 Various other proteins have also been tested: neuron
specific enolase (NSE), Tau and phosphorylated Tau and astrocytic (S100b) proteins,
prostaglandins, interleukins and Aß1-42.11,15-22
A combination of several markers might be used to improve the sensitivity and
specificity of clinical diagnosis.1,5,14,21,23-26 A rational approach to the early and specific
diagnosis of CJD is crucial and needs further consideration given that more biochemical
markers have been reported in recent years. The rationale of performing a panel of
biochemical tests has not yet been evaluated.
We have focused on the analysis of brain-derived proteins in the CSF in different
forms of TSE with respect to sensitivity and specificity and investigated the effect of
selected patient characteristics on these parameters.
Methods
Patients and database
The study was conducted within the framework of an EC-supported multinational study.
Patients were referred to the national surveillance units for the detection of CSF 14-3-3
protein, during the course of routine clinical diagnosis and surveillance. 
Samples were sent to the individual laboratories for the detection of CSF 14-3-3 in
participating countries between the years 1998 and 2003. All countries collected clinical
and neuropathological data from those patients with clinical suspicion of CJD or related
disorders. The corresponding diagnoses were obtained by follow-up. Data and samples
contributed by each laboratory, were as follows: Spain 906 (30% of the total), Germany
866 (29%), Italy 523 (18%), UK 443 (15%), Switzerland 164 (5.5%), Poland 39 (1.3%),
Greece 20 (0.7%), Slovakia 15 (0.5%).
Core clinical data such as age at onset, gender, disease duration, time point of the
lumbar puncture (LP), PRNP codon 129 genotype, PrPSc isotype and final clinical and
neuropathological diagnoses were collected by each centre. A database was set up,
which included detailed data on the CSF markers and patients' characteristics for 2976
samples from patients with CJD and control patients. In all participating centres, the
diagnoses of CJD and the various CJD subtypes were made according to established,
internationally agreed criteria.26-28 All participant countries belong to the EUROCJD
Surveillance network with comparable surveillance methods. Control patients were who
proved not to have CJD or other prion disease, however definite alternative diagnoses
were not always possible. The diagnoses in the control patients (non-CJD patients) were
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based on neuropathology (whenever possible) and clinical follow-up information. For
further analyses, the control patients were assigned to one of the following groups:
neurodegenerative, inflammatory, tumor-associated, ischaemic, psychiatric, metabolic
and other. In the analysis, only control patients with a definite clinical or neurological
diagnosis were included, and as a result data was excluded from 251 control patients.
CSF was taken by LP during the investigation of the patient at the notifying
hospital and tests were conducted in each laboratory according to common agreed
standards, described in more detail below. The results were entered into the database. 
14-3-3
At the initial stages of the data acquisition, we conducted a ring trial between the
participating laboratories in order to ensure the comparability of the results between
centers. We followed two approaches:
Ten selected CSF samples were sent to all participating laboratories. These ten CSF
samples were from patients with CJD, inflammatory disorders of the central nervous
system, Alzheimer's disease and a bloodstained CSF sample. Original 14-3-3 Western
blot films were scanned and the participants were asked to perform a visual analysis of
the Western blots (judged as negative, weak positive, positive) and the results compared.
The different centers were found to agree over the classification of the results and, in
addition, no individual centers differed from the whole group in terms of sensitivity and
specificity. In most cases, the anti-14-3-3 polyclonal rabbit antibody (SC-629, Santa
Cruz Biotechnology) was used as a primary detection antibody. Minor variations in the
14-3-3 detection protocols in individual laboratories had no influence on test results. The
median time of CSF storage between LP and 14-3-3 tests was 8 days and the median
time between disease onset and the LP was 4 months. 
In total, 14-3-3 tests were performed on 2934 samples (including 106 from a repeat
LP). This group comprised 1826 samples from patients with various forms of
transmissible spongiform encephalopathies (TSE) (1531 samples being from sCJD
patients) and 1108 from controls.
Tau
Tau protein levels were determined in 1295 samples from 1211 TSE patients (819 being
sCJD cases) and 220 control patients. Tau concentrations were measured by an enzyme-
linked immunosorbent assay (Innotest hTau-Ag, Innogenetics, Ghent, Belgium). A
previously established cut-off value of 1300 pg/ml was used for further calculations.23
S100b
S100b protein levels were determined in 966 samples from TSE patients (589 being
sCJD cases) and in 162 controls. S100b concentrations were measured by enzyme-
linked immunosorbent assays. Tests were performed in three centers (UK, Spain and
Germany) using various detection methodologies. In 533 samples, levels were
determined using a commercially available test kits (Byk Sangtec), while in the other
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433 samples, levels were determined using a previously described in-house ELISA.29
Since test sensitivity and specificity vary between methodologies, we used different cut-
off points for each test (Byk Sangtec, 4.2 ng/ml, in-house 0.5 ng/ml).
Neuron specific enolase, NSE 
NSE protein levels were determined in 748 samples from TSE patients (517 being from
sCJD cases) and in 113 controls. NSE concentrations were measured by enzyme-linked
immunosorbent assays. Various commercially available test kits were used. For 359
samples, a Hoffman LaRoche (Cobas-Core NSE EIA kit) test was used, in 312 samples
NSE was determined using a Delfia NSE, (Wallac ADL GmbH, Freiburg, Germany) and
in 77 samples cases a LIAISON NSE, (DiaSorin S.p.A. Saluggia, Italy). Since test
sensitivity and specificity vary among methodologies applied, we used different cut-off
points for each test used (Hoffman LaRoche, 35 ng/mL, Wallach 25 ng/mL and Byk
Sangtec, 25 ng/mL).1,30
Statistical analyses
Descriptive statistics were reported for sCJD and control patients; χ2 test and the non-
parametric Mann-Whitney test were used to assess differences between categorical and
continuous variables. For each CSF marker, sensitivity and specificity were calculated
in our overall population of TSE and control patients; χ2 was used to test differences in
these predictive characteristics between CSF markers. We also calculated positive result
rates for every subtype of TSE. 
A multiple logistic regression model was used to assess the effect of a set of
clinically relevant patient characteristics on the sensitivity of the different tests in sCJD
patients. We included the following characteristics in our model: disease duration (in
months), age at onset (in years), disease stage when the LP was performed (during the
first third of the total duration of the disease, during the second or during the third), and
PRNP codon 129 genotype; country of sample origin and patient gender were entered
also as covariates.
Age at onset was categorized in four clinically meaningful groups of age, being the
reference group patients younger than 40 years. Disease duration was categorized using
the median as a cut-off point we divided our patients in two groups (short or long
duration). PRNP codon 129 genotype was entered in the model using two dummy
variables with the MV group as reference. The effects of PRNP codon 129 genotype and
PrPSc isotype on the sensitivity of the tests, adjusted again by sex and country of sample
origin, were jointly assessed in another multiple logistic regression model, although, due
to small numbers for the rest of the markers, this analysis was performed only for 
14-3-3. Again, using multiple logistic regression with gender and country of origin
include as covariates, we also analyzed whether particular (or individual) clinical factors
influenced the false positive rate in controls. Due to small numbers for the other
markers, this analysis was performed only for 14-3-3. Adjusted odd ratios and 95%
confidence intervals were generated.
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Results
Patient characteristics
The database comprised detailed data on CSF levels of several proteins in 2976 samples.
Most of the samples belonged to the various TSE forms (n=1859). A definite
neuropathological diagnosis was available in 49% of sCJD, 47% genetic CJD (gCJD),
47% iatrogenic CJD, 61% vCJD, 76% FFI and one GSS patients. One thousand one
hundred and seventeen samples were from patients with another diagnosis. Most of the
diagnoses were assigned to the group with neurodegenerative disorders (n=604, 20% of
the total sample). The second largest group comprised patients with inflammatory
disorders of the central nervous system (n=213, 7%). Most of the TSE samples were
from sCJD patients (n=1552, 52% of the total group and 85% of the TSE group). This
group of TSE patients also had the highest post mortem-rate (49.9%, from 14.3 to
75.9%). Post mortem-rate was lower in control patients (12.4% of the total group) and
varied considerably among the subgroups (11.4% in neurodegenerative diseases, 26.9%
in ischaemia, and 39.7% in paraneoplastic or tumor associated group). 
The group with sCJD patients did not differ significantly from the control patients
with respect to gender (53% and 49% females in each group) and age at onset (67 years,
range 19-97 in cases and 66 years, range 5-92 in controls). 
Information on PRNP codon 129 genotype was available in 1319 cases (1069 sCJD
and 250 control patients). Most of the sCJD patients were homozygous for methionine
(n=656, 61.4%) or valine (n=175, 16.4%) and only 22.2% (n=238) were heterozygous.
In controls, 47% (n=118) were homozygous for methionine, 12% (n=29) for valine, and
41% (n=103) were heterozygous.
The PrPSc isotype was available in 251 sCJD cases, of which 175 had the PrPSc
isotype 1 and 76 type 2A. 
CSF markers in the diagnosis 
Initially, we calculated the sensitivity and specificity for each marker for all TSE forms
(Table 1). We worked with quantitative levels for all markers tested except for 14-3-3,
for which the test results were rated as positive or negative. One methodological problem
with this latter test is the detection of faint immunoreactive bands, which were rated as
weakly positive. Therefore, we decided to calculate the sensitivity and specificity of the
14-3-3 tests according to three different strategies to determine which one would be
most beneficial in formulating clinical diagnoses in cases of rapidly progressive
dementia: 
1. To consider only unequivocal results (by exclusion of trace bands)
Following this rule, we calculated an overall test sensitivity of 84.5% for TSE
disease (88.8% for sCJD) and specificity of 83.6% but we lost 79 cases (4.2%)
(including 61 sporadic cases) in our calculation. Since this approach is
impractical in a clinical setting, we analyzed the following strategies:
2. To consider trace bands as positive results or 
3. To consider trace bands  as negative results
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Following the second approach, the overall 14-3-3-test sensitivity was 85.2% (89.3
for sCJD) and the specificity was 79.2%. The third strategy revealed a lower overall
sensitivity of 80.7% (85.1% in sCJD) but a gain in the specificity (a 5.3% increase from
79.2% to 84.5%. (p<0.01)). Since the main purpose of our study was set up to develop a
strategy for the best clinical CJD diagnosis in context of differential diagnosis of rapid
progressive dementia, we selected the third strategy for our subsequent analyses (Table 1). 
Table 1: Sensitivity (positives/total) by subtypes of disease
*Trace result considered as negative.
†Cutoff point for Tau protein was 1300 pg/ml; for S100b 4.2ng/ml, for the Byk-Sangtec kit
and 0.5ng/ml and for the in house kit used in the UK; for NSE we used 35ng/ml for the
Hoffman La Roche kit and 25ng/ml for Byk-Diasorin, Byk-Sangtec and Wallac kits.
The sensitivity of 14-3-3 varied among TSE subtypes (Table 1). For sCJD, the
sensitivity was 85%. Iatrogenic and gCJD patients had elevated 14-3-3 levels in 75% and
78% of the cases. In variant CJD (vCJD), only 40% had elevated 14-3-3 levels. All GSS
patients were negative and only two FFI patients were 14-3-3 positive.
For Tau levels, we observed a similar distribution (Table 1). The sensitivity was the
highest in the group of sCJD patients, followed by genetic and iatrogenic cases. Using
the cut-off value of 1300 pg/ml, as suggested for sCJD, the sensitivity of Tau in vCJD
was 24%. However, by using a different cut-off point of 500 pg/ml, as suggested
previously,5 the sensitivity for vCJD increased to 86%.
Elevated S100b levels were observed in 82% of samples from sCJD patients. In
other TSE forms higher rates of positive results were observed with S100b than with
other markers (Table 1). However, the gain of sensitivity of S100b has to be balanced
against the lower specificity observed for this marker (76%).
Disease
subtype
14-3-3* 95%CI Tau† 95%CI S100b† 95%CI NSE† 95%CI
sCJD 85 (1240/1457) (83, 87) 86 (704/819) (83, 88) 82 (483/589) (79, 85) 73 (379/517) (69, 77)
iCJD 75 (15/20) (51, 90) 53 (8/15) (27, 78) 81 (13/16) (54, 95) 44 (4/9) (15, 77)
vCJD 40 (37/93) (30, 50) 24 (21/86) (16, 35) 62 (55/88) (51, 72) 24 (6/25) (10, 45)
gCJD 78 (109/139) (70, 85) 82 (47/57) (70, 91) 82 (28/34) (65, 93) 60 (21/35) (42, 76)
GSS 0 (0/7) (0, 44) 50 (1/2) (3, 97) 100 (1/1) (5, 100) 0 (0/2) (0, 80)
FFI 9 (2/23) (1, 29) 0 (0/12) (0, 30) 22 (2/9) (4, 60) 0 (0/10) (0, 34)
Total 81 (1403/1739) (79, 82) 79 (781/991) (76, 81) 79 (582/737) (76, 82) 69 (410/598) (65, 72)
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The CSF marker with the lowest sensitivity for sCJD was NSE (73%), which also
gave the highest specificity (95%). Again, in iatrogenic and gCJD, sensitivity was lower
(44% and 60%). The lowest NSE sensitivity was seen with vCJD (24%). None of the
GSS and FFI patients were positive in this test. 
Once the sensitivity had been determined for each marker, we analyzed the rate of
'false-positive' results by subgroups (Table 2). Inflammatory, ischaemic and neoplastic
disorders of the brain revealed a high false-positive rate. Usually, those conditions can
be ruled out by routine CSF tests and brain imaging. The truly problematic differential
diagnoses for CJD are other neurodegenerative disorders, however, when comparing
CJD and this subgroup, the specificity was high (90% for 14-3-3 and 89% for Tau).
Table 2: Proportion of positive marker results (positive/total) in control patients
†Trace result considered as negative.
‡Cutoff point for Tau protein was 1300 pg/ml; for S100b 4.2ng/ml, for the Byk-Sangtec kit and 0.5ng/ml and for
the in house kit used in the UK; For NSE we used 35ng/ml for the Hoffman La Roche kit and 25ng/ml for Byk-
Diasorin, Byk-Sangtec and Wallac kits.
Diagnostic
category
14-3-3† Tau‡ S100b‡ NSE‡
Neurodegenerative 10 (62/591) 11 (11/102) 34 (22/65) 3 (1/38)
Inflammatory 27 (56/208) 5 (3/58) 10 (5/50) 2 (1/43)
Paraneoplastic/CNS
tumor
27 (21/77) 22 (5/23) 44 (8/18) 20 (2/10)
Stroke 27 (14/51) 18 (3/17) 7 (1/14) 0 (0/11)
Epileptic fit 31 (11/36) 36 (4/11) 12 (1/8) 22 (2/9)
Psychiatric 0 (0/32) 0 (0/9) 29 (2/7) 0 (0/2)
Metabolic 6 (2/33) - - -
Other 5 (3/61) - - -
Total 16 (169/1089) 12 (26/220) 24 (39/162) 5 (6/113)
Specificity %
(95% CI)
84 (82, 86) 88 (8, 92) 76 (68, 82) 95 (88, 98)
Chapter 4
100
None of the individual markers could distinguish between the different forms of
TSE (data not shown). 
In the next step, we attempted to identify the value of each marker for each sCJD
subtype. The results are given in Table 3. We found that all markers were less sensitive
in patients with PrPSc isotype 2A protein than with isotype 1. The lowest sensitivity was
found in the MV2 subtype. Another attempt was made to classify CJD patients into
'classic' and 'atypical' subtypes according to previously suggested definitions given.9 For
all markers, the sensitivity was higher for 'classic' subtypes (Table 3).
Table 3: Test sensitivities in sporadic CJD subtypes
Sens: Sensitivity
* sporadic CJD, codon 129 genotype MM or MV and duration less than 8 month.
° sporadic CJD, codon 129 genotype VV (all), codon 129 genotype MM or MV and duration longer than 8
month.
Patient characteristics effects on test sensitivity and specificity
Univariate analysis revealed that all but one of the patient characteristics  studied
significantly influenced the sensitivity of all tests in sCJD patients i.e, disease duration,
PRNP codon 129 genotype, age at onset and time of the LP (the single exception being
the disease stage at the time of LP) (Table 4).
Subtype
+/n Sens +/n Sens +/n Sens +/n Sens
MM 1 129/140 92 92/94 98 74/81 91 48/64 75
MV 1 10/11 91 4/6 67 3/5 60 5/5 100
VV 1 6/6 100 4/5 80 2/6 33 2/4 50
MM 2 7/9 78 6/7 86 5/5 100 2/3 67
MV 2 20/31 65 10/19 53 13/20 65 6/12 50
VV 2 27/30 90 14/16 88 13/13 100 10/11 91
classical* 411/443 93 271/290 93 187/210 89 163/206 79
non-
classical°
350/410 85 245/294 83 180/231 78 150/220 68
14-3-3 Tau S100b NSE
Table 4: Factors influencing sensitivity of CSF markers in sCJD patients
Adjusted by country of origin and gender.
Ref : reference
° OR odds ratio
* p-value<0.01
†Trace result considered as negative.
‡Cutoff point for Tau protein was 1300pg/ml; for S100b 4.2ng/ml, for the Byk-Sangtec kit and 0.5ng/ml and for
the in house kit used in the UK; for NSE we used 35ng/ml for the Hoffman La Roche kit and 25ng/ml for Byk-
Diasorin, Byk-Sangtec and Wallac kits.
In the multivariate analysis, when we included all these characteristics plus the
covariates, all remained significant. When we analyzed disease stage at time of LP,
adjusted for the rest of the variables, we observed a trend to have higher sensitivity in
14-3-3 in later stages: 87.6% in the first, 88.0% in the second and 91.3% in the third
(p=0.07) and this pattern was the same for all markers. We found that in patients younger
than 40 years all tests had a significantly lower sensitivity than in older patients. In
patients with disease duration longer than six months, all tests had significantly lower
sensitivity than in patients with shorter disease duration (and therefore a more
aggressive course). Finally, in patients heterozygous for PRNP codon 129 genotype all
tests significantly showed lower sensitivity than in homozygous patients (Table 4). From
a different perspective, the predicted probability of having a positive 14-3-3 test in sCJD
patients was higher when the test was performed in an individual homozygous for the
PRNP codon 129 genotype, older than 40 years and with short disease duration. Similar
results were obtained for Tau, S100b and NSE (Figure 1).
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Factors 14-3-3† Tau‡ S100b‡ NSE‡
OR° (95% CI) OR° (95% CI) OR° (95% CI) OR° (95% CI)
PRNP c129 MV genotype ref ref ref ref
PRNP c129 MM genotype 2.1 (1.4, 3.2)* 2.7 (1.6, 4.4)* 2.5 (1.4, 4.6)* 3.1 (1.9, 5.1)*)
PRNP c129 VV genotype 3.9 (1.9, 7.9)* 8.7 (3.3, 22.7)* 7.9 (2.9, 21.3)* 6.5 (2.9, 14.5)*
Age at onset <40 ref ref ref ref
Age at onset 40-59 6.1 (3.2, 11.6)* 3.8 (1.8, 7.6)* 3.4 (1.5, 7.6)* 6.3 (2.3, 17.0)*
Age at onset 60-79 7.8 (4.3, 14.3)* 8.8 (4.4, 17.6)* 13.0 (5.7, 29.5)* 9.5 (3.5, 25.6)*
Age at onset >80 4.4 (1.7, 11.5)* 2.5 (0.8, 7.9) 3.7 (0.9, 14.4) 5.2 (1.4, 19.6)*
Duration below 6 months ref ref ref ref
Duration above 6 months 0.5 (0.3, 0.7)* 0.3 (0.2, 0.5)* 0.4 (0.3, 0.8)* 0.5 (0.3, 0.8)
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Figure 1: Comparison of predicted probabilities of a positive 14-3-3 or Tau CSF test according to age
at onset and duration of illness stratified by PRNP codon 129 genotype.
We also studied the influence of both PRNP codon 129 genotype and PrPSc isotype
on the sensitivity of 14-3-3. Including both variables in the same model showed that they
individually had a significant effect on 14-3-3 sensitivity. 14-3-3 had a significantly
lower sensitivity in patients with PrPSc isotype 2A than in patients with type 1 (OR=0.16;
95% confidence interval: from 0.04 to 0.63; p<0.01). There was also a significantly
lower sensitivity in patients heterozygous at PRNP codon 129 than in patients
homozygous for valine (OR=0.15; 95% confidence interval: from 0.003 to 0.66;
p=0.012); but no significant differences were found between heterozygotes and
methionine homozygotes.
Univariate analysis revealed that multiple clinical factors were related to an
increase in the false positive rate for the 14-3-3 test, namely: diagnostic category
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(p<0.001), older age at onset (p=0.054), shorter duration of the disease (p<0.01), shorter
time from disease onset to LP (p<0.05), and high number of cells in the CSF (p<0.001).
In the multivariate analysis, the following remained as significantly associated to a false
positive rate: having an inflammatory (p<0.01), or a paraneoplastic/CNS-tumor disease
(p<0.001) in comparison to a neurodegenerative disorder; and an increased number of
cells in the CSF (p<0.05). 
All analyses have been repeated using data on definite sCJD patients only with
similar results.
Marker combination
In order to analyze whether a combination of two markers might improve the sensitivity
and specificity of the clinical diagnosis in patients with rapidly progressive dementia, we
analyzed all possible test combinations (Table 5). The highest sensitivity was achieved
by a combination of 14-3-3 with elevated levels of either Tau, S100b or NSE, without
significant differences or by the combination of Tau and S100b. Concerning different
sCJD subtypes, the combination of two CSF markers revealed the highest sensitivity in
patients with PrPSc isotype 1 or in 'classic' phenotypes. Comparing with a single marker,
a combination of two tests increased the sensitivity in both, 'classic' and 'atypical'
phenotypes. The test sensitivity for each single marker in 'classic' phenotypes is already
very high, but for 'atypical' phenotypes, the combination of two CSF markers led to
increased test sensitivity. 
Concerning all non-TSE patients, the highest specificity was achieved with normal
Tau and NSE levels (88%). In a further analysis, we looked at the marker combination
in the subgroup of neurodegenerative diseases only (Table 5). Here we found also the
highest specificity by combination of negative Tau or NSE levels (91%), followed by
negative 14-3-3 or NSE (82%). For neurodegenerative disorders, a combination of two
markers revealed higher specificity as for whole non-TSE group except for test
combinations which included S100b.
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Repeated lumbar punctures
In 84 patients, at least two LP were performed. The median time between both 14-3-3
tests was 6 weeks. In these patients, 14-3-3 was positive in the first LP in 65% of the
CJD cases, but the sensitivity was higher in the second sample taken at a later stage of
the disease (79%). Specificity increased too when results of the second LP were taken
into account (63% and 69%). Table 6 shows a detailed analysis of repeated LP for
various brain-derived proteins. According to this, we observed a general trend for further
increase of levels of brain-derived proteins with disease progression in CJD patients.
Table 6: Repeated 14-3-3 tests: comparison of first LP versus subsequent LP
*Trace result considered as negative
†Cutoff point for Tau protein was 1300pg/ml; for S100b 4.2ng/ml, for the Byk-Sangtec kit and 0.5ng/ml and for
the in house kit used in the UK; For NSE we used 35ng/ml for the Hoffman La Roche kit and 25ng/ml for Byk-
Diasorin, Byk-Sangtec and Wallac kits.
Sens: sensitivity; Spec: specificity
Discussion
In our study, we tested a panel of brain-derived proteins in the CSF in patients who were
suspected cases of CJD to determine: (1) their diagnostic utility either combined or alone,
(2) the results in single CSF or in repeated CSF samples, and (3) to determine the effects
of selected patient characteristics on the test sensitivity and specificity.1-3,5-7,14,24,31
Test TSE patients Control
patients
Sens Spec
+ - + - % 95%CI % 95%CI
First 14-3-3* test 44 24 6 10 65 (52, 76) 63 (36, 84)
Repeated 14-3-3* test 54 14 5 11 79 (67, 88) 69 (41, 88)
First Tau† test 37 16 3 2 70 (55, 81) 40 (7, 83)
Repeated Tau† test 38 15 2 3 72 (57, 83) 60 (17, 93)
First S100b† test 20 18 0 4 53 (36, 69) 100 (40, 100)
Repeated S100b† test 25 13 1 3 66 (49, 80) 75 (22, 99)
First NSE† test 20 26 1 4 43 (29, 59) 80 (30, 99)
Repeated NSE† test 32 14 0 5 70 (54, 82) 100 (46, 100)
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Amongst the brain-derived proteins tested, 14-3-3 had the highest sensitivity for all
types of TSE. In sCJD, the sensitivity was 85%. This is lower than reported
previously.2,3,7,21,31 The lower sensitivity might be related to a higher number of patients
tested in this study, but also to the very rigid strategy of defining 14-3-3 'trace' results as
negative. We cannot exclude that the high rate of 'false-negative' 14-3-3 tests might also
be related to some atypical CJD subtypes which are increasingly recognized in
systematic surveillance studies (such as the MV2 subtype). The sensitivity of all tests
was highest for the sporadic group, lower for iatrogenic and genetic cases and the lowest
in vCJD, FFI and GSS patients. 
Most patients were analyzed for 14-3-3 after it had been adopted as part of
internationally agreed clinical diagnostic criteria.26,27 Although it is a common view that
this marker should be tested in only truly suspect cases of CJD, it has been widely used
for screening in dementia.3,32 Currently, it is an accepted tool for patient recruitment in
surveillance studies and its use has been reported to lead to a substantial improvement in
epidemiological figures.33-35 This approach has to be weighed against the concomitant
drop in specificity. In the former studies, specificity was high, as only truly suspect CJD
patients were tested.2,3,36 Subsequently, as the control group was extended with a variety
of acute neurological disorders, the specificity figures for those surrogate markers
dropped. Referring only to neurodegenerative disorders as potential differential diagnoses
of CJD, the previously reported specificity figures continue to apply (Table 2).2,3,36
A combination of 14-3-3 with another marker increases sensitivity.1,5,21,23,24 The
highest sensitivity was achieved by a combination of 14-3-3 with elevated levels of
either Tau, S100b or NSE, but the highest specificity was seen, when normal Tau and
NSE levels were combined. 
We observed a substantial increase in sensitivity and specificity for several
markers, when an additional LP was performed at later disease stages. This observation
is in agreement with published single case reports.10,13,21,37,38 In our analysis, both
sensitivity and specificity increased when the results of the second LP were taken into
account. The results of a second CSF test might help to exclude CJD, since with time,
levels of brain-derived proteins decline in some other conditions, but usually increase
further in CJD. Thus, in cases of doubt, an additional LP several weeks after the initial
one is recommended to help support or exclude the diagnosis of CJD. 
PRNP codon 129 genotype, PrPSc isotype, disease duration and age at onset
influenced the test sensitivity in sCJD patients. 
PRNP codon 129 heterozygous patients have lower sensitivity in all tests
performed in the CSF. In addition, the PrPSc isotype 2A is an independent influencing
factor and the effect is even more pronounced in patients with at least one methionine
allele. The influence of the PRNP codon 129 genotype and PrPSc isotype was assessed in
previous studies, but due to a lower number of cases, the results did not reach
significance levels at that time.8,9,21
We found a trend towards a higher sensitivity in 14-3-3 when the LP is performed
in the last third in the course of the disease, but the results were not statistically
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significant. Moreover, as shown in our analysis, the sensitivity of markers increased,
when a second LP was performed later in the disease. This is in line with previous
reports, where the disease stage was reported to correlate with levels of 14-3-39 or 
14-3-3, Tau and Aß1-42.21
The question of disease duration and sensitivity of tests has been addressed in
several studies.5,8 In general, many of the currently available tests are more sensitive in
patients with a typical short disease duration. This has been shown for the detection of
periodic sharp and slow wave complexes in the EEG, 14-3-3 in CSF and hyper-intense
basal ganglia in MRI or phosphorylated Tau concentrations in the CSF.9,39-41 In our study,
disease duration of less than 6 months was significantly associated with higher
sensitivity for 14-3-3, Tau and S100b proteins. 
Age at onset correlated significantly with test sensitivity, being lower in those
patients with disease onset before the age of 40. The reasons for this observation are not
clear at the moment, but some disease modifying factors might account for this
observation. One can assume that atypical CJD subtypes present more frequently at
younger age, such as MV2 subtypes. Survival is longer in young patients, which is also
related to a less progressive disease course and therefore potentially for a less acute
neuronal damage in those patients.42 On the other hand, in the logistic regression
analysis, age presented as an independent variable. Other factors, which remain to be
proven, include an age-dependent neuronal vulnerability that leads to a more
pronounced release of the brain-derived proteins into the CSF.
To conclude, in front of a single negative 14-3-3 test in suspected CJD patients, a
second test (such as Tau) should be requested. The determination of the codon 129
genotype is extremely helpful for the interpretation of the negative CSF results. In
heterozygous patients, the negative test must be interpreted with more caution and other
diagnostic tests such as magnetic resonance imaging including diffusion weighted
imaging for detection of hyperintense basal ganglia must be more intensely pursued.8,40
In addition, a second lumbar puncture at least six weeks after the initial one should be
considered. A negative result in patients younger than 40 years at onset should be
interpreted with extreme caution.
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4.2 
Influence of timing on CSF tests value for 
Creutzfeldt-Jakob disease diagnosis 
Abstract
The analysis of markers in the cerebrospinal fluid (CSF) is useful in the diagnosis of
sporadic Creutzfeldt-Jakob disease (sCJD). However, the time at which the study of
these markers is most sensitive remains controversal. The objective of our study is to
assess the influence of time of sampling on the value of CSF tests in the diagnosis of
sCJD. In the framework of a multinational European study, we studied the results of 
14-3-3, S100b, neurone specific enolase (NSE) and Tau protein in 833 CSFsamples
from sCJD patients at different stages of disease and in 68 sequentially repeated lumbar
punctures (LP). 14-3-3 and Tau protein increased in sensitivity from onset (88%, 81%)
to the advanced stage (91%, 90%). This was significant in the MV group of patients. The
absolute levels of S100b (p<0.05), NSE and Tau protein increased in the last stage of
disease. High levels of Tau protein, NSE and S100b were associated with shorter
survival times (p<0.01). Sixty-eight sCJD patients underwent repeated LP. These sCJD
patients were younger, had longer disease durations and were more frequently MV at
codon 129 (p<0.001) than the whole group. 14-3-3 sensitivity increased from 65% to
79% in the second LP (p=0.06) and 88% sCJD patients had at least one positive result.
Sensitivity and absolute levels of CJD markers increased with disease progression and
were modulated by the codon 129 genotype. Early negative results should be interpreted
with caution, especially in young patients or those who are MV at codon 129.
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Introduction
Creutzfeldt-Jakob disease (CJD) is a rapidly progressive neurodegenerative disease.
Presently, the definite diagnosis of CJD requires neuropathological confirmation.
Cerebrospinal fluid (CSF) analysis plays an important role in the diagnosis of CJD. After
the WHO consultation in 1998, a positive 14-3-3 result is considered as a criterion of
probable sporadic CJD (sCJD).1 Different studies have shown that in the appropriate
clinical circumstances a positive 14-3-3 is highly sensitive and specific for the diagnosis
of sCJD.2 However, the question remains open as to whether 14-3-3 is more sensitive in
the initial or late stages of disease. Increased levels of other brain-derived proteins, such
as microtubule-associated Tau protein3, S100b4 or neurone specific enolase (NSE)5 have
also been reported to be elevated in CSF in CJD. The published data about how the levels
of these proteins are modified during the course of disease are contradictory.6-8,9-11,12-13 In
addition, the time point during the disease, when biochemical markers are expected to
have the highest sensitivity, is not well-defined. These topics have not been studied
systematically, especially because data from sequential CSF analyses are rarely
available. 
In the framework of an European Union supported multinational study on CJD
markers, we performed an analysis of the results obtained in different stages of the
disease and in repeated lumbar punctures (LP) to assess the influence of time of
sampling on the value of CSF tests in the diagnosis of sCJD.
Methods
Study overview
This study was conducted in the framework of a European Union supported
multinational study (Early clinical diagnosis of human spongiform encephalopathies by
analysis of biological fluids (CJDmarkers), QLG3-CT-2002-81606). All participant
countries belong to the EUROCJD Surveillance network with comparable surveillance
methods. CSF samples were sent to the individual laboratories for 14-3-3 analysis in the
participating countries between 1998-2003 and clinical and pathological data were
collected. CSF was obtained by LP and the analyses were conducted in each laboratory
following standard protocols.14 An analysis of test validity and comparability between
laboratories revealed high agreement between laboratories.14 Previously published cut-
off values were used for the quantitative markers.3,5
In all countries, clinical and neuropathological data from patients with clinical
suspicion of CJD or related disorders were collected. The diagnoses of CJD and various
CJD subtypes were made according to the established criteria in all participating centers.
Core clinical data such as age at onset, gender, disease duration, time point of the LP,
codon 129 genotype, PrPSc type and final clinical and neuropathological diagnoses were
centralized by each center. A database was set up, which included detailed data on the
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CSF markers and patients' characteristics. The study was performed in accordance with
the ethical standards laid down in the 1964 Declaration of Helsinki. 
Statistical analyses 
Since the clinical duration within sCJD patients varies widely depending upon several
variables (e.g., age at onset, gender, codon 129 polymorphism of the PRNP gene, and
PrPSc type), the time interval between LP and disease onset is not an appropriate estimate
of the stage of disease when the LP was performed. To overcome this problem, we
normalized the time of LP to disease onset in each patient by the duration of disease.
Thus, we classified patients in three categories according to whether they underwent LP
in the first, second or third stage of disease. We analyzed the sensitivity of each marker
at different stages of the disease. The differences in sensitivities across strata were
analyzed using a logistic regression model adjusting for possible confounders and
covariates. We also performed a stratified analysis by codon 129 PRNP genotype. In a
similar way we assessed the absolute levels of quantitative markers across the different
stages of the disease. 
In order to evaluate the correlation between Tau protein, S100b or NSE levels and
disease duration we used the non-parametric correlation coefficient Spearman's Rho.
Differences in CSF Tau protein levels between patients with disease duration above or
below the median (5 months) were compared using the Mann-Witney test.  For the
second part of the study, we selected patients who underwent more than one LP during
the course of disease and then compared the sensitivity and evolution of each of the CJD
markers. Differences in sensitivities were assessed using χ2 test.
Results
One thousand five hundred and fifty two samples from sCJD patients were studied. The
time of LP and disease onset were available in 833 patients and the median time from
onset to LP was 3 months (range 0.1-84.5). The LP was performed during the first stage
of the disease in 16% (n=137), during the second stage in 38% (n=316), and in the final
stage in 46% (n=380). The data on test sensitivity for each marker stratified by the
disease stage are given in Table 1. The sensitivity of 14-3-3 tended to increase from the
first (88%) to the third stage of the disease (91%). When stratifying by codon 129 of
PRNP, this trend became significant in the group of MV patients (p=0.01).
Similar results were obtained for Tau protein (sensitivity of 81% in the first stage
and 90.5% in the third stage, p<0.05, n=342) (Table 1). When examining the sCJD
patients as a whole there were no significant differences found between the median level
of Tau protein across the three disease stages. However there was a trend of a gradual
increase of Tau levels in the MV patients, with the highest levels in the last stage (median
1909 pg/mL in the second and 2601 in the third) and in VV patients (median 5949
pg/mL in the second and 10422 in the third stage of the disease).
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S100b levels were analysed in 297 samples, 37 in the first stage (12%), 112 in the
second (38%), 148 in the third (50%). The disease stage clearly influenced the S100b
sensitivity with a significant increase (p=0.01) in the latest stage (Table 1). The absolute
levels of S100b (Byk-Sangtec® kit) also increased across the disease (p<0.05). 
NSE levels were assessed in 217 samples, and those obtained in the last stage gave
a significantly higher sensitivity (83%) when compared to the second stage (67%,
p=0.01).
Table 1: Sensitivity of markers in sporadic Creutzfeldt-Jakob disease at different disease stages, in the
whole group and stratified by codon 129 PRNP genotype
*Adjusted by country of origin, gender, disease duration, age of onset. 
† percentages
MM=  methionine homozygous; MV= methionine/valine; VV= valine homozygous
NSE= neurone specific enolase 
The cut-off value for Tau was 1300pg/ml; for S100b 4.2ng/ml, for the Byk-Sangtec® kit and 0.5ng/ml for the 
non-commercial kit used in the United Kingdom; and 35ng/ml for the Hoffman La Roche® kit and 25ng/ml for
Byk-Diasorin®, Byk-Sangtec® and Wallac® kits for NSE.
First
stage†
N Second
stage†
N Third
stage†
N P for
trend*
Positive 14-3-3 87.6 120/137 88.0 278/316 91.3 347/380 ns
MM 94.0 79/84 90.6 155/171 93.3 166/178 ns
MV 60.0 15/25 69.8 37/53 89.2 58/65 0.01
VV 100.0 6/6 95.7 44/46 92.2 47/51 ns
Positive Tau 80.9 38/47 84.9 107/126 90.5 153/169 ns
MM 83.9 26/31 88.2 60/68 92.9 79/85 ns
MV 42.9 3/7 65.2 15/23 80.6 25/31 0.048
VV 100.0 1/1 100.0 17/17 96.0 24/25 ns
Positive S100b 73.0 27/37 81.3 91/112 93.9 139/148 0.01
MM 78.6 22/28 81.4 48/59 97.1 68/70 0.02
MV 25.0 1/4 66.7 10/15 78.6 22/28 ns
VV 0.0 0/1 89.5 17/19 100.0 23/23 ns
Positive NSE 82.5 33/40 67.1 53/79 82.7 81/98 0.01
MM 86.7 26/30 68.9 31/45 84.9 45/53 0.02
MV 50.0 2/4 41.7 5/12 72.7 16/22 ns
VV 0.0 0/1 76.9 10/13 87.5 14/16 ns
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Levels of Tau protein, S100b and NSE in CSF were negatively correlated with
disease duration (non-parametric correlation coefficient Spearman's Rho=Tau
innogenetics -20% (p<0.001), S100b Byk-Sangtec® -17% (p=0.002), S100b in house
-18% (p=0.01), NSE Hoffman-la Roche® -21% (p=0.001)). Patients with a median
disease duration of 5 months or less had a median Tau protein level of 6407 pg/mL (75-
3623), whilst patients with a disease duration of longer than 5 months had a median Tau
protein level of 4411 pg/mL (75-47150), (Mann-Witney test p<0.001). 
Sixty-eight out of 1552 (4%) sCJD patients underwent more than one LP (at least
two). The median time lapse between the LPs was 6 weeks. Forty-four (65%) of these
cases were positive for 14-3-3 in the first LP (Figure 1). This value was different from
the sensitivity in the whole group (85%, p<0.01). Fifty-four (79%) of sCJD cases had a
positive 14-3-3 in the second sample (p=0.06). Thirty-eight (56%) sCJD patients had a
positive 14-3-3 in both samples, and 60 (88%) patients had at least one positive 14-3-3.
Twenty-two sCJD patients (32%) changed their result for 14-3-3 in the second LP. Sixty-
six percent of false negative sCJD became positive but 14% of those positive for 
14-3-3 became negative in the second LP. 
The sensitivity of the other markers was also significantly lower in the first LP
when compared to the whole group of sCJD (p<0.05). However, the sensitivity of these
markers increased in the second sample when compared to the first, although not
significantly. Eighty-one percent of sCJD cases had positive Tau protein levels in one of
the two LPs, but only 60% of cases had positive levels in both of them (Figure 1). With
respect to S100b and NSE, 66% and 70% of sCJD patients had positive results in one of
the two LPs and 53% and 33% in both of them, respectively.
Figure 1: Sensitivity of markers for sporadic Creutzfeldt-Jakob disease diagnosis in repeated lumbar
punctures (LP) and combined results in both LP. 
LP= lumbar puncture, + = positive, NSE= neurone specific enolase.
We also found that the absolute levels of all three quantitative markers tended to
increase in the second LP. This tendency was significant for S100b (median levels: 4.5
ng/ml (1-112) in the first LP, median levels: 7 ng/ml (1-38) in the second; p=0.027)
(Figure 2). In 39 out of 53 (74%) samples the levels of Tau protein were higher in the
second LP than in the first LP. NSE levels were higher in the second LP when compared
to the first in 32 out of 46 (70%) samples, and S100b levels were higher in the second
LP when compared to the first in 27 out of 38 (71%) samples.
Figure 2: Levels of quantitative markers in repeated lumbar punctures.
When we compared the characteristics of the sCJD patients who underwent
repeated LP to the overall group of sCJD we found that these patients were younger at
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onset (median/mean age: 61years SD 9.8 vs. 66 years SD 9.6) and more frequently under
40 years (6% vs.1%, p<0.001). They had a longer disease duration (median/mean: 12.8
months SD 8.7 vs. 7.9 months SD 7.8) and were more frequently heterozygous at codon
129 (p<0.001). 
Discussion
Previous data about the influence of timing on the levels of CSF markers for CJD
diagnosis are contradictory. The studies vary with respect to their methodology and
often, only single patients were included in the analysis. Jimi et al9 showed in a
sequential study that the levels of CJD markers increased during the course of the
disease and returned to normal or mildly elevated levels in the terminal stage.
Mollenhauer et al11 also discussed the difficulties of CJD diagnosis in advanced cases
presenting one sCJD case that became 14-3-3 negative in the final stage of the disease.
On the other hand, Giraud et al8 reported an increase in the levels of 14-3-3 proteins
during the course of the disease in a limited number of sCJD cases. Brandel et al7
performed a sequential study in iatrogenic CJD, and observed that 14-3-3 was rarely
detectable within the first 3 months of the disease but always positive after 7 months
associated with aggravation of the disease and the occurrence of dementia. The genotype
at PRNP codon 129 influenced the timing of the rise of 14-3-3 in the CSF in these cases.
Kropp et al10 studied NSE levels in 16 sCJD patients with repeated LP. In 15 of them,
NSE levels were higher in the second LP with respect to the first, but no other markers
were studied and the disease duration or the PRNP genotype were not analysed. Finally,
in a recent study, van Everbroeck et al13 reported that in 42 sCJD patients the
concentrations of 14-3-3 or Tau protein were higher in the middle point of the disease
(arbitrarily determined between the 25% and 85% of the total disease duration) than in
the early or late stage. 
In the framework of a multinational project, we studied the influence of timing on
the CSF marker results in 833 sCJD patients. As the disease duration differs among CJD
patients, we decided to analyse the influence of the stage of the disease, and not the
absolute time to the disease onset or death, on the results of the CSF markers in order to
avoid a bias towards the results in patients with shorter disease duration. On the other
hand, in order to study the influence of timing on the different PRNP genotypes we also
performed a stratified analysis by the PRNP genotype.
Our study showed a tendency for the sensitivity of all CSF markers to increase and
for the absolute levels of the quantitative markers to rise during the course of the disease,
using both the multivariate analysis and the assessment of the repeated LPs. Thus, CSF
markers had the highest sensitivity at advanced stages of disease. The codon 129 PRNP
genotype modified this effect. The trend for a higher sensitivity of 14-3-3 and Tau
protein for sCJD diagnosis in the later stages of disease became significant in the group
of codon 129 MV patients. In addition, we found that higher levels of Tau protein were
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associated with a shorter survival, similiar to the results of another study, where CSF
phosporylated Tau protein levels were analysed.12 High levels of other brain-derived
proteins (S100b, NSE) were also significantly associated with shorter survival. These
brain-derived proteins are released into the CSF as a result of cell damage or death, and
as such the levels of these markers reflect the rate of cell death are probably inversely
related to disease duration. In those sCJD patients who had more than one LP performed,
we found that the sensitivity of all CSF markers increased in the second LP when
compared to the first LP. In more than 70% of all sCJD cases tested the absolute levels
of the three quantitative markers also increased in the second LP. Sporadic CJD patients
who underwent a second LP differed from the whole group, in that they were younger,
had a longer disease duration and were more frequently heterozygous for PRNP codon
129 when compared to the whole group. These characteristics made them a more
difficult group to diagnose and may explain why a second LP was performed. In this
group of atypical sCJD patients a second LP increased the 14-3-3 sensitivity by 14%. 
In conclusion, in our study we found that the sensitivity of the CSF markers for
sCJD diagnosis increased during disease progression and that this was modulated by the
codon 129 genotype. High levels of CSF brain-derived proteins were associated with a
shorter survival. A negative CSF 14-3-3 result in the early stages should be interpreted
with caution, especially in MV patients. Although performing a second LP is not usual
clinical practice for the diagnosis of CJD, it may be useful to perform a second LP, 4-6
weeks after the initial one, in young patients, and those patients with long clinical course
or MV genotype. 
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4.3
CSF analysis in patients with sporadic CJD and other
transmissible spongiform encephalopathies
Abstract
Patients with suspected Creutzfeldt-Jakob disease (CJD) often have routine
cerebrospinal fluid (CSF) analysis performed to exclude treatable inflammatory
conditions, however little information is available about the range of results obtained for
CSF tests in patients with sporadic CJD and other transmissible spongiform
encephalopathies (TSE). The objective of our study was to examine the CSF white cell
counts, total protein concentrations and the presence of oligoclonal IgG in patients with
sporadic CJD and TSEs. Data from 450 patients with sporadic CJD and 47 patients with
other TSEs were collected as part of an EC-supported multinational study. Raised cell
counts of >5 cells/µl were found in three patients out of 298 patients with sporadic CJD,
but none had a cell count of >20 cells/µl. Total protein concentrations of >0.9g/l were
found in 5 of 438 patients with sporadic CJD, although none had a concentration of
>1g/l. CSF oligoclonal IgG was detected in eight out of 182 sporadic CJD patients. In
the patients with other TSEs none had CSF cell counts above 20 cells/µl or total protein
concentrations of >0.9g/l and only 1 patient with fatal familial insomnia had detectable
oligoclonal IgG. None of the patients with sporadic CJD or other TSEs had
abnormalities in all three tests. When investigating patients with suspected TSEs the
presence of a CSF cell count of more than 20 cells/µl or a total protein concentration of
1g/l or more suggests an alternative diagnosis.
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Introduction
The analysis of cerebrospinal fluid (CSF) in patients with suspected sporadic
Creutzfeldt-Jakob disease (CJD) is an important investigation in the diagnostic workup.
The detection of CSF 14-3-3 is a useful diagnostic test for this condition provided it is
used in the appropriate clinical circumstances.1,2 The major differential diagnosis of
sporadic CJD is other neurodegenerative diseases such as Alzheimer's disease, however
a small proportion of patients with suspected sporadic CJD may have inflammatory
conditions that are potentially treatable.3 Standard CSF examination has an important
utility in identifying these conditions in patients with suspected transmissible
spongiform encephalopathies (TSEs). There have been a number of studies showing that
there are no substantial inflammatory changes within the CSF of patients with CJD, but
most of these reports have only included small numbers of cases or are single case
reports.4-8 In this study we describe the results of the white cell count, total protein and
oligoclonal IgG found in neuropathologically confirmed cases of sporadic CJD, genetic
CJD, variant CJD and fatal familial insomnia.
Methods
The study was conducted in the framework of an EC-supported multinational study. The
countries involved were Greece, Germany, Italy, Poland, Spain, Slovakia, Switzerland
and the United Kingdom. CSF lumbar punctures were performed as part of the routine
diagnostic investigation of the patient by each of the requesting hospitals. As a part of
this examination CSF white cell count, total protein and the detection of oligoclonal IgG
were performed. CSF samples were also sent to national laboratories for 14-3-3 analysis
and the results of the white cell count, total protein and oligoclonal IgG were obtained
by the centres from the notifying hospitals. The diagnoses of sporadic CJD and the other
forms of TSE were made according to recognized neuropathological criteria and genetic
analysis.9,10 Core clinical data such as age at onset, gender, disease duration, codon 129
genotype and neuropathological diagnoses were centralized by each centre. A database
was set up which included detailed data on the CSF tests and patients characteristics.
CSF results were available from 450 patients with sporadic CJD, 32 patients with
genetic CJD, 7 patients with variant CJD, and 8 patients with fatal familial insomnia
(Table 1). All CSF samples included in the study were clear and colourless; any blood-
stained CSF samples were excluded. The patient demographics are shown in Table 1. A
white cell count greater than 5 cells/µl was considered to be raised and a total protein of
greater than 0.6g/l was considered to be abnormal.
All statistical analyses were performed using SPSS 11.0 for Windows 2000 (SPSS
Inc, Chicago, Illinois).  Fisher's exact and Mann-Whitney tests were used to assess
differences between qualitative and quantitative variables respectively.
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Table 1: Patient demographics and number of patients investigated for each of the cerebrospinal fluid
parameters, for each TSE group
FFI: fatal familial insomnia
Results
Raised white cell counts were detected in three out of 298 of patients with sporadic CJD,
three out of 23 patients with genetic CJD, one out of six patients with variant CJD and
two out of three patients with fatal familial insomnia (Table 2). Of the three patients with
sporadic CJD with raised cell counts, only one patient had a cell count of greater than
10 cells/µl, being 20 cells/µl.  In neither the FFI nor the genetic CJD cases did the cell
count exceed 20 cells/µl. In none of these cases were there any unusual features to
account for presence of a raised white cell count. 
Total protein concentrations of greater than 0.6g/l were found in 44 out of 438
patients with sporadic CJD, although only five of these patients had levels of greater
than 0.9g/l and none had a value of greater than 1g/l. These five patients had a median
age at disease onset of 75 (range: 66-82) and a median disease duration of nine months
(range: 2-15). Age at disease onset was significantly higher than that found in the
sporadic CJD group with total protein concentrations of <0.9g/l, (median 66 years, range
19-88), p<0.05. Two of these patients were homozygous for MM at codon 129 and the
remaining three were heterozygous for methionine and valine. Only one patient with
genetic CJD and one patient with FFI had total protein concentrations of greater than
0.6g/l but in neither of these cases did the protein concentration exceed 0.9g/l.
Oligoclonal IgG was detected in 4.4% of patients with sporadic CJD and in one patient
with FFI, but not in any patient with genetic CJD or variant CJD, (Table 2).
N Females
(%)
Median age
at onset in
years (range)
Median disease
duration in
months (range)
Number tested
for white cell
count
Number test-
ed for total
protein
Number tested
for presence of
oligoclonal IgG
Sporadic CJD 450 245 (54.4) 66 (19-88) 5 (1-48) 298 438 182
Genetic CJD 32 19 (59.4) 60 (41-77) 6 (2-34) 23 32 10
FFI 8 0 (0) 54 (24-63) 15 (8-23) 3 8 5
Variant CJD 7 2 (28.6) 33 (25-43) 14 (10-27) 6 7 0
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Table 2: Frequency of abnormal CSF white cell counts, raised total proteins and the presence of
oligoclonal IgG
* Significantly different from sporadic CJD, p=0.01. Fisher exact test 2-sided.
When the patients were considered together as a TSE group and the results of the
tests combined, only 0.6% of patients had a raised total protein concentration and an
elevated white cell count. Only 1% of patients had a raised total protein concentration
plus detectable oligoclonal IgG. None of the patients had abnormalities in all three CSF
parameters (Table 3).
Table 3: Number of patients with abnormalities in more than one CSF parameter
Discussion
A raised CSF total protein concentration was most common abnormality found in this
study, with 10% of sporadic CJD patients having concentrations of greater than 0.6g/l,
however only 1.1% of patients had a total protein concentration of greater than 0.9g/l.
Interestingly the median age at onset of disease of these patients was significantly higher
than that of the rest of the sporadic CJD group. There is evidence that the concentrations
Diagnosis CSF white cells
count >5/µl (%)
CSF total protein
>0.6g/l (%)
CSF total protein
>0.9 g/l (%)
Presence of oligo-
clonal IgG (%)
Sporadic CJD 3 (1.0) 44 (10.0) 5 (1.1) 8 (4.4)
Genetic CJD 3 (13.0)* 1 (3.1) 0 (0) 0 (0)
FFI 2 (66.7)* 1 (12.5) 0 (0) 1 (20.0)
Variant CJD 1 (16.7) 0 (0) 0 (0) 0 (0)
Test combination Number
tested
Number of patients
with abnormalities (%)
Raised white cell count + total protein >0.6 g/l 319 2 (0.6)
Raised white cell count + total protein >0.9 g/l 319 1 (0.3)
Oligoclonal IgG + total protein >0.6 g/l 194 2 (1.0)
Oligoclonal IgG + total protein >0.9 g/l 194 0 (0.0)
Raised white cell count + oligoclonal IgG 136 0 (0.0)
Raised white cell count + total protein >0.6 g/l + oligoclonal IgG 134 0 (0.0)
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of both albumin and IgG within the CSF increase with age,11,12 and as both of these are
the major proteins in CSF it suggests that the concentration of total protein will also
increase with age. It has also been proposed that reduced CSF flow rate may increase
total protein concentrations.13,14 As body movement aids the CSF flow rate being bed-
bound may reduce the CSF flow rate and, as a result increase CSF total protein
concentrations. In this study we found that the median disease duration in sporadic CJD
patients with a CSF total protein concentration of greater than 0.9g/l, was longer than
those with total protein concentrations of less than 0.9g/l.  Therefore it is possible that
the raised total protein concentrations found in these patients reflect the age and
immobility of the patient rather than any underlying pathology.
The prevalence of CSF oligoclonal IgG in sporadic CJD was found to be 4.4%,
which is less than that found in a previous study that reported a prevalence of oligoclonal
IgG of 8%.8 Interestingly, a study investigating patients with primary neurodegenerative
dementia also found oligoclonal IgG in 7% of their patients, although only a few of these
patients had neuropathological examination.15 All of the patients in our study had
neuropathological examination and none had evidence of an inflammatory disorder.
In the other sub-types of TSE investigated patients with FFI and genetic CJD had
a higher frequency of raised white cell counts when compared to those with sporadic
CJD. FFI patients also had elevated total protein concentrations and a higher frequency
of oligoclonal IgG. These results may reflect the small numbers of FFI and genetic CJD
patients investigated when compared to sporadic CJD. It is of interest that only a small
number of patients in this study had more than one abnormality and none had
abnormalities in all three of the parameters investigated. 
This study has shown that whilst a small percentage of patients with CJD may have
isolated increases in CSF white cell count or total protein the magnitude of these
changes are small and that the presence of CSF oligoclonal IgG is also rare. None of the
patients investigated had abnormalities in all three of these parameters which suggests
that the isolated changes seen are not due to a classical inflammatory response. Raised
white cell count and total protein in the CSF is unusual in TSE. The presence of more
than 20 cells/µl and/ or 1g/l of proteins in the CSF suggests an alternative diagnosis.
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4.4
Determinants of diagnostic investigation sensitivities
across the clinical spectrum of sporadic 
Creutzfeldt-Jakob disease
Abstract
To validate the provisional findings of a number of smaller studies and explore
additional determinants of characteristic diagnostic investigation results across the entire
clinical spectrum of sporadic Creutzfeldt-Jakob disease (CJD), an international
collaborative study was undertaken comprising 2451 pathologically confirmed
(definite) patients. We assessed the influence of age at disease onset, illness duration,
prion protein gene (PRNP) codon 129 polymorphism (either methionine or valine) and
molecular sub-type on the diagnostic sensitivity of EEG, cerebral MRI and the CSF 
14-3-3 immunoassay. For EEG and CSF 14-3-3 protein detection, we also assessed the
influence of the time point in the patient's illness at which the investigation was
performed on the likelihood of a typical or positive result. Analysis included a large
subset of patients (n=743) in whom molecular sub-typing had been performed using a
combination of the PRNP codon 129 polymorphism and the form of protease resistant
prion protein (type 1 or 2 according to Parchi et al1) present in the brain. Findings for the
whole group paralleled the subset with molecular sub-typing data available, showing
that age at disease onset and disease duration were independent determinants of typical
changes on EEG, while illness duration significantly influenced positive CSF 14-3-3
protein detection; changes on brain MRI were not influenced by either of these clinical
parameters but overall, imaging data were less complete and consequently conclusions
are more tentative. In addition to age at disease onset and illness duration, molecular
sub-type was re-affirmed as an important independent determinant of investigation
results. In multivariate analyses that included molecular sub-type, time point of the
investigation during a patient's illness was found not to influence the occurrence of a
typical or positive EEG or CSF 14-3-3 protein result. A typical EEG was most often seen
in MM1 patients and was significantly less likely in the MV1, MV2 and VV2 sub-types,
whereas VV2 patients had an increased likelihood of a typical brain MRI. Overall, the
CSF 14-3-3 immunoassay was the most frequently positive investigation (88.1%) but
performed significantly less well in the very uncommon MV2 and MM2 sub-types. Our
findings confirm a number of determinants of principal investigation results in sporadic
CJD and underscore the importance of recognizing these pre-test limitations before
accepting the diagnosis excluded or confirmed. Combinations of investigations offer the
best chance of detection, especially for the less common molecular sub-types such as
MV2 and MM2.
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Introduction
Pre-mortem diagnosis of the rare, transmissible neurodegenerative disorder, sporadic
Creutzfeldt-Jakob disease (CJD), largely relies on an appropriate clinical profile
supported by characteristic findings on routine investigations such as the electroen-
cephalogram (EEG) and cerebrospinal fluid (CSF) analysis.2 Neuropathological
examination of the brain remains necessary to achieve a definite diagnosis. Cerebral
magnetic resonance imaging (MRI) may also demonstrate highly suggestive changes
and is assuming a greater role in CJD evaluation but is not currently included in
diagnostic criteria for surveillance purposes.3-6 Although the diagnostic utility of these
investigations (particularly the EEG and CSF 14-3-3 protein detection) has been
supported by a number of studies7-9, they remain imperfect surrogate markers, with
apparent non-uniform sensitivity across the clinical spectrum of sporadic CJD.1
Different clinical and pathological sub-types of sporadic CJD have been linked to
polymorphism status at codon 129 of PRNP combined with the type (1 or 2) of protease-
resistant prion protein (PrPSc) found in the brain, and together these probably define
different human prion strains.1,10,11 The most widely used scheme distinguishes only two
PrPSc types,1 while another commonly employed nomenclature delineates a greater
number.10 Employing this nosology to sub-type sporadic CJD, the EEG has been shown
to vary widely between the specific molecular sub-types in demonstrating characteristic
or typical changes.1,12 Generally, the likelihood of characteristic changes on the EEG was
reported to be highest in MM homozygotes, reduced in heterozygotes and lowest in VV
carriers. Immunoassay for 14-3-3 proteins in CSF, increasingly utilized in the diagnostic
evaluation of patients with suspect CJD,9 has also been shown to vary in rates of
positivity according to molecular sub-type, with the likelihood of noticeably reduced
detection rates in heterozygous patients with type 2 PrPSc (MV2).12-14 A notable difficulty
with all previous reports assessing rates of positive diagnostic investigations in
molecular sub-types of sporadic CJD is the small numbers of patients studied, especially
the less common phenotypic sub-types. Such small patient numbers militate against the
reliability of the observations and have precluded multivariate analyses to assess for
covariates and probable confounding factors. As a corollary, unexplored so far, is
whether within each of the molecular sub-groups and across the phenotypic spectrum of
sporadic CJD, there are additional independent variables influencing diagnostic test
results. Consequently, there remains a need to more confidently establish the diagnostic
utility of these investigations across the various molecular sub-types of sporadic CJD
and define further determinants of their sensitivity and specificity across the entire
clinical range. More clearly defining additional factors influencing the sensitivity and
specificity of these principal investigations has important practical implications when
investigating individual patients. 
As part of a collaborative, multi-national, CJD surveillance program (EUROCJD)
initiated in 1993, we assessed the effect of patient clinical features such as age at onset,
illness duration and PRNP codon 129 polymorphism on the diagnostic sensitivity of
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EEG, CSF 14-3-3 immunoassay and cerebral MRI in a large, population-based sample
of 2451 pathologically confirmed (definite) sporadic cases of CJD, employing
harmonized case definitions and data sets. Further, similar analysis was undertaken in a
subset of patients (n=743) in whom molecular sub-typing using brain PrPSc isotype and
codon 129 polymorphism had been determined. Inclusion of this data allowed detailed
assessment of the variation in positive test results across the molecular sub-types, as well
as whether patient parameters such as of age at onset, illness duration and time point at
which the investigation was performed were additional independent determinants of
investigation results.
Patients and Methods
The present study was undertaken as part of the ongoing activities of the prospective
CJD surveillance program (EUROCJD) conducted by the European Union and allied
countries. In 1993, national surveillance registers commenced in France, Germany, Italy,
the Netherlands, Slovakia and the United Kingdom, with the aim of ascertaining all
patients diagnosed with probable or definite CJD in the respective countries. The study
was extended in 1997 and again in 1998 to include Australia, Austria, Canada, Spain and
Switzerland. EUROCJD collaborative study methods utilizing standardized case
definitions and centralized harmonized demographic data sets were as described
previously.15,16
The study comprised all patients (n=2451) with definite sporadic CJD who died
between December 31st, 1992 and December 31st, 2002; 136 cases from Australia, 68
from Austria, 146 from Canada, 491 from France, 450 from Germany, 342 from Italy,
100 from the Netherlands, 438 from the UK, 18 from Slovakia, 183 from Spain and 79
from Switzerland. A diagnosis of definite sporadic CJD required neuropathological
confirmation most commonly performed post-mortem but occasionally through brain
biopsy. Analysis of the PRNP open reading frame was performed in the majority of
patients to exclude genetic CJD, as clinical differentiation from sporadic CJD is not
always possible.17,18 Of the 2451 patients, 746 had their brain PrPSc isotype determined,
which in combination with PRNP codon 129 genotyping allowed molecular sub-typing
according to the system of Parchi et al.1 Whenever possible, PrPSc typing was based on
analysis of a number of brain regions, including cerebral cortex, striatum or thalamus
and cerebellum, although the preferred number and precise location of sampling sites
varied between participating countries. 
Whenever possible, all EEGs and MRI brain scans were reviewed by a member of
the surveillance system and scored for the presence or absence of typical or
characteristic diagnostic features. EEG records were scored positive or characteristic
when they fulfilled validated criteria:8 sustained periodic sharp wave complexes
(PSWC) with a variability of less than 500 ms, with the periodic complexes (lasting 100-
600ms) demonstrating a bi-or tri-phasic morphology and seen in a generalized or
lateralized distribution. The CSF 14-3-3 immunoassays were performed in each of the
national surveillance centres using Western blotting, with conformity of testing methods
and results interpretation confirmed by blinded sample exchange programs. On cerebral
MRI, high signal in the putamen and caudate nucleus when using long-repetition time
pulse sequences was considered a positive finding for sporadic CJD;3 however, there was
no systematic use of particular techniques such as fluid attenuated inversion recovery
(FLAIR) or diffusion weighted imaging (DWI). For assessment of the influence of the
timing of the investigation during a patient's illness on the test result, data sets for EEG
and CSF 14-3-3 protein detection were sufficient to allow this type of analysis. We chose
to divide the symptomatic phase into thirds (initial, middle and last) rather than into a
greater number of epochs. This was to ensure avoiding the creation of illness periods of
such brevity, especially at the onset of symptoms, that they would be unlikely to
correspond to a clinically meaningful phase of a patient's illness during which
investigations would usually be undertaken, and if undertaken because of the
development of symptoms suggesting neurological dysfunction, that these features were
sufficiently developed that the investigations had a reasonable likelihood of displaying
abnormalities. All data were centralized and analyzed collaboratively. 
Statistical analysis
Descriptive statistics were calculated for the whole sample and for every molecular sub-
type of the disease. Fisher's Exact and Mann-Whitney tests were used to assess
differences between qualitative and quantitative variables, respectively. The number of
positive findings, (acknowledging patient may have undergone multiple tests) over the
total number of tested CJD cases for EEG, MRI and the CSF 14-3-3 immunoassay was
determined for each stratum. The frequency of positive results (number of positive test
results in total number of patients) was then calculated for EEG, MRI and the CSF 
14-3-3 test for each stratum. 
In order to analyze the independent effect of each factor on positive test results,
taking into account possible confounders, we fitted two multiple logistic regression
models with the test result as output. Both models included age at onset, and disease
duration as predictors, and included country of origin, year of death and gender as
covariates.
In the first model PRNP codon 129 genotype was entered as a predictor, while in
the second model we used the molecular sub-type (combination of PRNP codon 129
genotype and PrPSc type). Age at onset was categorized into clinically meaningful
groups, with patients younger than 50 years serving as the reference group. Disease
duration was also categorized with the same criteria into three groups: duration <6
months, 6 months to <1 year, and longer than 1 year. PRNP codon 129 genotype was
entered in the model using two dummy variables, with MM as the reference group; for
molecular sub-types we created eight dummy variables (MM2, MM1/2, MV1, MV2,
MV1/2, VV1, VV2, and VV1/2) with MM1 group as reference. Adjusted odd ratios and
95% confidence intervals were generated. All statistical analyses were performed using
SPSS 11.0 for Windows 2000 (SPSS, Inc, Chicago, Illinois).
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Results
Table 1 summarizes the salient features of all definite sporadic CJD cases. Of the 2451
patients identified, 1329 were females (54.2%). The median age at death was 68 years
(range 20-95 years), while the median disease duration was five months (range 1-81
months). 
Table 1: Summary of clinical features of all patients, including the subset undergoing molecular sub-typing
Total number All patients Patients with molecular
sub-typing
Female (%) 1329 (54.2) 392 (52.8)
Median of age at onset (range) 67.2 (15.6-94.9) 66.2 (15.6-90.0)
Age at onset <50 (%) 116 (5.1) 39 (5.5)
Age at onset 50-59 (%) 412 (18.2) 141 (19.7)
Age at onset 60-69 (%) 867 (38.3) 286 (40.0)
Age at onset 70-79 (%) 729 (32.2) 212 (29.7)
Age at onset >80 (%) 137 (6.1) 37 (5.2)
Median duration of illness in months (range) 5 (1-81) 5 (1-62)
Patients with durations <6months (%) 1332 (58.8) 404 (56.5)
Patients with duration 6-12 months (%) 611 (27.0) 179 (25.0)
Patients with durations >12months (%) 321 (14.2) 132 (18.5)
Codon 129 genotype
Met-Met/Total (%) 1061/1604 (66.1) 504/743 (67.8)
Met-Val/Total (%) 272/1604 (17.0) 117/743 (15.7)
Val-Val/Total (%) 271/1604 (16.9) 122/743 (16.4)
Patients with PRNP gene sequenced (%) 1492 (63.6) 650 (87.5)
PrP isotype
type 1 495/743 (66.6) 495/743 (66.6)
type 1 and 2 44/743 (5.9) 44/743 (5.9)
type 2 204/743 (27.5) 204/743 (27.5)
EEG
Typical/Total (%) 1216/2083 (58.4) 371/666 (55.7)
14-3-3 protein in CSF
Positive/Total (%) 1340/1521 (88.1) 486/554 (87.7)
MRI
Characteristic findings/Total (%) 405/1036 (39.1) 150/387 (38.8)
An EEG was performed on 2083 patients (85%). Of those undergoing EEG, 1216
cases showed typical PSWCs (58.4%) (Table 1). The codon 129 genotype had a
significant effect on the likelihood of a positive result of the EEG in sporadic CJD
patients (Table 2), which ranged from 73.2% in MM homozygotes to 21.5% in VV
homozygotes. After adjusting for possible confounding variables (country, sex, year of
death, age at onset and disease duration), the prevalence of PSWC on the EEG was
significantly decreased in heterozygotes (p<0.001) and VV homozygotes (p<0.001).
The median age of death of sporadic CJD patients with a typical EEG was 69.0 years
(range 34 to 92) versus 66 years (range 20 to 88) in patients with an atypical EEG
(p<0.001). The presence of PSWC was further analyzed by age at onset and disease
duration (Table 3). The likelihood of a typical EEG steadily increased with age
(p<0.001, adjusted for the same variables), while there was an inverse correlation with
disease duration (p=0.001).
Table 2: Summary of principal investigation findings for all patients who underwent PRNP codon
129 genotyping
Adjusted by: age at onset, disease duration, sex, country of origin, year of death.
CSF 14-3-3 protein analysis was performed on 1521 cases (62.1%) of sporadic
CJD. Of these, 1340 cases were positive (88.1%) (Table 1). Although the frequency of a
positive CSF 14-3-3 immunoassay was high for all three codon 129 genotypes,
heterozygotes had a significantly lower rate (77.0%) in adjusted analyses than VV
(p<0.001) and MM (p<0.05) (Table 2). Age at disease onset did not influence CSF 
14-3-3 protein detection but as for the EEG a positive result was less likely with longer
disease duration (Table 3) (p<0.001).
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EEG MRI 14-3-3 protein in CSF
Typical/Total (%) Typical/Total (%) Positive/Total (%)
PRNP genotype
M/M 710/970 (73.2) 172/474 (36.3) 709/796 (89.1)
M/V 99/245 (40.4) 65/134 (48.5) 147/191 (77.0)
V/V 50/233 (21.5) 71/139 (51.1) 184/196 (93.9)
P-value <0.001 0.004 0.002
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Table 3: Principal investigation findings for all patients according to age at disease onset and 
duration of illness
Adjusted by: PRNP codon 129 genotype, sex, country of origin, year of death.
EEG MRI 14-3-3 protein in CSF
Typical/Total (%) Typical/Total (%) Positive/Total (%)
Age at onset
Age at onset <50 (%) 35/104 (33.7) 18/58 (31.0) 62/77 (80.5)
Age at onset 50-59 (%) 197/371 (53.1) 83/196 (42.3) 222/260 (85.4)
Age at onset 60-69 (%) 457/796 (57.4) 166/415 (40.0) 472/545 (86.6)
Age at onset 70-79 (%) 438/675 (64.9) 126/328 (38.4) 452/492 (91.9)
Age at onset >80 (%) 81/124 (65.3) 12/37 (32.4) 73/83 (88.0)
P for trend <0.001 0.3 0.4
Disease duration
Patients with durations <6 months (%) 814/1228 (66.3) 203/587 (34.6) 779/840 (92.7)
Patients with durations 6-12months (%) 283/558(50.7) 125/287 (43.6) 358/408 (87.7)
Patients with durations >12months (%) 115/288 (39.9) 77/160 (48.1) 146/211 (69.2)
P for trend 0.001 0.4 <0.001
MR brain imaging was performed on 1063 patients (42.3%). Of these patients, 405
patients showed characteristic changes (39.1%) (Table 1). In contrast with the EEG, the
likelihood of a positive MRI scan was higher in cases with the MV (p<0.05) and VV
genotypes (p=0.002) in comparison to those with an MM genotype (Table 2). MRI
results were not significantly associated with age at onset or disease duration (Table 3).
Analysis of sporadic CJD patients according to molecular sub-type
In 743 patients their codon 129 polymorphism and brain PrPSc isotype were determined
allowing molecular phenotypic sub-stratification (Table 1).1 In 87 % of these patients the
PRNP gene was sequenced, ruling out pathological mutations associated with genetic
CJD. In comparison to the entire group, the median age at onset, median disease
duration and PRNP codon 129 polymorphism distributions were similar, and there were
no significant differences in the overall rates of positive results for each of the
investigations. The most common PrPSc isotype was type 1 (67%); type 2 was present in
27% of the sample, and in 44 cases (6%) there was coexistence of both type 1 and 2. 
The relative frequency of the various molecular sub-types is provided in Table 4.
There were occasional significant differences in demographic characteristics between
sub-groups. MM1 patients were the oldest at disease onset (median 67.8years) and VV1
patients the youngest (median 47.2 years). The duration of the disease was significantly
shorter in MM1 patients (median 4 months) in comparison to the rest, especially the
MM2 (median 12.5 months) and MV2 (median 12 months) sub-groups, with these
groups also demonstrating a higher percentage of patients with disease lasting more than
one year (57% and 52%, respectively). Of note, albeit the small patient numbers
preclude statistically significant differences, patients with co-existence of PrPSc types 1
and 2 (MM1/2, VV1/2, and MV1/2) tended to have intermediate phenotypes but
generally aligning more to the most common molecular PrPSc sub-type within each
PRNP codon 129 genotype. 
Overall, determinants of investigation findings in patients who underwent
molecular sub-typing were the same as for the entire group. Independent of disease
duration and molecular sub-type, age at disease onset correlated significantly with a
positive EEG result (p=0.007) (Figure1). Patients who developed symptoms below age
50 years had a lower rate of typical PSWCs (22%) than patients presenting after age 60
years. The median age at onset of the patients with an atypical EEG was 64 years (range
16 to 86), compared with 68 years (range 31 to 90) in patients showing the typical
findings. CSF 14-3-3 protein immunoassay and MRI results were not significantly
correlated with patient's age at disease onset.
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Figure 1: The principal investigation results for EEG, brain MRI, and CSF 14-3-3 protein analysis
were correlated with age at disease onset in sporadic CJD for all patients undergoing molecular sub-
typing. Patients were grouped by age at onset; <50 years, 50-59 years, 60-69 years, 70-70 years, and
> 80 years. Only the EEG showed a significant correlation with age at disease onset.
† Significantly lower than in <50years group (p<0.05). Adjusted by molecular sub-type, disease duration, sex,
country of origin and year of death.
The duration of disease was independently associated with the likelihood of
PSWCs. Patients with disease duration shorter than 6 months had a significantly higher
rate (p=0.02) of a typical EEG than patients with duration longer than 12 months (65%
versus 35%, respectively). The median disease duration of patients with an atypical EEG
was 6 months (range from 1 to 62) versus 4 months (range from 1 to 39) in patients with
typical EEG. Disease duration significantly (p=0.004) influenced the likelihood of a
positive CSF 14-3-3 test result. Those patients with disease duration shorter than 6
months had a higher rate of positive test results than those with duration longer than 12
months (91% versus 72%, respectively). On average, patients with 14-3-3 proteins
detectable in their CSF had shorter disease durations (median 5 months, range from 1 to
39) than patients with a negative test result (median 11 months, range from 2 to 54).
MRI results did not correlate with disease duration (Figure 2).
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Figure 2: The principal investigation results for EEG, brain MRI, and CSF 14-3-3 protein analysis
were correlated with disease duration in sporadic CJD for all patients undergoing molecular sub-
typing. Disease duration was arranged as; <6 months, 6-12 months, and >12 months. For both the
EEG and CSF 14-3-3 protein detection there was a significant inverse correlation with disease
duration of greater than 12 months.
* Significantly lower than in <12months group (p<0.05). Adjusted by molecular sub-type, age at onset, sex, country
of origin and year of death.
Certain molecular sub-types showed significant correlations with investigation
results. MM1 patients demonstrated the highest frequency of positive EEG results (73%)
followed by MV1 patients (53%), although after adjusting for covariates the significance
was reduced (p=0.01). VV2 and MV2 patients had infrequent occurrence of a typical
EEG, with a positive result only observed in 12.8% and 17.5% of the cases, respectively
(Figure 3). Of the sub-groups with coexistence of PrPSc types, only VV1/2 patients were
significantly lower. CSF 14-3-3 immunoassay was the most frequently positive
investigation, with an overall positive rate of 88%. However, there were some significant
variations across molecular sub-types, with the test significantly more often positive (all
p<0.05) for MM1 and VV2 patients (91% and 95%) than for MM2 (61%) and MV2
(71%) (Figure 3). Of the patient groups with coexistence of PrPSc types, only MM
homozygotes had a significantly lower rate of positive results for this test (Figure 3). For
MRI, only the VV2 sub-group demonstrated a significantly increased likelihood of a
typical positive result. Of note, within each molecular sub-type except VV1, occasional
patients did not display typical or characteristic findings with any of the three
investigations.
Figure 3: The sensitivities of EEG, brain MRI and CSF 14-3-3 protein detection were assessed
according to the sporadic CJD molecular sub-type: MM1, MM2, MM1/2; MV1, MV2, MV1/2; and
VV1, VV2, and VV1/2. The MV1, MV2, VV2 and VV1/2 sub-types all showed a significantly reduced
EEG sensitivity, while the VV2 sub-type displayed a significantly higher likelihood of a typical MRI
result. The MM2, MM1/2, and MV2 sub-types all showed significantly reduced rates of CSF 14-3-3
protein positivity. 
*Significantly lower than MM1 (p<0.05). 
† Significantly higher than MMI (p<0.05). Adjusted by age at onset, disease duration, sex, country of origin and
year of death.
Assessment of the influence of the time point of the investigation during a patient's
illness on the test result
For both EEG and the detection of CSF 14-3-3 proteins, sufficient data were available
to also analyse the influence of the time point at which the investigation was performed
during the patient's illness on the likelihood of a typical or positive result. With the
median duration of illness only 5 months, we chose to divide the symptomatic phase into
thirds (initial, middle and last) rather than into a greater number of epochs. This was
undertaken to avoid the creation of illness phases of such brevity, especially at the onset
of symptoms, that they would be unlikely to correspond to a clinically meaningful period
of a patient's illness during which investigations would usually be undertaken and that
the test would have a reasonable chance of showing typical abnormalities. 
With respect to EEGs, 2425 recordings with a known time point in relation to the
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chronology of the patient's illness were available for analysis. When analysed in
isolation, the likelihood of a typical EEG was significantly less in the first third of a
patient's illness compared to the last third (p=0.02). Multivariate analysis (adjusted by
country, gender, year of death, age at onset, disease duration and codon 129
polymorphism) also showed a positive EEG was significantly more likely in the last
third of a patient's illness compared to the first third (p=0.001). When a patient's
molecular sub-type was substituted for codon 129 polymorphism in the same regression
model however, a typical periodic EEG was no longer significantly more likely in any
particular time period of the patient's illness. These results are consistent with a patient's
molecular sub-type constituting the dominant determinant of the likelihood of a positive
EEG rather than the specific time point at which the test is undertaken in the
symptomatic period. Detection of CSF 14-3-3 proteins showed no significant
association with the time point of sampling during a patient's illness, regardless of
whether assessed in isolation or in analogous multivariate analyses.
Discussion
The current study is by far the largest to date to assess the diagnostic sensitivity of
investigations usually employed in the evaluation of suspected sporadic CJD. By virtue
of the large number of definite sporadic CJD patients comprising our study we have
been able to confidently delineate the sensitivities of the principal investigation results
across the entire phenotypic spectrum, especially the less common molecular sub-types,
as well as clarify and extend hitherto uncertain independent determinants of
investigation results.16 Analysis of only neuropathologically confirmed CJD patients has
allowed us to avoid the inherent difficulties that arise from analysis of investigations that
also serve in case definition criteria for probable cases; however, it is noteworthy that
separate analysis of all EUROCJD sporadic CJD patients from this time period, that is,
inclusion of clinically probable cases, gave the same results as analysis of just definite
cases (data not shown). Multivariate regression modelling demonstrated that age at
disease onset and disease duration both act as independent determinants of some
investigation results in sporadic CJD, in addition to the influence of molecular sub-type.
Consequently, in the clinical evaluation of suspect CJD, our findings reinforce the
importance of fully appreciating the limitations of specific investigations relative to
these salient patient clinical features, otherwise the heightened likelihood of a negative test
result may be underestimated and incorrectly interpreted as undue reassurance against the
diagnosis. Specifically, the probability that an EEG will demonstrate PSWCs increases
with age and conversely decreases with disease duration, especially if longer than 12
months. Hence, in a patient under 50 years it is most likely that an EEG will not show
typical changes, and even in older patients, if their illness is longer than 6 months, the
probability of PSWCs is at best only around 50%. In contrast to a prior smaller study12
disease duration longer than 12 months was also observed to significantly lessen the
likelihood of a positive CSF 14-3-3 result. This underscores the importance of
acknowledging illness duration when interpreting a negative result in an individual
patient suspected to be manifesting sporadic CJD.
The present study re-affirmed that molecular sub-type, in addition to age at onset
and illness duration, is also an important independent determinant of principal
investigation results.1,4,10,12-14 In contrast to the EEG, where the presence of valine alleles
at codon 129 additively reduces the likelihood PSWCs, valine homozygotes (especially
VV2 patients) were significantly more likely to demonstrate a typical MRI scan than
methionine homozygotes (particularly the MM1 sub-group). These data conform to a
pattern whereby sub-types with 'classical' sporadic CJD and predominant cerebral
cortical involvement (MM1 and MV1) are more likely to manifest PSWCs on EEG,
while those with ataxia and subcortical neuropathological changes (VV2 and MV2) are
more likely to demonstrate characteristic basal ganglia changes on MRI. However, in
contrast to a prior report suggesting phenotypic homogeneity between the MM1 and
MV1 sub-types,1 we found that the likelihood of a typical EEG was significantly lower
and the average illness duration significantly longer in the MV1 patients. The most
likely explanation for this difference in findings is the much larger sample of MV1
patients available for analysis in our study.
The CSF 14-3-3 protein immunoassay was the most sensitive investigation across
the sporadic CJD phenotypic spectrum, but the influence of molecular sub-type was still
evident. Codon 129 heterozygotes, especially the MV2 sub-group, were significantly
less likely to be associated with a positive result,9,12-14 as were the very uncommon MM2
and MM1/2 sub-groups. In comparison to the simple demographic features of age at
disease onset and illness duration, the molecular sub-typing profile is much less likely
to be available pre-mortem in individual patients. Nevertheless, if this information is
available investigation results would also need to be interpreted in this specific context
for the most accurate estimation of excluding or confirming the likelihood of sporadic
CJD. Recognizing these overall limitations and variations across the molecular sub-
types, from a practical clinical perspective it would appear prudent to utilize all three
principal investigations (brain MRI, CSF 14-3-3 protein analysis and EEG), as
irrespective of molecular sub-type only very uncommonly (except the rare MM2 sub-
group) will all three investigations not show characteristic findings in an individual
patient with sporadic CJD.5
Our analyses do not support that the time point at which the investigation is
undertaken during a patient's illness is an important determinant of the test result. This
was particularly evident for CSF 14-3-3 protein detection, for which no association
between time point of sampling and a positive result was found regardless of analytical
approach. For EEG, the apparent reduced likelihood of a typical or periodic recording in
the first third of a patient's illness compared to the last period, when examined in
isolation or with one of the multivariate regression models, was no longer evident when
the regression model included molecular sub-type. These findings are again consistent
with the generally dominant influence of age at onset, illness duration and molecular
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sub-type as the key independent determinants of investigation results compared to the
time point of test sampling during a patient's illness.
Although molecular sub-typing of sporadic CJD patients has proven a useful
phenotypic classification system, there are some difficulties with this approach. Not
uncommonly, more than one PrPSc type may be present in the brain of a patient dying
from sporadic CJD1, and it is likely that the frequency of occurrence increases with the
number of regions assessed.19,20 At present, there is no consensus on how to classify such
patients and whether it is generally better to adopt a dichotomised approach based on
predominance of one type when several regions are studied or accept classification
based on the analysis of only one or two brain sites. In our study, patients with more than
one PrPrSc type were a small minority, but such patients were allowed status as a separate
group within each PRNP genotype without attempting to adjust for relative abundance
of the two PrPSc types. Regardless of PRNP genotype, our patients with simultaneous
occurrence of both PrPSc types tended to present a different phenotype, sometimes
intermediate between those with a single PrPSc isotype and the same codon 129 status,
but often extending beyond the range observed. This suggests that the simultaneous
presence of two PrPSc types may evoke a third or unique phenotype within each codon
129 genotype, although our small patient numbers militated against achieving
significance with these observations. Analysis of investigation results also generally
suggests that sub-groups with co-existence of PrPSc isotypes tended to appear different
although not invariably. For CSF 14-3-3 results, the MM1/2 group behaved more like
MM2 patients, and for the EEG the VV1/2 group were also more like the VV2 patients.
The latter is in keeping with the predominant phenotypic influence of type 2 PrPSc on
these investigations or may simply represent a sampling bias wherein type 2 PrPSc was
under-appreciated as the dominant protease resistant isotype across the brain. 
MRI brain imaging is now very commonly employed in the diagnostic evaluation
of suspected sporadic CJD but its ultimate sensitivity and specificity is still being
defined.3-6,21 For a number of reasons, our overall sensitivity for typical changes on MRI
scan is lower than that reported in much smaller studies.4-6,12,22 Importantly, patient MRI
data collected for this study extended over a decade, during which time this imaging
technique was increasingly used in the evaluation of suspect sporadic CJD, and there
were concurrent improvements in the diagnostic sensitivity of pulse sequences used for
this illness.3,5,6 Consequently, the overall number of patients studied with MRI was
relatively low (42.3%), and the utilisation of optimised MRI techniques such as DWI and
FLAIR mainly occurred only in the very latter phase of our study epoch and even then
was not uniformly adopted by all neuro-imaging services. Further, during the study
period there was progressive appreciation that increased cerebral cortical signal using
the more sensitive techniques of DWI and FLAIR is probably a reasonably common
feature in sporadic CJD.5,6 Consequently, another reason for our low MRI sensitivity
relates to our restrictive definition of what changes we considered characteristic of the
diagnosis (i.e. signal hyperintensity limited to the basal ganglia). Overall, this
combination of factors has compromised our assessment of the true diagnostic
sensitivity and clinical utility of MRI in the evaluation of sporadic CJD. This sub-
optimal aspect of the present study is being redressed by a further prospective
EUROCJD collaborative project. 
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Introduction
Due to the unique characteristics of the transmissible agent and its public health
implications, the group of transmissible spongiform encephalopathies (TSE) has been
object of a considerable amount of attention from the scientific community and even for
the general society, especially after the bovine spongiform encephalopathy (BSE) crisis.
Taking into account that the estimated incidence of this group of diseases is around 1 to
2 cases per million-year,1,2 this is something exceptional. Since the transmissibility of the
disease was proven3 and the protein-only hypothesis proposed as the most commonly
accepted pathogenic theory,4 both achievements awarded with the Nobel Prize, we have
learnt a great deal about the mechanisms involved in these diseases. However, important
challenges remain, the most important one is perhaps that of developing an effective
treatment.
This thesis focuses on two issues: aetiological factors and clinical diagnosis. The
data collected have been scrutinized under two main prisms: classical epidemiology in
search of environmental factors, and genetic epidemiology in search of genetic
determinants and interactions between genetic and environmental factors. The studies
are all product of collaborative efforts, fruit of the work of multidisciplinary teams of
national and international epidemiological surveillance networks.
The objectives of this chapter are the following to: present the main findings of the
studies included in this thesis, put them into perspective of each other and of the current
scientific knowledge, discuss the most relevant methodological issues and finally
outline the directions for further research in light of the findings of this thesis.
Epidemiology of CJD
The national Creutzfeldt-Jakob disease (CJD) surveillance systems were originally
created with the objective of monitoring the disease trends and detecting the potential
emergence of atypical cases, especially cases of variant CJD (vCJD).5 Moreover,
independently of its public health function, the establishment of international
surveillance networks has contributed enormously to broaden the scientific knowledge
of TSEs, favoring the exchange of knowledge among experts from different countries,
encouraging scientific collaborations, and facilitating the generalization and
standardization of new diagnostic techniques. Most importantly, it enabled to collect
large series of cases and controls using a common protocol and homogeneous
procedures.
In chapter 2.1 we discussed methodological issues concerning the set up of a
multinational collaborative network like the extended European collaborative study
group of CJD (NEUROCJD) and the results of their monitoring activities during a 
8-years period in Belgium, Denmark, Finland, Greece, Iceland, Ireland, Israel, Norway,
Portugal, Sweden and the United Kingdom. The overall annual mortality rate of CJD in
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the 11 studied countries from 1997 to 2004 was 1 case per million inhabitants. This
figure is in agreement with most of the studies carried out until now.2 There were some
variations across time and among countries but they were not statistically significant. 
The main objective of the CJD surveillance systems is the detection of cases
related to the BSE epizootic. These include vCJD cases which are known to be related
to BSE, but also new clinical forms of disease. The potential occurrence of these new
phenotypes might be determined by factors like host genome and route of infection. We
first aimed to unravel how frequent the different clinical presentations of CJD were,
starting with the most common subtype: sCJD. The commonest clinical presentations
were the rapidly progressive dementia (74%), followed by the ataxic onset (9%).
Although much less frequent than the first two, visual presentation (Heidenhein's
syndrome) (4%) was also well recognized. Other clinical presentations, psychiatric
(3%), sensory (2%), and extrapyramidal (0.4%) were recognized less frequently. Finally,
6% of the cases presented with a slowly progressive dementia syndrome. Furthermore,
we defined atypical CJD cases according to three criteria: age at onset<50 years, illness
duration >1 year and atypical clinical presentation being defined as any other than
rapidly progressive dementia, cerebellar or Heidenhein's. During the study period we
ascertained 27 sCJD patients (6% of the total) younger than 50 years at onset, 51 sCJD
patients (12% of the total) with disease duration superior to one year, and 69 (6%) sCJD
patients with atypical clinical onset. Excluding the UK, only one case of vCJD, in the
Republic of Ireland, was diagnosed during the period of observation in the countries
participating in NEUROCJD.
In chapter 2.2 we present a case-report of the first vCJD patient ascertained in the
Netherlands. The clinical characteristics of the patient, MRI scan images,
neuropathological study, PrPSc western blot profile and PRNP M129V genotype, were all
indistinguishable from that reported in UK vCJD patients. These similarities suggest that
our patient shares a common etiological agent with the UK cases. The identification of
this patient had important public health implications for the country. The most
immediate one was that it contributed to call attention of the medical community. Soon
after the description of the first case a second one was identified.6
Case-reports are often criticized as anecdotic7 and not reliable scientific evidence.
However, the history of CJD research is a very good example of their potential
importance in the study of rare diseases. Case-reports have played a fundamental role in
CJD research. After the first experimental transmission of CJD in 1968 further evidence
came through the descriptions of cases transmitted iatrogenically via corneal
transplantation and neurosurgical procedures.9,10 It was thanks to a series of cases, vCJD
was first identified in the UK.11 It also has been an important tool for identifying new
vCJD cases linked to blood transfusion.12 However, case reports have obvious limitations
for assessing the effect of common exposures, offering sometimes contradictory
evidences. Even for well-established risk factors, it is sometimes very difficult to
confirm a solid causal link with the disease. For instance, the second iatrogenic CJD
case associated to human growth hormone in the Netherlands received only a very small
dose with diagnostic purposes 38 years before the disease onset.13
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Another question addressed in this thesis (chapter 3.1) is the origin of vCJD cases
outside the UK. The fact that the first Dutch vCJD patient never traveled to the UK, and
the relatively low BSE incidence in the Netherlands, less than 80 BSE cases14 had been
detected until that time, led us to the conclusion that the most likely cause of our
patient's disease had been the bovine material imported from the UK during the BSE
epizootic in that country. In chapter 3.1 we assessed the role of UK bovine exports in the
spread of vCJD to countries outside the UK. We found a positive correlation between the
amounts of material imported from the UK during the 80s and the number of vCJD cases
ascertained. Specifically, live bovine seemed to be the main independent factor
associated to the occurrence of vCJD outside the UK. The greatest volume of these
exports went to France, the Netherlands and Ireland, the three countries with higher
number of vCJD cases outside the UK.
The occurrence of vCJD and its causal link with bovine spongiform
encephalopathy in cattle15 have increased interest in the search for possible
environmental sources of sCJD. Iatrogenic CJD is rare. Horizontal transmission of the
disease has been linked to human corneal grafting, human dura mater grafts, human
growth hormone treatment, human pituitary gonadotrophin therapy and neurosurgical
procedures or stereotactic EEG electrodes.16 Epidemiological studies have tried to
elucidate the role of hidden environmental factors in the etiology of sCJD.17-30 Despite
these efforts, the mode of transmission of sCJD, if any, remains unknown. However, the
rarity of this entity, and the fact that in case of transmission the disease develops after a
usually very long incubation period, makes its epidemiological study very challenging.
In chapter 3.2 we present the results of a case control study carried out in the UK
assessing the past history of ophthalmic surgery as a risk factor for sCJD and vCJD. We
did not find evidence of any association between past history of ophthalmic surgery and
risk of either sCJD or vCJD. The findings of our study are consistent with several
previous case-control studies assessing the history of eye surgical procedures as a
possible hidden risk factor for sporadic CJD.22,23 However, these findings contrast with
an Australian study in which cataract/eye surgery increased risk of sCJD more than 6
folds in comparison to community controls.24 One interesting finding in our study is that
sCJD patients with early visual symptoms, especially patients with Heidenhein's form of
CJD, are often referred at first to ophthalmologists, and not infrequently they are
diagnosed with cataracts and often treated. Considering that the eye of CJD patients has
proved to be infectious, and the level of infectivity is thought to increase with the clinical
course of the disease,31 the information included in our study is of potential interest for
ophthalmologists and public health. 
Epidemiological studies assessing the role of common exposures as CJD risk
factors face important methodological challenges. Classically, in CJD research, the case-
control design has been the main approach in looking for environmental etiological
factors. However, there are important methodological issues. First of all, and due to the
special characteristics of the disease, it is very unlikely that at the moment of the
diagnosis the patient is able to answer a questionnaire about past exposure. Therefore,
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this information comes most of the times from an interview with their relatives, and this
should be taken into account when interviewing controls, which ideally should be
carried out with identical methodology in order to avoid information bias. Another
possible source of information bias is the different means of obtaining the information
in cases and controls. For example, in a surgical risk assessment study, community
controls were interviewed telephonically by non-medically trained interviewers.24 The
selection of controls is always a crucial issue for all case-control studies. A potential
problem of the use of hospital controls is that it may lead to bias towards high exposures
for medical disorders, surgery or blood transfusion because a person that is already
hospitalized is more likely to have a history of previous medical or surgical
interventions. On the other hand, in studies with community controls it is likely that
some patient's relatives may report more events than controls, simply because they are
more willing to thoroughly recall past exposures motivated by the disease in their
relative. This would lead us to a recall bias, which is certainly another source of
information bias. A possible way to avoid information bias when assessing surgery as a
possible risk factor for CJD would be to collect all case and control data directly from
the medical records. This implies a considerable effort and would require excellent
medical records, which are not likely to be available in all countries. But some countries
like the Scandinavian would be suitable, and indeed a study with such characteristics is
currently ongoing.
Genetic determinants of CJD
Clustering of CJD has been shown by several studies. Common environmental factors
have been proposed as a possible explanation but this clustering might be caused by
genetic factors as well.27 Genealogical clustering of Dutch sCJD cases included in our
national registry is higher than expected by chance (data no published). Several case-
control studies have shown an association with family history of dementia.22 There are
animal studies suggesting that genetic loci, other than the prion protein gene (PRNP)
open reading frame, might be involved in the disease susceptibility and incubation
period.32 In this thesis we have performed two genetic association studies in order to
assess other genetic factors independently of the well-known PRNP M129V
polymorphism associated with CJD.
Genetic association studies are one of the main tools of genetic epidemiology for
identifying genomic variants underlying susceptibility to genetically complex diseases.
However, obtaining replication of the initial findings has proved to be difficult.33
Multiple reasons may explain this problem including inadequacies in study design, small
samples, population admixture, multiple testing or genotyping errors. A common
concern is multiple testing. Currently, most molecular biology techniques are highly
automated. This has made it possible to genotype large numbers of single nucleotide
polymorphisms (SNPs) across the whole genome. One of the prices that we have to pay
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for this great advance is the increase in false positive rate (type I error) or spurious
associations due to the exponential increase of statistical tests with a very low a priori
probability. There are several options in order to deal with this problem. It has been
proposed to decrease the cutoff point level of what we consider as statistically
significant proportionally to the number of tests performed, as the case of Bonferroni
correction. Less conservative approaches like the permutation test are being developed.
A strategy to possibly minimize type I error due to multiple testing is to always design
and interpret the statistical analysis in the light of what we know about biology. In
chapter 3.3 we studied the association between CJD risk and genetic variations in the
non-coding region upstream PRNP gene. The polymorphisms studied were selected
based on their location in a region known to affect the expression of the PRNP gene. By
studying functional polymorphisms we increase the a priori probability of our test,
hence, diminishing type I error. In our population based study we found that being
carrier of the infrequent allele of the regulatory region polymorphism PRNP G310C was
associated to increased risk of sCJD and earlier disease onset. Moreover we found
statistical evidences of an interaction between the effects associated to the PRNP G310C
polymorphism and PRNP M129V. A possible explanation for our findings may stem
from in vitro experiments suggesting that the PRNP 129M allele results in a higher
propensity of the PrP to form beta-sheet-rich oligomers.34 This indicates that 
PRNP 129M may facilitate self-perpetuating conformational changes of the human
prion protein. Therefore, PRNP 129M may be by itself a potential risk factor for sCJD.
Assuming that PRNP 310C allele increases PRNP expression, if the overexpressed prion
protein carries M instead of V, this haplotype may work synergistically increasing the
risk of sCJD and diminishing the age at symptoms onset.
In chapter 3.4 we performed another genetic association study. We examined the
association between the Tau protein gene (MAPT) haplotypic variants and risk of CJD.
Although MAPT is a good candidate gene, which has been associated before to several
neurodegenerative diseases, its possible relationship with CJD has never been tested
before. We examined 6 haplotype tagging SNPs (htSNPs), which capture 95 % of MAPT
genetic variability in Caucasians. A Dutch population-based sample of sCJD patients
and a cognitively normal control group of similar age distribution were genotyped. We
genotyped the same polymorphisms in two other sCJD samples from Italy and the UK.
Single locus and haplotype analyses did not detect any significant difference between
sCJD cases and controls. 
Apart from PRNP 129MM genotype selectivity, susceptibility to vCJD is still
largely unexplained. A recent publication showed that CSF levels of phosphorilated-Tau
are higher in vCJD patients than in sCJD35 suggesting that there might be some
differences in the mechanisms governing Tau protein phosphorilation between sCJD and
vCJD. Therefore, we were interested in comparing MAPT variations between sCJD and
vCJD. We did not find any differences in allelic or genotypic distributions between the
two groups. When we compared MAPT haplotypes, we found that two of them were
represented differently in sCJD and vCJD patients (H1f: 8% in sCJD versus 2% in
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vCJD; H1j:1% in SCJD versus 7% in vCJD). However, these two haplotypes were rare
in both groups of patients, and taking the small sample sizes into account, we think that
the differences are likely due to chance. None of the p-values (p=0.04 and p=0.01)
would remain statistically significant after applying a multiple testing correction like
Bonferroni. Although our findings are compatible with a role of MAPT in vCJD
susceptibility, the evidence is far from convincing at this stage.
Diagnostic investigations of CJD
There have been several studies assessing specificity and sensitivity of the three main
diagnostic tests of CJD.36-38 An important section of this thesis is devoted to the study of
the main tests employed for the clinical diagnosis of human TSEs. This is a crucial issue
because, until now, there are no clinical tests allowing a definite diagnosis of CJD. The
available diagnostic investigations currently used in clinical practice are imperfect
surrogate markers of CJD. Thus, in order to correctly interpret results, it is very
important to know which factors are modulating the test sensitivities and specificities.
Equally important is to know how these tests do perform across the wide phenotypic
spectrum of TSEs, understanding the variation of test sensitivities associated to the
disease subtype. Studies addressing these questions are scanty in the scientific
literature.39-42
Determinants of diagnostic investigations of CJD
Currently, the definite diagnosis of CJD relies on the neuropathological examination of
the brain, which is in the majority of cases carried out post-mortem because the
performance of brain biopsy needs special precautions and it is rarely indicated during
the diagnosis workup. The pre-mortem diagnosis of CJD largely depends on an
appropriate clinical context supported by characteristic findings on routine
investigations such as the electroencephalogram (EEG) and the cerebrospinal fluid
(CSF) analysis. Therefore, when a diagnosis of CJD is suspected, investigations are
required first to rule out any alternative diagnosis and to support the diagnosis of CJD.
Current diagnostic criteria (Table 1) are based upon the combination of progressive
dementia, myoclonus, multifocal neurological dysfunction and a characteristic EEG or
CSF detection of 14-3-3 protein.43
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Table 1: Diagnostic criteria for sporadic, familial and iatrogenic CJD
When assessing the main factors likely to modulate CJD diagnostic tests
sensitivities we faced several methodological difficulties. Many of the factors that we
have investigated, as possibly influencing tests outputs, are correlated among each other.
This complicates the interpretation of our statistical analyses because multiple
confounders and covariates have to be taken into account. A multivariate analysis
adjusting for all these covariates and confounders is therefore needed in order to assess
independently the relation between these factors and the output of diagnostic tests.
However, in order to perform this kind of analysis with enough statistical power, we need
a large sample of patients. The only possible way to perform these studies with such a
rare disease is within the framework of international collaborations which are able to
collect sufficient data studied with a homogeneous methodology. In order to make a
correct estimate of the sensitivity of a test, a gold standard for comparison is needed. In
the case of TSEs the diagnostic gold standard is the neuropathological confirmation.
Therefore, in theory, we should include only definite cases for this kind of studies. This
restriction considerably reduces the number of available patients. An additional specific
problem of sCJD, may be the fact that the probable diagnosis is based on both clinical
signs/symptoms and diagnostic tests. Therefore, if we assess the sensitivity of a sCJD
diagnostic test with cases that have been defined based on the result of that same test,
we are entering a vicious circle. Although conceptually this may look a serious hazard,
in practice, our results do not change considerably whith or without excluding probable
Disease type Classification Criteria
Sporadic CJD definite post mortem examination
probable I progressive dementia and
II at least two out of four features (myoclonus, visual or cerebellar distur-
bances, pyramidal or extrapyramida features, akinetic mutism) and
III a. typical periodic sharp wave complexes on EEG or
b. (since 1998) positive 14-3-3 CSF test and duration less than two 
years
Familial CJD definite I CJD confirmed at autopsy and 
II a. definite or probable CJD described in a first degree relative and/or 
b. disease-specific PRNP mutation in the index patient or the first-
degree relative
probable I probable diagnosis of CJD plus definite or probable CJD in a first
degree relative or 
II progressive neuropsychiatric disorder plus disease-specific PRNP
mutation
Iatrogenic CJD definite CJD confirmed at autopsy and patient known with a recognized exposure risk
probable I progressive cerebellar syndrome in a pituitary hormone recipient or 
II probable CJD case with a recognized exposure risk
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cases from our analyses. This is most likely due to the very high reliability of the current
CJD clinical criteria. A more difficult question is how to study specificity. It is well
known that there are false positive results for all CJD diagnostic tests, but most of the
diseases that can yield false positive results can be easily ruled out by the clinical history.
Hence, in order to assess how accurately these tests discriminate non CJD patients, it is
very important to take the clinical context into account. A clear example of that is the
CSF 14-3-3 protein determination. In theory, a positive result of this test in a compatible
clinical context is thought to be highly specific.38 However, with the increasing
availability of the test, its use is becoming more and more frequent every day, and very
often it is employed not only in patients who fulfill clinical criteria for CJD. For
example, it is often undertaken as part of the diagnostic workup of any other type of
dementia with atypical features or ataxic syndromes. Therefore, it is very difficult to
estimate global specificity, because a large sample of prospectively studied cases with a
common methodology would be needed. As this would be extremely difficult, in order
to study specificity of CSF tests we took a different approach collecting all cases studied
in the national surveillance centers that turned out to be no CJD patients, but had a final
diagnosis, clinical or pathological. That way we focused on describing the false positive
rate of the test for each of the main differential diagnosis of CJD. We believe that this is
a more realistic approach and the information obtained is more useful for the clinician
who can judge each particular patient in the light of her or his clinical context. 
EEG. The presence of characteristic periodic sharp wave complexes (PSWCs) in the
EEG is the most classical sign supporting the diagnosis of sCJD, and it has been the part
of the original diagnostic criteria.44 However, PSWCs are not always present in sCJD
patients. Although they are associated with the most common phenotype of the disease,
other less common forms usually lack this finding.40 EEG plays an important role in the
differential diagnosis between sCJD and vCJD, because in the latter only exceptionally
PSWCs appear. In fact, there are only two reported cases in the literature in whom, at a
very advanced disease stage, PSWCs were detected in the EEG.45,46
We found out that the probability that an EEG demonstrate PSWCs increases with
age at disease onset, and conversely decreases with disease duration. Therefore, these
two factors should be taken into account when interpreting a negative EEG result.
Independently of the previous clinical factors, PRNP V129M modulated EEG sensitivity
to demonstrate PSWCs. We found that EEG positive results ranged from 73% in MM
patients to 21% in VV. Hence, it seems that the presence of V allele reduces the
likelihood of finding PSWCs. This could be explained by the different pathological
profiles associated with the three genotypes with predominant cortical involvement in
MM patients in comparison with the other genotypes.
We specifically assessed the influence of EEG performance time point during the
course of the disease on test sensitivity. We found that the frequency of EEG showing
PSWCs was significantly higher when the test was performed in the last third of the total
disease duration. However, when we adjusted our analysis by the disease molecular
subtype, that difference was not statistically significant. This suggests that the specific
time point when the EEG is undertaken during the course of the disease is not
influencing its sensitivity independently of molecular subtype.
CSF analysis. The development of a method allowing the detection of PrPSc in a
biological fluid remains as the ultimate aim in the field of CJD diagnosis. Meanwhile,
the main diagnostic tool available right now is the detection of brain-derived proteins
present in the CSF as a result of neuronal damage. The presence of these proteins in the
CSF is not specific of CJD, almost any acute brain insult, like inflammation, stroke or
infections can raise the concentration of these markers in the CSF. Therefore they cannot
be used for a general screening of CJD. However, in an appropriate clinical context, like
the case of a patient who fulfills the clinical criteria for possible CJD, the results of these
tests have a very high sensitivity and specificity.38 In 1998 WHO disease criteria
included the 14-3-3 determination in the CSF, making the presence of periodic
complexes in the EEG for the diagnosis of probable sCJD43 not anymore compulsary.
The introduction of the neuronal protein 14-3-3, as part of the CJD diagnostic criteria,
has produced a considerable impact, increasing in most countries the number of CJD
patients ascertained and allowing the identification of uncommon phenotypes usually
lacking PSWCs in the EEG. On the other hand, the use of 14-3-3 test has widely
generalized in the neurological practice and the test is frequently performed in patients
who fail to fulfill the clinical criteria for possible CJD. As one might have expected, the
increase in cases ascertained thanks to the 14-3-3 has paralleled a drop in the global
specificity of the test.47
Even though some studies have previously assessed sensitivity and specificity of
some of these markers,38,48-50 several important questions remain unanswered. In
particular, the question of which factors influence test sensitivities have been only
partially delineated. In order to address some of those important issues an EU-concerted
multinational study (EPICJD) was set up leaded by Professor Inga Zerr from the Georg-
August-University of Göttingen, collecting the largest series of patients to date. The
studies enclosed in chapters 4.1, 4.2 and 4.3 are all product of this collaboration.
In our study we assessed the independent influence on several clinical parameters
like age at disease onset and disease duration on sensitivity of the main CSF markers of
CJD: 14-3-3 protein, Tau protein, neuronal specific enolase (NSE) and the glial protein
S100b. We could show that being older than 40 years and having short disease duration
were independently associated to higher test sensitivity. We also assessed, conjointly
with the previous factors, the role of genetic variations like PRNP codon 129
polymorphism. We showed that being heterozygote for PRNP codon 129 polymorphism
decreased the test sensitivities independently of other factors. Remarkably, we found
similar results for all four markers consistent with a disease dependent effect.
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We specifically addressed the question of the influence of the CSF sample point
timing during the course of the disease as a factor likely to contribute to test sensitivities
of 14-3-3, Tau protein, NSE, and S100b. We observed that 14-3-3 and Tau protein tended
to increase from onset to advanced stage, and this trend was significant for the patients
heterozygotes for PRNP V129M. A possible explanation for this effect of PRNP V129M
polymorphism could be the fact that heterozygote patients may have a lower neuronal
death rate. Therefore, the level of the marker in sCJD may need more time to reach the
threshold established as the cutoff point for a positive test result. As part of the same
study we also analyzed a group of patients who underwent repeated lumbar punctures.
The results were also concordant, and on average we found higher sensitivity in the
second test than in the first. 
Another question that we were able to address was whether a combination of CSF
markers might improve sensitivity and specificity. The combined determination of 
14-3-3 and Tau increased the sensitivity from 85% and 86% to 93%, at the expense of a
specificity drop from 89% to 72% in the group of neurodegenerative diseases.
We also studied the factors modulating specificity when these tests are applied to
a population of patients referred to the surveillance centers. Not surprisingly, the main
predictors of false positive tests were a final diagnosis of inflammatory or
paraneoplastic/CNS tumor disease and the presence of increased cells in the CSF.
In a separate study, but in the same population, we studied routine CSF analysis in
TSE patients. The routine analysis of the CSF is very often performed as part of the
diagnosis workup of CJD patients. Classically, the CSF of CJD patients do not show
inflammatory signs like pleocytosis or significantly high protein elevation. Therefore,
the utility of this test is mainly the exclusion of treatable inflammatory conditions.
However, in the literature the information about the usual range of these main CSF
parameters in TSE patients is scarce as it mostly comes from small studies and it is
restricted to sCJD patients. We studied the main parameters of the CSF routine analysis
in a series of 450 sCJD cases, and 47 patients with other TSEs, including 8 fatal familial
insomnia (FFI) patients, 7 vCJD patients and 32 genetic CJD (gCJD) patients, all of
them with a pathologically confirmed diagnosis. Our study showed that an elevated
number of inflammatory cells (>20cells/µl) strongly militates against the diagnosis of
TSE. Raised levels of total CSF proteins concentration was a common finding in our
patients. However, none of them presented concentrations higher than 1g/l. In 4.4%
percent of our pathologically defined sCJD patients oligoclonal IgG was detected in
CSF, which is lower than that of a previous publication which included cases without a
definite diagnosis.51
MRI scan. The magnetic resonance imaging (MRI) scan is the other fundamental
diagnostic test in the diagnostic workup of sCJD. Currently, the main function of MRI
scaning is the exclusion of alternative diagnoses. However, characteristic signal
alterations in basal ganglia and cerebral cortex are common in sCJD patients52-55 and their
utility for the clinical diagnosis and even their inclusion as part of the sCJD diagnostic
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criteria are currently subject of investigation. Furthermore, MRI scan is already the main
diagnostic test included in the clinical criteria for probable vCJD. In this TSE subtype
the bilateral hyperintensity of the pulvinar nuclei of the thalamus is considered as a very
sensitive sign, present in 78 % of vCJD cases.56 The specificity of the pulvinar sign is
thought to be almost 100%, with just a few false positive cases published in the
literature.57-59
In our analysis we found a lower MRI scan sensitivity than that reported in
previous smaller studies.39,54 However, our data on MRI scans had some important
caveats which made our results less reliable. The MRI scan data collection for this study
extended for more than one decade. Therefore, the imaging techniques employed were
not homogeneous. During the course of the study new sequences with higher sensitivity
to detect the typical findings, like FLAIR or DWI, were progressively employed in CJD
diagnostics. The other main issue that can explain this discrepancy is that for this study,
cerebral cortical increased signal, a sign commonly found in sCJD using the more
sensitive techniques as FLAIR and DWI was not considered as part of the typical
findings. 
Independently of clinical factors, we found out that the probability that a MRI will
show hyperintensity in the basal ganglia is strongly modulated by PRNP V129M
genotype. In contrast to what we found in EEG, the likelihood of a typical MRI scan was
higher in cases with the MV and VV genotypes. A likely explanation for this finding
would be again the different pathological profiles associated to PRNP V129M
genotypes. In that way, MRI scan seems to be a good complementary test to EEG
because is more sensitive in those patients in whom EEG tests do not frequently show
PSWCs.
Diagnostic test sensitivities across the phenotypic spectrum of sCJD
TSEs have a very wide phenotypic spectrum. The clinical profile and the sensitivity to
the different diagnostic tests are different depending of the disease subtype. Moreover,
within each subtype there is also high variability. In general, the disease phenotype
depends on the interplay between the host characteristics and the etiological agent.
However, the mechanisms underlying this variability are not completely well
understood. One good example is the differences between the clinical profile of the
classical forms of sCJD and vCJD. In vCJD, PSWCs are absent in the EEG almost in
100% of cases, in contrast to the majority of classical sCJD patients in whom this sign
is very a characteristic feature. Another example is the variability of gCJD phenotype
depending on the causal PRNP mutation. For example, as we have shown in our study,
while patients carrying the PRNP E200K mutation present a clinical profile identical to
classical sCJD, with a high percentage of positive 14-3-3 tests, patients carrying any of
the Gerstmann-Straussler-Scheinker (GSS) mutations are negative in most cases. In
addition to the causal agent, also the route of transmission is important. Iatrogenic CJD
(iCJD) presents different phenotypes depending of how the infectious agent reached the
brain, via blood, as in the case of human growth hormone linked cases, or directly put in
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contact to the CNS as the cases linked to dura mater grafts. Last but not least, the
different clinical and pathological subtypes that comprise the wide phenotypic spectrum
of sCJD have been linked to the PRNP M129V polymorphism combined with the type
(1 or 2) of PrPSc found in the brain. These combinations probably define the different
human prion strains.40,60 Some of the phenotypic variants are extremely infrequent and,
therefore, having them all represented in a study requires a very large number of patients
enrolled. Most studies assessing the variations in sensitivity of the sCJD tests across the
phenotypic spectrum of the disease are scarce and of small size. Several of them have
found variations in the sensitivity of the three main tests across the different disease
subtypes.39-42 However, these studies did not perform multivariate analysis and did not
include a sufficient number of cases for some of the rare subtypes. The studies presented
in chapter 4 focus on this fundamental question. We analyzed these variations in
sensitivity of the sCJD tests in the light of the molecular classification of the disease.
They are all international collaborative efforts and comprise the biggest series of
patients ever collected for these purposes.
In order to better understand the interrelations of the different biological factors
likely to influence sensitivity, like age at onset, duration of the disease, or time point
when the test was undertaken we aimed to perform a multivariate analysis. To this end,
we studied, together with the molecular subtypes, all predictors in a multiple logistic
regression model.
We found that the molecular subtypes are indeed the strongest determinants of all
three test sensitivities. Table 2 displays the different test sensitivities across the
molecular classification of sCJD, including as independent groups the combinations
with more than one type of PrPSc in the brain. MM1 and MV1 showed a similar profile,
as reported before (ref Parchi). However, we found significantly higher EEG sensitivity
in MM1 patients. VV2 and MV2 patients rarely presented PSWCs in the EEG. More
frequently than MM1 and MV1 patients they had typical MRI scans. Their main
difference was in 14-3-3 test sensitivity, which was higher in VV2 patients. Tests
performed on patients belonging to the infrequent VV1 subtype usually presented
similar profile than VV2, but the sensitivity of EEG tended to be higher in VV1.
However, the numbers were low. Taking into account our results, MM2 patients seem to
be the most challenging subgroup for diagnosis. In these patients the 14-3-3
determination in CSF had a sensitivity of only 61%, less than 50% for EEG, whereas
MRI was only positive in less than 33% of the patients. Moreover, 5 out of the 16 MM2
patients to whom the three tests were performed were negative for all three
investigations, the highest percentage of all molecular subtypes. Finally, although the
number of patients included in the combined subgroups was too small to draw solid
conclusions, these patients tended to present an intermediate phenotype between those
with single PrPSc type and the same PRNP M129V genotype.
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Table 2: Diagnostic tests sensitivities across the molecular subtype of sCJD
*Significantly lower than MM1 (p<0.05)
†Significantly higher than MM1 (p<0.05)
Adjusted by age at onset, disease duration, gender and country of origin.
Our results offer some useful knowledge to clinicians that may help them when
interpreting these diagnostic investigations. Even though the PrPSc type is most of the
times not available at the moment of the diagnosis, the clinical profile together with the
PRNP M129V information may offer the clinicians enough hints to grasp the patient's
disease subtype, which may help them to better interpret the test results. This
underscores the importance of the PRNP M129V polymorphism testing, especially in
atypical patients, adding extremely valuable information to the clinical context. Finally,
another important lesson that we have learnt from our analysis is the importance of
performing all three tests in the diagnostic workup of patients with suspected TSE, as it
increases the diagnostic probabilities.
Further research
Human surveillance has successfully identified new cases of vCJD, however there
remain possible new challenges. Recent findings like the discovery of new variants of
BSE61 and the proven transmission of vCJD via blood to genotypes other than PRNP
codon 129 MM12 are a warning call to remain watchful for new disease phenotypes.
The question whether iatrogenic exposure via surgery is involved in a significant
proportion of sCJD cases remains without a satisfactory answer. The development of
new epidemiological approaches tackling some of the important caveats of the previous
case-controls studies would be an interesting step forward in order to clarify this issue.
For instance, the use of hospital records instead of interviewing relatives and controls
may be an interesting strategy in order to reduce some unavoidable bias.
Molecular Phenotypes
MM1 MM2 MM1/2 MV1 MV2 MV1/2 VV1 VV2 VV1/2
EEG
Typical/total (%)
294/404
(72.8)
12/27
(44.4)
16/25
(64.0)
18/34
(52.9)*
11/63
(17.5)*
3/7
(42.9)
5/12
(41.7)
11/86
(12.8)*
1/8
(12.5)
MRI
Characteristic
findings/total (%)
70/ 210
(33.3)
5/18
(27.8)
1/16
(6.3)
5/16
(31.3)
24/45
(53.3)
1/3
(33.3)
6/9
(66.7)
37/67
(55.2)†
1/3
(33.3)
14-3-3 protein 
in CSF
positive/total (%)
300/329
(91.2)
14/23
(60.9)*
16/20
(80.0)
25/29
(86.2)
36/51
(70.6)*
4/6
(66.7)
9/10
(90.0)
79/83
(95.2)
3/3
(100.0)
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On the other hand, in the near future it is likely that new genetic determinants of
sCJD will be discovered. Transgenic mice studies have shown that other polymorphisms
inside or outside the open reading frame of PRNP, and even other genes, might be
involved in the disease susceptibility. 
The availability of high throughput genome wide SNP genotyping is opening new
opportunities for genetic epidemiological research like genome wide association studies.
The performance of such studies in large samples of sCJD patients is likely to offer soon
important new insights about the genetic determinants of the disease.
In this same field, an obvious next step for us would be to perform functional
studies assessing whether the PRNP G310C polymorphism is associated with changes
in PRNP expression, and therefore, supporting the findings of our genetic association
study.
It is mandatory to clarify the role of MRI in the diagnosis of sCJD, with studies,
specifically designed to take into account the phenotypic spectrum of the disease, and to
include large numbers of patients. It is important to define what the typical findings for
each of the disease subtypes are, which the most reliable image techniques are, and
finally, to consider the inclusion of MRI scan as part of the sCJD criteria.
The development of a diagnostic technique enabling an early definite diagnosis of
TSEs would be the main goal in terms of diagnostic research. This fundamental step
would facilitate the development and testing of new treatments, which remains as the
most important challenge in the field.
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Summary
Transmissible spongiform encephalopathies (TSE) or prion diseases constitute a
fascinating group of neurological disorders. In spite of their rarity, their unique
etiopathological mechanisms and epidemiological aspects have attracted a considerable
number of researchers. 
This thesis focuses on two facets: etiological mechanisms and diagnostic tests of
Creutzfeldt-Jakob disease (CJD). We have searched new insights into these two topics
using genetic and classic epidemiological methodology. 
For the studies presented in this book, we have used data from the Dutch, Italian
and UK CJD National Surveillance Systems, the 'European collaborative Study group of
CJD' (EUROCJD), the 'extended European collaborative Study group of CJD'
(NEUROCJD), the 'Early clinical diagnosis of human spongiform encephalopathies by
analysis of biological fluids-CJD Markers collaboration' (EPICJD), and the 'Rotterdam
Study'.
Chapter 1 provides the scope of the thesis. Chapter 2.1 describes the design and
characteristics of the extended collaborative study group of CJD (NEUROCJD), and the
results of their monitoring activities during an 8-year period. In this chapter we
summarize relevant methodological issues and discuss the main problems encountered.
The average mortality rate of sporadic CJD during the period of observation was 1 death
per million person-year. The main focus of the study is on describing the disease clinical
presentation of sporadic CJD and the characteristic of the atypical patients. Variant CJD
cases in Ireland and in Portugal were successfully detected by their national surveillance
centres. Chapter 2.2 reports the case of the first variant CJD patient identified in the
Netherlands. The clinical characteristics of the patient, MRI scan images,
neuropathological study, PrPSc western blot profile and PRNP M129V genotype, were all
indistinguishable from that reported in UK vCJD patients.
Chapter 3 explores different hypothesis in relation to the origin of sporadic and
variant CJD aetiology. In chapter 3.1 we correlated UK bovine exports with the spread
of variant CJD to countries outside the UK. We found a positive correlation between the
amounts of material imported from the UK during the 80s and the number of variant
CJD cases ascertained. Specifically, live bovine was found to be the main independent
factor associated to the occurrence of variant CJD outside the UK (rs=0.73; 95%CI=0.42
to 0.89; p<0.001). The greatest volume of these exports went to France, the Netherlands
and Ireland, the three countries with higher number of variant CJD cases outside the UK.
In chapter 3.2 we assessed the causal role of past history of ophthalmic surgery in
sporadic and variant CJD. We found no association with either form of the disease. We
observed that a proportion of sporadic CJD patients presenting with visual symptoms
were often referred at first to ophthalmologists, and not infrequent they were diagnosed
with cataracts and often treated. In chapter 3.3 we studied the association between
sporadic CJD risk and genetic variations in the non-coding region upstream the prion
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protein gene (PRNP). In our population based study we found that being carrier of the
G allele of the regulatory region polymorphism PRNP G310C was statistically
associated (p=0.03) with a 2.4 fold increased risk of developing sporadic CJD
(95%CI=1.1 to 5.4). Cases of sporadic CJD carrying a PRNP 310C allele presented at a
younger age (on average 8.9 years younger than those without this allele), which was of
statistical significance (p=0.05). The polymorphism studied was selected based on their
location in a region known to affect the expression of the PRNP gene. Therefore, our
findings support the hypothesis that genetic variations in the PRNP promoter may have
a role in the pathogenesis of sporadic CJD. In chapter 3.4 we tested the association
between the Tau protein gene (MAPT) haplotypic variants and risk of CJD. We
examined 6 haplotype tagging SNPs (htSNPs), in a Dutch population-based sample of
sporadic CJD patients and a cognitively normal control group of similar age distribution.
We genotyped the same polymorphisms in two other sporadic CJD samples from Italy
and the UK. Single locus and haplotype analyses did not detect any significant
difference between sporadic CJD cases and controls. We did not find any differences in
allelic or genotypic distributions between sporadic and variant CJD. However, we found
that two of them were represented differently in sporadic CJD and variant CJD patients
(H1f: 8% in sporadic CJD versus 2% in variant CJD; H1j:1% in sporadic CJD versus
7% in variant CJD). Yet, when we corrected for the number of tests that were performed,
none of these associations remained statistically significant.
Chapter 4 focuses on the main diagnostic investigations of CJD. In chapter 4.1 we
analysed the diagnostic sensitivity and specificity of various brain-derived proteins 
(14-3-3, Tau, NSE and S100b) in the cerebrospinal fluid (CSF) of patients with CJD and
the biological factors that modify these parameters. In the framework of a multinational
European study (EPICJD), CSF was tested for 14-3-3, Tau, NSE and S100b in 1859
patients with sporadic, genetic, iatrogenic and variant CJD, and in 1117 controls. The
highest sensitivity was achieved for 14-3-3 and Tau in sporadic CJD (85% and 86%),
and a combined determination of 14-3-3 and either Tau S100b or NSE increased the
sensitivity to over 93%. A multivariate analysis showed that the sensitivity of all tests
was highest in patients with the shortest disease duration, age at onset >40 years, and
homozygosity at codon 129 of the PRNP. In a group of patients with repeated lumbar
punctures (LP), a second test also increased the diagnostic sensitivity. Our results
reaffirm that the detection of elevated levels of brain-derived proteins in the CSF in
patients with suspected of CJD is a valuable diagnostic test. The second LP should be
performed in patients with atypical clinical course in whom the first test was negative.
Chapter 4.2 assessed the influence of the time of sampling on the value of CSF tests in
the diagnosis of sporadic CJD. We studied the results of 14-3-3, S100b, NSE and Tau
protein in 833 CSF samples from sporadic CJD patients at different stages of disease and
in 68 sequentially repeated LP. 14-3-3 and Tau protein increased in sensitivity from onset
(88%, 81%) to the advanced stage (91%, 90%). This was significant in the group of
patients with methionine-valine (MV) PRNP codon 129 genotype. The absolute levels
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of S100b (p<0.05), NSE and Tau protein increased in the last stage of disease. High
levels of Tau protein, NSE and S100b were associated with shorter survival times
(p<0.01). Sixty-eight sporadic CJD patients underwent repeated LP. These sporadic CJD
patients were younger, had longer disease durations and were more frequently MV at
codon 129 (p<0.001) than the whole group. 14-3-3 sensitivity increased from 65% to
79% in the second LP (p=0.06) and 88% sporadic CJD patients had at least one positive
result. Sensitivity and absolute levels of CJD markers increased with disease progression
and were modulated by the codon 129 genotype. Early negative results should be
interpreted with caution, especially in young patients or those who are MV at codon 129.
Chapter 4.3 examined the CSF white cell counts, total protein concentrations and the
presence of oligoclonal IgG in patients with human prion diseases. Data from 450
patients with sporadic CJD and 47 patients with other prion diseases were collected.
Raised cell counts of >5 cells/µl were found in three patients out of 298 patients with
sporadic CJD, but none had a cell count of >20 cells/µl. Total protein concentrations of
>0.9g/l were found in 5 of 438 patients with sporadic CJD, although none had a
concentration of >1g/l. CSF oligoclonal IgG was detected in eight out of 182 sporadic
CJD patients. In those patients with other prion diseases, none had CSF cell counts
above 20 cells/µl or total protein concentrations of >0.9g/l and only 1 patient with fatal
familial insomnia had detectable oligoclonal IgG. None of the patients with sporadic
CJD or other prion diseases had abnormalities in all three tests. When investigating
patients with suspected prion disease, the presence of a CSF cell count of more than 20
cells/µl or a total protein concentration of 1g/l or more suggests an alternative diagnosis.
In chapter 4.4 we aimed to define the main determinants of the three characteristic
diagnostic investigations (EEG, MRI scan and CSF 14-3-3 test) sensitivity across the
entire clinical spectrum of sporadic CJD. Our analysis, embedded in the international
collaborative study EUROCJD, comprised 2451 pathologically confirmed patients. Our
results showed that age at disease onset and disease duration were independent
determinants of typical changes on EEG, while illness duration significantly influenced
positive CSF 14-3-3 protein detection. Changes on brain MRI were not influenced by
either of these clinical parameters, but overall imaging data were less complete and,
consequently, conclusions are more tentative. In addition to age at disease onset and
illness duration, molecular subtype (defined as the combination of PRNP codon 129
genotype and PrP type) was re-affirmed as an important independent determinant of
investigation results. In multivariate analyses that included molecular subtype, time
point of the investigation during a patient's illness was found not to influence the
occurrence of a typical or positive EEG or CSF 14-3-3 protein result. A typical EEG was
most often seen in MM1 patients and was significantly less likely in the MV1, MV2 and
VV2 subtypes, whereas VV2 patients had an increased likelihood of a typical brain
MRI. Overall, the CSF 14-3-3 test was the most frequently positive investigation
(88.1%) but performed significantly worse in the very uncommon MV2 and MM2
subtypes. Our findings confirm a number of determinants of clinical, laboratory and
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imaging investigations results in sporadic CJD and underscore the importance of
recognizing these pre-test limitations before accepting the diagnosis excluded or
confirmed. Combinations of investigations offer the best chance of detection, especially
for the less common molecular subtypes such as MV2 and MM2.
In Chapter 5 the main findings of this thesis are presented and put into perspective
of each other, and of the current scientific knowledge. The most relevant methodological
issues are discussed, and finally the directions for further research in light of the
findings of this thesis are outlined.
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Samenvatting
Overdraagbare spongiforme encefalopathie (TSE) oftewel prionziekten vormen een
fascinerende groep van neurologische aandoeningen. Ze komen slechts sporadisch voor,
maar dankzij hun unieke pathologische mechanismen en epidemiologische aspecten
vormen ze een inspiratiebron voor veel onderzoekers. 
Dit proefschrift richt zich op 2 aspecten: de etiologische mechanismen en
diagnostische tests van de ziekte van Creutzfeldt-Jacob (CJD). Met behulp van zowel de
genetische als de klassieke epidemiologische methodologie zochten we naar nieuwe
inzichten in deze twee onderwerpen.
Voor het onderzoek dat in dit proefschrift beschreven staan, maakten we gebruik
van de Nederlandse, Italiaanse en Britse nationale surveillance systemen voor CJD, de
European Collaborative Study Group of CJD (EUROCJD), de Extended European
Collaborative Study Group of CJD (NEUROCJD), de Early clinical diagnosis of human
spongiform encephalopathies by analysis of biological fluids-CJD markers collaboration
(EPICJD) en de Rotterdam Studie.
In hoofdstuk 1 wordt het doel van dit proefschrift uiteengezet. Hoofdstuk 2.1
beschrijft het design en de kenmerken van de extended collaborative study group of CJD
(NEUROCJD), en de resultaten van hun monitoring activiteiten gedurende een periode
van 8 jaar. In dit hoofdstuk vatten we de relevante methodologische vraagstukken samen
en bespreken we de belangrijkste problemen die zich voordeden. Het gemiddelde
sterftecijfer van sporadische CJD gedurende de observatieperiode was 1 geval per
miljoen inwoners. Het belangrijkste doel van de studie was het beschrijven van de
klinische presentatie van de sporadische CJD en de kenmerken van atypische patiënten.
Patiënten met variant CJD in Ierland en Portugal werden succesvol geïdentificeerd door
nationale surveillance centra. Hoofdstuk 2.2 beschrijft het geval van de eerste variant-
CJD patiënt die in Nederland ontdekt werd. Deze vertoont een grote gelijkenis met
eerdere patiënten uit het Verenigd Koninkrijk. Dit suggereert een zelfde oorsprong van
de ziekte. 
In hoofdstuk 3 worden verschillende hypothesen met betrekking tot de etiologie
van sporadische en variant CJD getoetst. In hoofdstuk 3.1 correleerden we de export van
runderen met de verspreiding van variant CJD naar andere landen dan het Verenigd
Koninkrijk. We vonden een positieve correlatie tussen de hoeveelheid materiaal dat
geïmporteerd werd uit het Verenigd Koninkrijk tijdens de jaren '80 en het aantal gevallen
van variant-CJD. De import van levende runderen leek als belangrijkste onafhankelijke
factor gerelateerd te zijn aan het vóórkomen van variant CJD buiten het Verenigd
Koninkrijk (rs=0.73; 95% betrouwbaarheidsinterval=0.42-0.89; p<0.001. Het merendeel
van de export richtte zich op Frankrijk, Nederland en Ierland, de drie landen met het
grootste aantal variant CJD gevallen buiten het Verenigd Koninkrijk. In hoofdstuk 3.2
onderzochten we of er een oorzakelijk verband is tussen het ondergaan van
oogheelkundige chirurgie en het ontwikkelen van sporadische en variant-CJD. Er werd
geen verband gevonden, wel vonden we dat een deel van de sporadische CJD patiënten
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die visuele symptomen had vaak in eerste instantie naar oogartsen werd verwezen en
daar werd gediagnosticeerd met staar en daarvoor behandeld. In hoofdstuk 3.3
bestudeerden we het verband tussen de kans op sporadisch CJD en genetische variaties
in de niet-coderende regio upstream van het prion eiwit gen (PRNP). In ons onderzoek
vonden we dat dragers van het zeldzame allel van het regulerende-regio-polymorfisme
PRNP G310C een 2.4 maal verhoogde kans hebben op de sporadische vorm van CJD.
Dit verhoogde risico was statistisch significant (95% betrouwbaarheidsinterval 1.1-5.4,
p=0.03). Patiënten met sporadische CJD die drager waren van een PRNP 310C allel
werden op jongere leeftijd ziek (gemiddeld 8.9 jaar jonger dan degenen zonder dit allel).
Dit leeftijdsverschil was statistisch significant (p=0.05). De polymorfismes die we
bestudeerden werden geselecteerd gebaseerd op hun lokalisatie in een regio waarvan we
weten dat die de expressie van het PRNP gen beïnvloedt. Onze bevindingen
ondersteunen de hypothese dat genetische variaties in de promoter van het PRNP gen
een rol spelen in de pathogenese van sporadisch CJD. In hoofdstuk 3.4 testten we de
associatie tussen haplotype varianten in het gen dat codeert voor het Tau eiwit (MAPT)
en de kans op CJD. We onderzochten 6 haplotype tagging SNPs (htSNPs), in een
Nederlandse steekproef van sporadische CJD patiënten en een cognitief normale
controle groep met een vergelijkbare leeftijdsverdeling. We genotypeerden dezelfde
polymorfismen in twee andere series patiënten met de sporadische vorm van CJD uit
Italië en het Verenigd Koninkrijk. Met single locus en haplotype analyses werden geen
significante verschillen tussen de sporadische CJD cases en controles gevonden. Ook
vonden we geen verschillen in de allelische of genotypische verdelingen tussen
sporadische en variant CJD. Bij het vergelijken van de MAPT haplotypes ontdekten we
dat twee haplotypen verschillend verdeeld waren bij sporadische CJD en variant CJD
patiënten (H1f: 8% in sporadische CJD en 2% in variant CJD; H1j: 1% in sporadische
CJD en 7% in variant CJD). Echter, na correctie voor het aantal uitgevoerde testen bleek
geen van deze associaties statistisch significant te zijn. 
Hoofdstuk 4 richt zich op de studie van de belangrijkste diagnostische
onderzoeken voor CJD. In hoofdstuk 4.1 analyseerden we de diagnostische sensitiviteit
en specificiteit van verschillende eiwitten uit de hersenen (14-3-3, Tau, NSE en S100b)
in de cerebrospinale vloeistof (CSF) van patiënten met CJD en biologische factoren die
deze parameters modificeren. Binnen een Europese studie (EPICJD) werd het CSF van
1859 patiënten met sporadische, genetische, iatrogene en variant CJD en 1117
controlepersonen getest op 14-3-3, Tau, NSE en S100b. De hoogste sensitiviteit werd
gevonden voor 14-3-3 en Tau voor sporadisch CJD (85% en 86%), en een
gecombineerde bepaling van 14-3-3, óf Tau, óf S100b óf NSE verhoogde de sensitiviteit
tot boven de 93%. Een multivariate analyse toonde aan dat de sensitiviteit van alle tests
het hoogst was voor patiënten met een korte ziekteduur, een leeftijd van 40 jaar of ouder
bij de manifestatie van de ziekte, en homozygositeit op codon 129 van het PRNP. In een
groep patiënten die herhaalde lumbaalpuncties ondergingen, verhoogde een tweede test
de diagnostische sensitiviteit. Onze resultaten herbevestigen dat de detectie van
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verhoogde niveaus van hersen eiwitten in het CSF voor patiënten met een verdenking op
CJD een goede diagnostische test is. Een tweede lumbaalpunctie zou moeten worden
uitgevoerd bij patiënten met een atypisch klinisch verloop waarbij de eerste test negatief
was. In hoofdstuk 4.2 beschrijven we de invloed van het tijdstip van afname op de
waarde van de CSF tests voor de diagnose van sporadische CJD. We onderzochten de
resultaten voor 14-3-3, S100b, NSE en Tau eiwit in 833 monsters van sporadische CJD
patiënten in verschillende ziektestadia en in 68 sequentieel herhaalde lumbaalpuncties
(LP). Tau-eiwit en 14-3-3 verhoogden in sensitiviteit van de beginstadia (onset) (81% en
88%) naar geavanceerde stadia (90% en 91%). Dit was significant voor de groep
patiënten met het genotype methionine-valine (MV) PRNP codon 129. De absolute
niveaus van S100b (p<0.05), NSE en Tau eitwit namen toe in het hoogste ziektestadium.
Hoge niveaus van het Tau eiwit, NSE en S100b waren geassocieerd met kortere
overlevingsduur (p<0.01). Achtenzestig sporadische CJD patiënten ondergingen
herhaalde LP. Deze sporadische CJD patiënten waren jonger, hadden langere
ziekteduren en waren vaker MV voor codon 129 (p<0.001) dan de rest van de groep. De
sensitiviteit voor 14-3-3 steeg van 65% naar 79% bij de tweede LP (p=0.06) en 88% van
sporadische CJD patiënten had ten minste één positief testresultaat. De sensitiviteit en
absolute niveaus van CJD markers namen toe met progressie van de ziekte en werden
gemoduleerd door het codon 129 genotype. Vroege negatieve resultaten moeten
voorzichtig geïnterpreteerd worden, in het bijzonder als het gaat om jonge patiënten of
patiënten die MV zijn voor codon 129. In hoofdstuk 4.3 onderzochten we het CSF op
het aantal witte bloedcellen (cell counts), totale eiwit concentraties en de aanwezigheid
van oligoclonale IgG onder patiënten met humane prionziekten. Er werden gegevens
verzameld van 450 patiënten met sporadische CJD en 47 patiënten met andere
prionziekten. Verhoogde cell counts van >5 cellen per microliter werden gevonden bij
drie van 298 patiënten met sporadische CJD, maar geen van hen had een cell count van
>20 cellen per micoliter. Totale eiwitconcentraties van >0.9 gram per liter werden
gevonden bij 5 van 438 patiënten met sporadisch CJD. Er werden geen concentraties
boven de 1 gram per liter gevonden. CSF oligoclonaal IgG werd gedetecteerd bij acht
van 182 sporadische CJD patiënten. Van de patiënten met andere prionziekten had er
geen een cell count boven de 20 cellen per microliter of totale eiwitconcentraties boven
0.9 gram per liter, slechts 1 patiënt met fatale familiaire slapeloosheid (insomnie) had
detecteerbaar oligonaal IgG. Bij geen van de patiënten met sporadisch CJD of andere
prionziekten werden abnormaliteiten gevonden in de drie tests. Bij het onderzoeken van
patiënten met een verdenking op prionziekten suggereert een CSF cell count van meer
dan 20 cellen per microliter of een totale eiwitconcentratie van 1 gram per liter of meer
een alternatieve diagnose. In hoofdstuk 4.4 onderzochten we de belangrijkste
determinanten van de sensitiviteit van drie karakteristieke diagnostische onderzoeken
(EEG, MRI scan en CSP 14-3-3 tests) over het hele klinische spectrum van sporadische
CJD. Er werd een internationaal samenwerkingsverband (EUROCJD) opgezet  waarbij
2451 pathologisch bevestigde patiënten werden geïncludeerd. Onze resultaten toonden
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aan dat de leeftijd waarop de ziekte zich manifesteerde en ziekteduur onafhankelijke
determinanten van typische veranderingen op een EEG waren, terwijl ziekteduur
significant de detectie van CSF 14-3-3 eiwitten verhoogde. Veranderingen op hersen-
MRI's werden niet beïnvloed door deze klinische parameters, maar in het algemeen
waren de gegevens van de beeldvorming minder compleet en de conclusies hieromtrent
deshalve meer specalutief. Naast de leeftijd van ziekte-manifestatie en ziekteduur, werd
het moleculaire subtype (gedefinieerd als de combinatie van het PRNP codon 129
genotype en PrP type) herbevestigd als belangrijke onafhankelijke determinant van de
testresultaten. Multivariate analyses toonden aan dat moleculair subtype en het tijdstip
van bepalingen tijdens het ziekteverloop van de patiënt geen invloed hadden op het
vóórkomen van een typisch of positief EEG of CSF 14-3-3 eiwit testresultaat. Een
typisch EEG werd het vaakst gezien bij MM1 patiënten en kwam significant minder
vaak voor bij de MV1, MV2, en VV2 subtypes, terwijl bij VV2 patiënten vaker een
typisch hersen-MRI werd gezien. Een positieve CSF 14-3-3 test kwam het vaakst voor
(88.1%) maar deze test deed het minder goed bij de zeer zeldzame MV2 en MM2
subtypes. Onze bevindingen bevestigen een aantal determinanten van belangrijke
onderzoeksresultaten voor sporadisch CJD en onderstrepen het belang van het erkennen
van de beperkingen van deze tests voordat de diagnose al dan niet bevestigd kan worden.
Combinaties van onderzoeken geven de beste detectie-kans, met name voor zeldzame
moleculaire subtypes zoals MV2 en MM2.
In hoofdstuk 5 worden de belangrijkste bevindingen van dit proefschrift
beschreven en in elkaars perspectief en dat van de huidige wetenschappelijke kennis
geplaatst. De meest relevante methodologische aspecten worden bediscussieerd en ten
slotte worden toekomstige onderzoeksrichtingen besproken.
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Resumen
Las encefalopatías espongiformes transmisibles (EET) o enfermedades por priones
constituyen un fascinante grupo de enfermedades neurológicas. A pesar de su baja
incidencia, sus singulares mecanismos etiopatogénicos y el complejo perfil
epidemiológico han atraído a un considerable número de investigadores.
Esta tesis se centra en dos aspectos: los mecanismos etiológicos y pruebas
diagnósticas de la enfermedad de Creutzfeldt-Jakob (ECJ) y otras EET. En esta
compilación de trabajos hemos buscado nuevas claves para entender mejor estos dos
aspectos de la enfermedad, utilizando herramientas tomadas tanto de la epidemiología
genética como de la epidemiología clásica.
En los estudios que se han llevado a cabo se han utilizado datos procedentes tanto
de los centros de vigilancia epidemiológica de Países Bajos, Italia y Reino Unido, como
de los grupos 'European collaborative study of CJD' (EUROCJD), 'extended European
collaborative study of CJD' (NEUROCJD), 'Early clinical diagnosis of human
spongiform encephalopathies by analysis of biological fluids-CJD Markers
collaboration (EPICJD), y el 'Rotterdam Study'.
En el capítulo 1 se introducen los temas tratados en el libro.
En el capítulo 2 se describe la metodología empleada y los problemas más
comúnmente encontrados durante la puesta en marcha de un estudio de colaboración
internacional para la vigilancia de la ECJ (NEUROCJD). Los resultados de las
actividades de vigilancia epidemiológica quedan resumidos en este capítulo. La tasa de
mortalidad durante el periodo de observación fue de 1 caso por millón de habitantes y
año. Se prestó especial atención a las distintas formas de presentación clínica de los
casos de ECJ esporádica así como a los pacientes con clínica atípica. Casos de la
variante de la ECJ fueron detectados con por los servicios de vigilancia de Irlanda y
Portugal. En el capítulo 2.2 se describe las características del primer paciente de variante
de la ECJ detectado en los Países Bajos. Su perfil clínico, genético y neuropatológico
fue en todo punto indistinguible del presentado por los casos británicos, lo que apunta a
un origen etiológico común.
En el capítulo 3 se exploran diversas hipótesis etiológicas en relación con la ECJ
esporádica y con la variante. En el capítulo 3.1 estudiamos la relación entre el material
bovino exportado desde el Reino Unido y la aparición en otros países de casos de
variante de la ECJ. En este análisis encontramos una fuerte asociación entre dicho
material exportado durante la década de los 80 y el número de casos de variante de ECJ
detectados. En concreto el número de animales vivos, de forma independiente, es el
factor que tiene una mayor relación con el número de casos de variante aparecidos fuera
del Reino Unido (rs=0,73; 95%CI=de 0,42 a 0,89; p<0,001). El mayor número de
animales tuvo como destino Francia, Países Bajos e Irlanda, los tres países con mayor
incidencia de variante de la ECJ. En el capítulo 3.2 estudiamos el posible papel de la
cirugía oftálmica como factor de riesgo para el desarrollo de la ECJ esporádica y de la
variante. No encontramos asociación con ninguna de esas dos formas de la enfermedad,
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pero una observación interesante fue el hecho de que un grupo de pacientes esporádicos
que debutaron con clínica visual fueron remitidos en primer lugar al oftalmólogo, y con
frecuencia fueron diagnosticados y tratados de cataratas. En el capítulo 3.3 estudiamos
la asociación entre la ECJ esporádica y cierta variante genética en la región no
codificante del extremo 5' del gen de la proteína priónica (PRNP). En nuestro estudio
poblacional encontramos que el ser portador del alelo G del polimorfismo genético en
estudio (PRNP G310C) estaba estadísticamente asociado (p=0,03) con un riesgo de
enfermedad 2,4 veces mayor (IC95% de 1,1 a 5,4). Los casos de ECJ esporádica
portadores del alelo PRNP 310G comenzaron la enfermedad como media 8,9 años más
jóvenes que los no portadores (p=0,05). El polimorfismo estudiado fue seleccionado en
base a su localización en una región asociada a la expresión de PRNP. Nuestros
hallazgos apoyan la hipótesis de que las variaciones en la región reguladora de PRNP
podrían tener un papel etiopatogénico en la ECJ esporádica. En el capítulo 3.4
estudiamos la asociación entre las diferentes variantes haplotípicas del gen de la proteína
Tau (MAPT) y el riesgo de ECJ. En una muestra de población de los Países Bajos
examinamos seis polimorfismos de MAPT en enfermos de ECJ y controles
cognitivamente sanos, todos de origen caucásico y con similar distribución de edad.
Genotipamos los mismos seis polimorfismos en otras dos muestras de ECJ originarios
de Italia y del Reino Unido. El análisis de cada polimorfismo en singular y formando
haplotipos no detectó ninguna diferencia estadísticamente significativa entre controles y
pacientes de ECJ esporádica. Cuando comparamos los haplotipos entre ECJ variante y
esporádica observamos diferentes frecuencias en dos de ellos (H1f: 8% esporádicos
versus 2% en variante; H1j: 1% esporádicos versus 7% en variante). El significado de
estas diferencias es incierto, pues al tener en cuenta el número de tests realizados, las
diferencias no son estadísticamente significativas.
El capítulo 4 se centra en el estudio de las principales pruebas diagnósticas de la
ECJ. En el capítulo 4.1 estudiamos la sensibilidad y especificidad del análisis de varias
proteínas de origen cerebral (14-3-3, Tau, NSE y S100b) en líquido cefalorraquídeo
(LCR) para el diagnóstico de la ECJ. También estudiamos los diferentes factores
biológicos que modifican esos parámetros. En el marco de un estudio europeo de
colaboración multinacional (EPICJD), analizamos 14-3-3, Tau, NSE y S100b en 1859
pacientes con ECJ esporádica, iatrogénica, genética y variante, y 1117 controles. La
mayor sensibilidad en ECJ esporádica se alcanzó con 14-3-3 y Tau (85% y 86%); la
determinación combinada de 14-3-3 bien con Tau, bien con s100b o NSE incrementó la
sensibilidad hasta aproximadamente un 93%. Un análisis multivariante en los pacientes
esporádicos mostró que la sensibilidad de todas las pruebas fue máxima en pacientes
con duración breve de la enfermedad, edad de inicio superior a los 40 años y
homocigotos para el codon 129 de PRNP. En el subgrupo de pacientes a los que se les
realizaron repetidas punciones lumbares se observó que la segunda prueba incrementó
la sensibilidad diagnóstica. Nuestros resultados reafirman que la detección de niveles
altos de estas proteínas de origen cerebral en LCR, en pacientes con sospecha clínica de
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ECJ, supone una valiosa herramienta diagnóstica. Se recomienda la repetición de la
punción lumbar en aquellos pacientes con clínica atípica y un primer resultado negativo.
En el capítulo 4.2 se estudia la influencia del momento en el que se realiza la punción
lumbar sobre la sensibilidad de los análisis de LCR. Se estudiaron los resultados de
distintas pruebas (14-3-3, Tau, S100b y NSE) en 833 pacientes de ECJ esporádica
realizados en distintos estadios de la enfermedad, así como en 68 pacientes en los que
se realizaron estudios secuenciales. Se observó que la determinación de las proteínas 
14-3-3 y Tau aumenta su sensibilidad progresivamente desde el inicio (88% y 81%)
hasta estadios avanzados (91% y 90%). Esa tendencia fue estadísticamente significativa
en el grupo de pacientes heterocigotos para el codon 129 de PRNP. Globalmente, los
niveles absolutos de Tau, S100b (p<0,05) y NSE se incrementaron en el último estadio
de la enfermedad en relación al primero. Niveles altos de Tau, NSE y S100b se asociaron
a menor supervivencia (p<0,01). El subgrupo de pacientes en los que se realizó al menos
una segunda punción lumbar eran más jóvenes que la media, con duración de
enfermedad mayor, y con mayor frecuencia de heterocigotos para el codon 129 de PRNP
(p<0,001). La sensibilidad de la detección de 14-3-3 se incrementó de un 65% hasta un
79% en la segunda punción lumbar (p=0,06) y el 88% de los pacientes tuvieron al menos
uno de los dos resultados positivos. La sensibilidad y los niveles absolutos de los
marcadores de la ECJ en LCR aumentaron con la progresión de la enfermedad
modulados por el genotipo del codón 129. Resultados negativos obtenidos en estadios
precoces se deben interpretar con cautela, especialmente en pacientes jóvenes o
heterocigotos para el codón 129. En el capítulo 4.3 se examina los resultados de los
estudios de rutina de LCR (número de células blancas y proteínas totales) y la presencia
de bandas oligoclonales IgG en pacientes con EET. Se analizaron datos de 450 pacientes
esporádicos y 47 con otros tipos de enfermedades. Un números de células en LCR
mayor de cinco cels/µl se encontró sólo en tres pacientes esporádicos de los 298
estudiados; ninguno de ellos superaba las 20 cels/µl. Concentraciones de proteínas
superiores a 0,9 gr/l se encontraron en cinco de los 438 pacientes esporádicos
estudiados; ninguno de ellos alcanzó niveles superiores a un gr/l. Se detectaron bandas
oligoclonales IgG en ocho de los 182 pacientes esporádicos. Ninguno de los pacientes
con otras EET presentó un número de células superior a 20 o concentración de proteínas
superior a 0,9 gr/l, y sólo en un paciente con insomnio familiar fatal se detectaron
bandas oligoclonales IgG. Ninguno de los pacientes esporádicos o con otra ETT
presentó anomalías en las tres pruebas. En resumen, la presencia en el LCR de más de
20 cels/µl o de concentraciones de proteínas superior a un gr/l debe sugerir un
diagnostico alternativo. El objetivo del capítulo 4.4 es definir los principales
determinantes de la sensibilidad de las tres pruebas diagnósticas características de la
ECJ en todo su espectro fenotípico: electroencefalograma (EEG), resonancia magnética
(RM) y determinación de 14-3-3 en LCR. A este fin realizamos un estudio en el seno
del grupo EUROCJD incluyendo información de 2451 pacientes con diagnóstico
definitivo. Nuestros resultados demuestran que tanto la edad de inicio como la duración
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de la enfermedad influyen, como factores independientes, en la aparición de los cambios
típicos en el EEG; por su parte la duración de la enfermedad lo hace también en la
detección de la proteína 14-3-3; la aparición de los cambios característicos en la RM no
parece depender de estos dos factores clínicos, aunque los datos a ese respecto son
incompletos y por ello las conclusiones mas provisionales. Además de los previos, el
subtipo molecular de la enfermedad (definido por la combinación del genotipo del
codón 129 de PRNP y el tipo de PrP) se reafirmó como el factor más influyente en los
resultados de las pruebas. En un análisis multivariante incluyendo todos los factores
mencionados con anterioridad se observó que el momento en el que se realiza la prueba
diagnóstica no influye de una manera estadísticamente significativa,
independientemente del subtipo molecular, en la sensibilidad del EEG o en el resultado
de la determinación de 14-3-3. Los pacientes con subtipo MM1 presentaron con mayor
frecuencia EEG típico de ECJ esporádico que los pacientes MV1, MV2, y VV2, sin
embargo, los VV2 presentaron con mayor frecuencia cambios típicos en la RM.
Globalmente, la detección de proteína 14-3-3 en LCR demostró ser la prueba más
sensible (88,1%), aunque su rendimiento fue significativamente peor en los subtipos
infrecuentes MV2 y MM2. Nuestros hallazgos definen y confirman una serie de
factores moduladores del rendimiento de las principales pruebas diagnósticas de la ECJ,
y subrayan la importancia de tenerlos en cuenta a la hora del juicio diagnóstico. La
combinación de las distintas pruebas incrementa las posibilidades diagnósticas, sobre
todo en los subtipos infrecuentes como MM2 o MV2. En el capítulo 5 los principales
hallazgos de esta tesis son expuestos y analizados tanto en su conjunto como en el
contexto de la literatura científica actual. Se discuten los aspectos metodológicos más
relevantes, y por último se mencionan las líneas futuras de investigación a la vista de los
hallazgos presentados en este texto.
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